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The aetiology of multiple sclerosis (MS) is unclear, but an aberrant immune response 
to Epstein-Barr virus (EBV) and infectious mononucleosis,a history of tobacco 
smoking, insufficient exposure to ultraviolet radiation, or decreased levels of 25-
hydroxy vitamin D [25(OH)D] contribute to the onset in genetically susceptible 
individuals. Other factors such as human herpesvirus 6 (HHV6) infection, stressful 
life events (SLEs), number of offspring, and marijuana use may be associated with 
MS onset, but the evidence is currently less consistent. The effects of these factors on 
the age of symptom onset (ASO) and clinical course of patients with MS are also still 
uncertain. 
This thesis used three databases to investigate the roles of these established/potential 
risk factors in ASO and the clinical course of MS. MSBase (chapter 4) is an 
international neurologist database, which I used to assess whether a latitudinal 
gradient of ASO exists in MS patients. The Ausimmune study (chapter 5) is a 
population-based incident case-control study conducted in four different locations in 
eastern Australia that I used to assess whether environmental/behavioural factors 
could influence the ASO in MS patients. The AusLong study (chapters 6 and 7) is a 
prospective cohort study that followed cases in the Ausimmune Study for at least 5 
years; I used the latter to assess whether HHV6/EBV infection and SLEs could 
influence MS clinical course.  
Within MSBase, including 22,162 patients from 21 countries, I found an inverse 
association between latitude and ASO, such that each 10° of increased latitude was 
Abstract 
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associated with a 0.8-year earlier onset. Variation of ultraviolet radiation may play an 
important role in this latitudinal gradient. Using the Ausimmune Study, I showed that 
higher offspring number, a history of tobacco smoking, cerebral dysfunction at their 
first clinical diagnosis of CNS demyelination (FCD), and a primary progressive MS 
(PPMS) onset type were associated with a later onset, whereas a history of marijuana 
use was associated with an earlier onset. Both of these analyses supported the effects 
of modifiable factors on the age of symptom onset in MS, which may help improve 
surveillance and diagnostic efforts, as well as aid in planning for future case load.  
Using the AusLong Study, I found little evidence supporting associations between 
immune response to EBV/HHV6 and MS clinical course, indicating that the viral 
infection repertoire detected at baseline could not predict the subsequent disease 
course or prognosis of MS. However, using this study I found a protective effect of 
perceived positive SLEs on MS disease activity, such that preceding perceived 
positive SLEs (number, severity, and duration) were associated with a decreased 
hazard of subsequent conversion to MS or relapses. These results support the 
important role of maintaining a positive psychological well-being in reduction of the 
frequency of disease activity. 
The findings of the significant associations between environmental/behavioural 
factors and age of symptom onset and disease activity of MS, if replicated in other 
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Chapter 1 Introduction 
1.1 Multiple sclerosis and its impact 
Multiple sclerosis (MS), a chronic autoimmune disease of the central nervous system 
(CNS), is the primary cause of neurological disability in young adults
1
. Improvements
in diagnostic criteria and paraclinical evidence on magnetic resonance imaging (MRI) 
have improved the accuracy of MS frequency estimates generally, but particularly in 
non-Asian European-descent countries. The improved accuracy of frequency 
estimates is responsible for increasing trends in the prevalence and incidence of MS 
that have been found globally during the last few decades. According to the Atlas of 
MS database 2013
2
, there are 2.3 million people with MS worldwide. With disease
onset usually occurring during the third or fourth decade of life but with low case 
fatality rates (1%–4% per year), MS is associated with significant personal morbidity 
and economic burden
3 4
. Its impact on the economy in Europe alone is more than 15
billion euros, including direct medical costs and loss of productivity
4
. For patients
with MS, quality of life is affected considerably
5-9
. MS has a highly variable inter- 
and intra-personal clinical course, both in pattern and rate of neurological 
deterioration, strongly suggesting multiple contributory factors that include both 
genetic and environmental influences. 
1.2 Main objectives of this thesis 
Studies about the aetiology of MS have advanced markedly during the last decade: 
environmental factors such as a higher immune response to Epstein-Barr virus (EBV) 




, lower levels of





, and insufficient exposure to ultraviolet radiation (UVR)
13
 have 
been consistently associated with MS onset. Some other environmental/behavioural 
factors, such as parity, marijuana use, and stressful life events (SLEs), have shown a 
potential relationship with MS onset. However, the nature of these effects on age of 
symptom onset (ASO) and clinical course of MS is still uncertain.  
My aims in this thesis are:  
1. To examine whether a higher latitude of residence in patients with MS is 
associated with an earlier ASO, after controlling for factors such as sex, type 
of onset, and some distinct characteristics in each region such as mean age of 
the population, sex ratio, and MS onset type ratio (data source: MSBase).  
2. To examine whether sex, latitude, UVR, serum vitamin D, tobacco smoking, 
marijuana use, offspring number, age at menarche, and clinical presentation 
features are associated with ASO (data source: Ausimmune Study).  
3. To examine whether a higher immune response to EBV/human herpesvirus 6 
(HHV6) infection at baseline is associated with an increased hazard of 
conversion to MS, relapses, and disability progression after adjustment for 
confounding factors (data source: AusLong Study). 
4. To examine the association between SLEs and MS clinical course, and explore 
the different effects between perceived positive and negative SLEs (data 
source: AusLong Study).  
1.3 The projects central to this thesis 
To examine the association between latitude and ASO, an international neurologist 
database, MSBase, was used. This study
14
 commenced in July 2004 and, by the time 
we started our analysis, 30,415 patients from 26 countries were recruited in the study.  
The Ausimmune Study
15
, funded by the US MS Society, the National Health and 
Medical Research Council (NHMRC), and MS Research Australia, was a population-
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based, multicentre incident case-control study. It included the following regions: 
Brisbane city, the Newcastle region, Geelong and the Western Districts of Victoria, 
and Tasmania, spanning 16 degrees of latitude. The primary purpose of this study was 
to explore factors and mechanisms underlying MS development. A total of 282 
incident cases with the first diagnosis of a demyelinating event were recruited into the 
study from 1 November 2003 to 31 December 2006. Extensive individual information 
and health history that occurred prior to symptom onset was obtained for each 
participant, and this dataset was used to analyse the associations between 
environmental/behavioural factors and ASO.  
To examine associations between established/potential beneficial/detrimental factors 
and the rate of MS progression, cases in the Ausimmune Study were prospectively 
followed for at least 5 years in the AusLong Study. The main endpoints of this study 
were as follows: (1) hazard of time to conversion to MS; (2) hazard of time to 
subsequent relapses; and (3) annualised disability progression as measured by change 
in the Expanded Disability Status Scale. With this prospective cohort study, we 
investigated the associations between EBV/HHV6 infections, SLEs, and MS clinical 
course.  
1.4 Outline of the thesis 
The focus of this thesis is to examine the effects of environmental/behavioural factors 
on the ASO and clinical course of MS. In Chapter 2, a brief overview of MS is given. 
Chapter 3 reviews the role of viral infection (EBV, HHV6, and human endogenous 
retrovirus) on MS development and progression. This chapter has been published in 
the Journal of the Neurological Sciences. Chapter 4 discusses the first aim of this 
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thesis – assessing the association between latitude and ASO. This chapter has been 
published in the Journal of Neurology, Neurosurgery & Psychiatry. Chapter 5 
discusses the second aim of this thesis – the role of a range of environmental or 
behavioural factors on ASO. Chapter 6 discusses the third aim of this thesis – the 
association between baseline-measured serological and viral load measures of 
EBV/HHV6 infection and MS clinical course (conversion to MS, relapse, and 
disability progression). Chapter 7 discusses the fourth aim of this thesis–the 
association between SLEs and MS clinical course. Chapter 8 draws the primary 
conclusions of this thesis and discusses future research. 
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Chapter 2 Literature review of multiple sclerosis 
2.1 Preface 
This chapter discusses different aspects of multiple sclerosis (MS) that are important 
for the understanding of the subsequent chapters, including phenotypes, age of 
symptom onset (ASO), clinical course, risk factors, diagnosis, and treatment. This 
chapter does not provide a full literature overview on MS, but merely focuses on the 
topics of this thesis.   
2.2 Clinical phenotypes of MS 
2.2.1 Relapsing-onset MS 
According to the pattern of disability progression after disease onset, MS can be 
classified into two major onset types: relapsing and progressive MS. Further 
subcategorisation is based on the presence/absence of disease activity. The relapsing-
onset type is the most common type and characterised by multiple episodes of 
neurological dysfunction. Typical relapsing-onset MS consists of four stages: at-risk 
of MS, asymptomatic, relapsing phase, and progressive phase. Full or partial recovery 
from relapses during early stages of the disease constitutes the major clinical 
characteristic
1
, incomplete recovery from severe relapses lead to the disability 
progression. Accumulation of intermittently focal inflammation over time contribute 
to the progression of disability in people with MS. Approximately 85% of relapsing-
remitting MS (RRMS) patients will develop secondary-progressive MS (SPMS) 
within 10 or 20 years after disease onset, which is characterised by the relentlessly 
progressive accumulation of disability with or without superimposed relapses. It is 
currently recognised that the process of progression to SPMS is gradual
1
, where the 
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frequency of relapses decreases
2 3
 and shifts to a sustained deterioration of 
neurological function.  
2.2.2 Progressive-onset MS 
According to the absence/presence of disease activity (clinical relapses and MRI-
identified lesions) in patients with progressive MS, clinical phenotypes of progressive 
MS can be categorised into active and non-active, respectively
1
. This classification 
includes inflammatory lesion activity and gradual worsening.  
Notably, pathological mechanisms underlying progressive-onset MS are 
quantitatively different from RRMS. Focal new and active lesions in the white matter 
tissue are common in the early stages, but become rare when patients enter the 
progressive phase
4
. Cortical demyelination increases massively when patients suffer 
from a progressive phase, and diffuse changes in the normal-appearing white matter 
also become pronounced
5
.Focal lesions in RRMS patients tend to arise from regions 
with high venous density, while in patients with the progressive phase, lesions tend to 
locate at regions with a lower venous density
6
. A higher perfusion may aid the lesions 
in patients with RRMS in recovering more complete, but in patients who are in the 
progressive phase, lesions may become permanent due to the lack of perfusion. Over 
the course of disease, diffuse microglial activation and neurodegeneration become 
more prominent in normal-appearing white and grey matter
7
. Failure of remyelination 
cause axonal degeneration and disease progression.  
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2.2.3 Paediatric-onset and late-onset MS 
Paediatric-onset MS (POMS) is commonly defined as patients with the onset of MS 
prior to the age of 18 years. Similar to patients with adult-onset MS (AOMS), EBV 
infection
8-10
 and HLA-DR15 genotype
11
 have been associated with an increased risk of 
MS in paediatric patients. More than 98% of paediatric MS manifests as relapsing-
onset form, so progressive-onset disease in paediatric MS patients should be 
diagnosed carefully with extensive assessment for alternative diseases
12
. Compared to 
AOMS patients, rate of relapses tends to be higher in patients with POMS. Relapses 
in POMS tended to be more severe than AOMS, but recovery was also more 
complete
13 14
. Although patients with POMS take a longer period to convert to SPMS, 
they still tend to have an earlier age at onset of SPMS (41 years for patients with 
paediatric MS vs 52 years for adult)
15
. Incomplete recovery from the first attack has 
been associated with a shorter time until reaching an EDSS 4 (13.5 years in those with 
residual disability vs. 25.4 years in those with complete recovery from the first 
attack)
15
. Like AOMS, a female preponderance has been found in patients with POMS 
as well, with female:male ratio up to 4.5:1
12
. Notably, for those with an extremely 
early onset (<12 years of age), the sex ratio could be is close to 1:1. The marked 
increase in the proportion of female patients after 12 years of age is thought to be 
driven by change in hormonal state
16
. The initial clinical manifestation of paediatric 
MS patients is highly variable, but the attack tends to be monofocal and localise to 
one area of the CNS in up to 90% paediatric patients
17
. Treatment for POMS is 
similar to AOMS, and interferon-β was commonly treated as first-linetreatment
18 19
. 
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In most studies, it has been found that 1.4%-9.9% of all patients have late-onset MS 
(LOMS), defined as symptoms onset at 50 years of age or later
21
. A female 
preponderance is also found in patients with LOMS, with a similar sex ratio to adult 
onset MS
22
. Initial presentation in LOMS is commonly monosymptomatic, with 
motor and cerebellar dysfunction
23
. Like patients with adult-onset MS, progressive-
onset type is the most common clinical course in LOMS
24
. LOMS is associated with a 
shorter period before reaching EDSS 6.0
25 26
. 
In summary, with increasing of age at onset (POMS-AOMS-LOMS), the proportions 
of patients with progressive-onset forms increased, disability progression is 
accelerated, and female comprise an increasing proportion of cases.  
2.3 Age of symptom onset 
The primary outcome of chapters 4 and 5 is ASO, the age of the first demyelinating 
event, we will discuss the clinical significance of ASO here. Associations between 
environmental/genetic factors and ASO will be discussed separately when the effects 
of each factor are introduced. A timely diagnosis of MS is difficult for patients with 
atypical symptoms, which may lead to the inaccurate measurement of ASO. In the 
AusLong study, all patients were carefully reviewed, especially those with a 
previously undiagnosed neurological event thought to be demyelination. Also, for 
patients with progressive-onset MS, an accurate measure of ASO was extremely 
difficult, given the more insidious development of symptoms over time. Therefore, in 
Chapter 5, a sensitivity analysis was performed that was restricted to patients with 
relapsing-onset MS to avoid the potential measurement error. However, in Chapter 4, 
ASO was measured by different neurologists in different clinical centres, potential 
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measurement error of ASO was hard to avoid and may influence the validity of the 
results.  
2.3.1 Associations between ASO and long-term prognosis 
Associations between ASO and consequent disease progression are complicated: an 
earlier onset is associated with a slower progression, whereas a later onset is 
associated with an accelerated progression, the age of reaching severe disability or 
progressive-MS is similar
26-29
. Although it has been recognised that late onset is 
associated with a more aggressive clinical course and can lead to severe disability 
sooner, delaying disease onset is still of great importance for patients with MS. 
Mounting evidence has confirmed that an earlier onset could increase the risk of 
conversion from clinically isolated syndrome (CIS) to MS
30-34
. Following 114 patients 
with acute partial transverse myelopathy, Ruet et al
30
 found that patients with a 
younger age had a significantly higher odds of conversion to MS (OR 7.82, p<0.001). 
The authors controlled for some covariates in the multivariable analysis. The strong 
magnitude supported the validity of the result, however, some limitations influenced 
the generalisation: 1) all patients were recruited from one hospital and were not 
population-based which could have led to selection bias; and 2) only patients with 
acute partial transverse myelopathy were recruited, which led to spectrum bias. 
Therefore, the results in this study were not representative of the MS population. 
Recruiting CIS patients from 33 centres in 17 countries, one large prospective cohort 
study with 623 CIS patients demonstrated that an earlier onset was associated with a 
higher hazard of conversion to MS [hazard ratio (HR)per year=0.98, 95% confidence 
interval (CI) = 0.98–0.99, p<0.001]
31
. The lack of standardised protocols and not 
controlling for the difference between study centres influenced the interpretation of 
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the results. However, the large sample size and controlling for confounder bias 
supported the significant association between age and conversion to MS. Following 
1015 CIS patients prospectively for approximately 7 years, Tintore et al
33
 reported 
that cases with an earlier onset had a higher hazard of conversion to MS: when 
compared with those with a late onset (>40 years), the HR of those aged 30 to 39 
years, 20 to 29 years, and 19 years or less were 1.4, 1.8, and 1.9, respectively. Patients 
were recruited from 2005 to 2013, so birth cohort effects may influence the results, 
but the prospective cohort design and large sample size supported the detrimental 
effects of younger age on conversion to MS. Results from the MSBase registry
34
 also 
supported the significant association between older onset and decreased hazard of 
conversion to MS (HR 0.91, 95% CI = 0.89-0.93; p<0.001). In brief, consistent results 
from a number of studies supported the association between earlier onset and higher 
hazard of conversion to MS.  
2.4 Conversion to MS, relapses, and disability progression 
The outcome of chapters 6 and 7 is MS clinical course, which includes conversion to 
MS, relapses, and disability progression. Conversion to MS and relapses represent the 
disease activity, whereas disability progression represents a sustained accumulation of 
neurological impairment. The diagnostic criteria used for conversion to MS and 
relapses in MSBase and the Ausimmune Study is the McDonald criteria
35 36
, which 
will be discussed in detail later. Quantification of the degree of disability due to MS is 
commonly measured with the Disability Status Scale (DSS, 10-point scale)
37
 or the 
Expanded Disability Status Scale (EDSS, 10-point scale with half-step increments 
(not between 0-1)
38
. A lower score (<4) of EDSS is measured with neurological 
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examination of eight functional systems, while the higher score is predominantly 
based on walking ability (>4) or handicaps (>6). 
Several studies have demonstrated that the intra-rater agreement is slightly higher 
than the inter-rater agreement, and the reliability is significantly lower when the 
EDSS score is less than 4
38-40
. Since most patients in AusLong study were still at the 
benign stage, the reliability of EDSS might be inaccurate. EDSS at baseline interview 
and 5-year review in Ausimmune and AusLong study were measured with an 
experienced neurologist in each study centre, and all EDSS was reviewed thereafter to 
ensure the reliability. No evidence suggested that this potential measurement error of 
EDSS would be differential by the exposures of interest, and we believed this 
potential measurement error would not impact the results materially. 
An advantage of the EDSS is the comparability of the scores between different 
studies, and the measurement is robust during a long period of follow-up. It is 
acknowledged that the increase of EDSS is not linear, however, the AusLong study 
participants were people with a first clinical diagnosis of demyelination at study entry 
and 87.6% had an EDSS score ≤ 4 at the 5-year review. Previous research has 
suggested that the disability progression is comparative linear when EDSS was ≤ 4. 
Time to particular EDSS hallmarks were less suitable as the participants were not 
assessed frequently enough by neurologists to reliably determine the date participants 
reached an EDSS of three or four. Therefore, annualised change of EDSS in the 
AusLong study was the best measure of disability progression. 
All relapses in AusLong study were diagnosed with a standardised protocol by an 
experienced neurologist in each study centre. Moreover, every relapse was reviewed 
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thereafter to ensure the validity of the diagnosis. However, due to the nature of MS, 
some minor attacks are extremely difficult to detect. It would be difficult to predict 
whether these minor attacks affected our main associations of interest and in which 
direction. 
Time to relapse rather than annualised relapse rates was used in this thesis, which 
increased the temporal precision, as all information was included about the clinical 
course (dates of relapses, rather than just their number) and the fluctuation of status 
over time. While relapses of the same person were clustered, multiple relapses were 
regarded as independent observations on the assumption that time until a prior event 
does not affect the composition of the risk set for a subsequent event. Cox 
proportional hazards models were used to include the information of repeated 
events
39




Here we will discuss the relationship between conversion to MS, relapses, and 
disability progression, and their associations with MRI parameters. Associations 
between environmental or behavioural factors and MS clinical course will be 
discussed next when each risk factor is introduced.  
2.4.1 Conversion to MS 
Using clinical and biochemical variables that are assessable at baseline to predict the 
risk of conversion from CIS to MS is always a complex puzzle in clinical practice. 
Current evidence indicates that whether or when a patient with CIS will convert to 
MS is predictable to some extent. A number of factors have been assumed to 
contribute to increased risk, and among them, higher load of lesions on MRI is the 
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strongest predictive factor in MS prognostic study
30 31 33 34 42-45
. Current diagnostic 
criteria refer to patients with disseminated lesions on MRI, but without repeated 
clinical attacks, as possible MS
35
. A retrospective cohort study
42
 with 137 CIS 
patients (median time of follow-up: 3.1 years) reported that a higher load of MRI 
lesions (HR 1.67, 95% CI: 1.1–2.6, p=0.028) at baseline was associated with an 
earlier conversion to MS. Following 220 CIS patients (receiving interferon-β) 
prospectively for 2 years, Kalincik et al
45
 found that more than 1% decrease in the 
corpus callosum cross-sectional area between baseline interview and 6 months after 
CIS (HR 2.5, 95% CI: 1.5-4) and an increased volume of T2 lesions (HR 1.8, 95% CI: 
1.1-2.9) were associated with a higher hazard of conversion to MS. A multicentre and 
retrospective study
43
 of 1165 CIS patients found that increased lesion load at baseline 
(7.6 ± 8.1 cm
3
 vs. 4.6 ± 6.7 cm
3
, p<0.001) was associated with an increased risk of 
conversion to MS. Current studies have confirmed the clinical significance of a high 
load of MRI lesions in MS prognosis.  
Mounting research has indicated that the presence of oligoclonal bands in 
cerebrospinal fluid (CSF) is associated with a higher hazard of conversion to MS. One 
recent natural history study
33
 with 1015 CIS patients found that presence of 
oligoclonal bands increased the hazard (HR 1.3, 95% CI: 1.0-1.8) of conversion to 
MS. A similar magnitude was reported from the MSBase registry (HR 1.40, 95% CI: 
1.11-1.77; p=0.004)
34
. Converging evidence supports that the presence of oligoclonal 
bands should be regarded as a medium prognostic factor for conversion to MS.  




More than 85% of patients with MS experience relapses during the disease course
46
. 
The relapse rate varies between 0.3 and 1.0
47
; however, this may slightly 
underestimate the actual rate, owing to a proportion of patients who do not 
identify/report their attacks
48
. The relapse rate is highest in patients with MS aged less 
than 30 years [odds ratio (OR): 1.42, p<0.001]
49
. The severity of relapses increases 
with age, and the ability to recover from them decreases
50
.  
A number of long-term follow-up therapeutic studies
51-56
 supported that relapses 
could predict disability in the long run; however, potential influences of therapy and 
the lack of association between pre-study relapses and disability
56
 weakened the 
strength of the relationship. Natural history studies have suggested that only relapses 
that occurred early in the disease course are associated with long-term disability 
(reviewed by Goodin
57
). With the analysis of 806 relapsing-onset patients from an 
original population-based natural history cohort, Scalfariet al
3
 discovered that only 
relapses that occurred within 2 years after disease onset could predict the long-term 
severity of disability, whereas relapses occurring beyond 2 years showed no 
relationship with disability levels. Disability level was measured with the DSS, and 
time to DSS was analysed with survival analysis in this study. Although some 
important confounders were not controlled in this study, the elegant study design and 
appropriate statistical method still supported the validity and generalisation of the 
results. With the same cohort, Scalfari et al
58
 also found that a shorter interval 
between the first and second attack was associated with a faster progression of 
disability. Following 1609 relapsing-onset CDMS patients for about 13 years, 
Emmanuelle et al
59
 found that the number of relapses during the first 2 years were 
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significantly correlated with disability progression, as time to irreversible DSS 3 was 
12.2 years in those with only 1 relapse in the first two years, while the duration 
decreased to 7.7 years if patients experienced 2 or more relapses.  However, number 
of relapses during the first two years was not associated with the duration from DSS 3 
to DSS 6, which suggested the hypothesis that disability progression in patients with 
MS follows a two stage process, from disease onset to irreversible DSS 3 and from 
DSS 3 to DSS 6. The results were supported by the assumption
60
 that focal 
inflammation was responsible for the disease at early stage while diffuse 
inflammation and neurodegeneration was responsible for the late stage. In this study, 
all patients were selected from a regional referral centre and diagnosed with Poser‘s 
criteria. Strengths of this study were the prospective cohort study design and the 
consideration of important confounders.   
Interestingly, male patients have shown a faster progression of disability despite a 
lower frequency of relapses compared to female patients
61 62
. The difference of 
clinical symptoms between male and female patients may contribute to this paradox. 
Female patients tend to present with sensory and visual symptoms while male patients 
tend to present with brainstem, pyramidal and cerebellar symptoms
50
. An improved 
recovery has been observed for those with visual, sensory and brainstem symptoms
50
.  
Most studies in the literature supported a high correlation between MRI lesions and 
clinical relapses in patients with MS, owing to the quantitative relation of treatment 
effects detected by MRI parameters and relapse rates from randomised controlled trial 
(RCT) studies
63-68
. A number of clinical trials have used MRI parameters as a 
surrogate for clinical relapses.  




A number of RCT studies
65-67
 have supported the high correlation between treatment 
effects on MRI lesions and disability progression. Mounting studies
67
 have suggested 
that brain atrophy and lesion volumes could predict the long-term clinical evolution in 
patients with MS. A retrospective study
69
 including 261 MS patients with a follow-up 
period of 10 years found that central atrophy and lesion volume change within 2 years 
after disease diagnosis were associated with EDSS at 10 years: the correlation was 
0.74, controlling for imaging protocol, baseline EDSS, and disease modifying therapy 
(DMT). This study was designed retrospectively and patients were recruited from 8 
centres. The correct temporality of association (exposure before outcome) and 
application of standardised protocols supported the conclusion that changes of MRI 
signs at early stages of disease may predict the subsequent disability progression. 
Following 107 CIS patients (recruited from 1984 to 1987) for approximately 20 years, 
Fisniku et al
70
 found that change of lesion volume at the early stage of disease (0-5 
years) was associated with the level of disability after 20 years (r=0.48, p<0.001). 
Uher et al
71
 conducted a prospective cohort study of 220 CIS patients, and during the 
48 months of follow-up, they found that increased lateral ventricle volume (p<0.001), 
decreased grey matter (p=0.011), and decreased cortical volume (p=0.001) were 
associated with a sustained disability progression. A prospective cohort study
52
 
following 163 CIS patients for 15 years treated with interferon-β showed that 
enhancing lesions (OR: 8.96, p<0.001) were associated with worsening disability 
progression. Several limitations such as the initial RCT design, the fact that all 
patients were administered with interferon, and that EDSS scores being self-reported 
influenced the validity and generalisability of the results. In summary, several 
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prospective cohort studies supported that MRI changes at the early stages of disease 
could predict the long-term disability progression in patients with MS. 
Disability levels also showed a close relationship with psychological dysfunction. 
With 1040 patients, Ruano et al
72
 showed that a higher level of EDSS was associated 
with the presence of cognitive impairment (OR: 1.80, 95% CI: 1.51-2.15; p<0.001). 
Another cross-sectional study
73
 with 253 MS patients also supported this conclusion. 
Following 260 MS patients after the participation of a RCT study, Goodin et al
56
 
reported that disability at disease onset was significantly correlated with cognitive 
impairment (r=0.12, p<0.001) after approximately 16 years. However, making use of 
recruitment from RCTs can lead to biased recruitment and generalisability issues to 
the broader population with MS, while not controlling for possible confounders limits 
the interpretation of results. 
2.5 Associations between smoking, UVR/25(OH)D, offspring number, 
stressful life events, genetic factors, and MS clinical course 
2.5.1 Tobacco smoking 
Tobacco use was more common in patients with MS than in the general populations
74
, 
with approximately half of MS patients having smoked tobacco at some time
75
. 
Tobacco smoking is viewed as an established risk factor for MS, due to the consistent 
associations and the evidence from good-quality cohort studies
76-79
.  
Using the Hill criteria for causation, one recent meta-analysis
18
 including 23 studies 
demonstrated strong evidence for a causal role of tobacco smoking on MS 
development, with 6 criteria (consistency, temporality, biological gradient, 
plausibility, and coherence) being satisfied and only one criteria was modestly 
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satisfied (strength, OR/RR 1.54, 95% CI 1.46-1.63). The interesting and superficially 
counterintuitive phenomena wherein the prevalence of multiple sclerosis has 
increased while that of smoking has decreased may be the result of a number of 
factors: 1) the implementation of MRI and the application of McDonald‘s criteria 
allowed an earlier and more accurate diagnosis of MS, 2) the onset of MS was driven 
by the interaction of many factors, of which smoking is but one, the population 
attributable fraction of smoking was around 40%. Indeed, not all MS patients need to 
have a history of smoking, since smoking was only one underlying cause in a 
proportion of patients. Rothman‘s ―causal pie model‖ is an useful framework to 
understand this phenomenon: tobacco smoking is an event that plays a necessary role 
in the onset of MS in some people, however, some persons can get MS through other 
pathways (such as EBV infection, low vitamin D levels, and HLA-DR15*1501 
genotype). 
Mechanisms underlying the association between tobacco smoking and MS natural 
history are complex, with direct effects of tobacco smoking on detrimental 
modulation of humoral and cell-mediated immunity
81
, acceleration of axonal 
degeneration
82
, and increased concentration of cyanide intoxication in serum that 
could cause the wide demyelination
83 84
. In addition, associated comorbidities such as 
increased risk of respiratory infections may also be involved
85
.  
The risk of MS in smokers is approximately 50% higher than in non-smokers
86
. 
Among all environmental risk factors [smoking, low actinic damage, history of 
infectious mononucleosis (IM), and low 25-hydroxy vitamin D at MS onset], the 
population attributable fraction of tobacco smoking was 35.1%
87
. Current research has 
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suggested that passive smoke exposure could also increase the risk of MS
88-90
. A large 
case-control study
90
 with 695 incident MS cases and 1635 control subjects who had 
never smoked found that MS cases had a higher exposure to passive smoking (OR 
1.3, 95% CI: 1.1-1.6), and the effects were stronger when the duration of passive 
smoking increased (test for trend p=0.003). With the assessment of cotinine levels in 





 both found that elevated cotinine levels were associated with 
increased risk of MS. 
The association between tobacco smoking and MS clinical course is not as strong as 
for MS onset, but there is a fair amount of evidence supporting that smoking may also 
have adverse effects on the clinical course of MS. Table 1 shows some key studies 
about tobacco smoking and its effect on MS clinical course. A prospective cohort 
study following 129 CIS patients for 3 years found that cases with a history of 
smoking (smokers vs. non-smokers) at baseline had a higher hazard of conversion to 
MS (HR: 1.83, 95% CI: 1.17-2.84, p=0.008) than non-smokers, and the association 
did not alter much after controlling for sex, age at onset, interferon-β use, and number 
of T2 lesions on MRI
93
. This study also found that the EDSS score was not different 
between smokers and non-smokers (p=0.90) after 3 years. Recruitment of all patients 
was in single clinical centre from 1994 to 2004, the long period of recruitment and not 
being a population-based study design does negatively influenced the external validity 
of the findings. Two other studies
94 95
 found a significant association between tobacco 
smoking and disability progression as measured by Multiple Sclerosis Severity Score 
(MSSS) or time to EDSS. Some large prospective cohort studies showed that smoking 
status was associated with numbers and volumes of contrast enhancing lesions
96
, and 
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with whole brain volume
97
. Although selection bias
93





 and insufficient time of follow-up
96
 could have influenced the validity 
of some of these studies, this combined research suggests that tobacco smoking has a 
detrimental effect on MS clinical course.  
Most studies
98-101
also supported a detrimental effect of tobacco smoking on 
subsequent progression from RRMS to SPMS. Following 179 RRMS patients for 5 
years, Hernan and colleagues
98
 found a higher hazard (HR: 3.6, 95% CI: 1.3-9.9) of 
progression to SPMS when comparing smokers with non-smokers. This was a 
prospective study with patients selected from a database with more than 3 million 
Britons, and all patients were diagnosed using the Poser‘s criteria, and age, sex, and 
initial symptoms were controlled for in the multivariable analysis. Healy and 
colleagues conducted a similar study
99
 following 891 patients for approximately 3 
years, and found a higher hazard of progression to SPMS (HR: 2.50, 95% CI: 1.42-
4.41) when comparing current smokers to never-smokers, but no association was seen 
when comparing ex-smokers with never-smokers (HR: 1.05, 95% CI: 0.59-1.84).  










study, 129 CIS 
patients for 36 months 
A history of smoking at baseline was associated with a 







study, 203 MS 
patients for 3 years 
Cumulative pack-years smoked after study entry was 





cross-sectional study,  
1372 MS patients 
In RRMS, cigarette smoking was associated with a higher 






study, 211 CIS 
patients for 24 months 
Active smoking status was associated with increased 
number and volume of T1 Gd+ but not with relapses, 






study, 468 CIS 
patients for 5 years 
No association between cotinine levels and conversion to 
MS, risk of relapses, and MRI measures. 








study, 87 RRMS 
patients for 2 years 
No association between cotinine levels and new T1 Gd+ 
lesions [OR: 0.76 (0.39-1.50), p=0.43; new T2 lesions 
[OR: 0.87 (0.43-1.75), p=0.69]; number of relapses 






study, 179 RRMS 
patients for 5 years 
Smokers had a higher hazard of progression to SPMS 





Cross-sectional study,  
364 MS patients 
No association between smoking behaviours and 
progression to SPMS and disability progression.  
CIS, clinically isolated syndrome; HR, hazard ratio; MS, multiple sclerosis; RRMS, relapsing-
remitting MS; OR, odds ratio; CI, confidence interval; SPMS, secondary progressive MS. 
2.5.2 UVR exposure/25(OH)D level 





 in MS patients have been among the most striking findings in MS 
epidemiological studies. This latitudinal gradient may arise from a range of factors: 
social-economic factors, EBV infection and ultraviolet radiation. One pooled 
analysis
107
 showed the significant association between latitude of residence and 
positivity of EBV infection in patients with MS. Another meta-analysis
108
 with more 
than 40,000 participants from northern hemisphere, found that patients with MS were 
more likely to be born in May and less likely to be born in November, which suggests 
that seasonality may be a risk factor. The variation of ultraviolet radiation levels may 
contribute substantially to this latitudinal gradient
109
. With data of 54 studies across 
Canada, Sloka et al
110
 found that UVB intensity had a closer relationship (about 20-
fold) with the geographic distribution of patients with MS than latitude, which 
suggests that the latitudinal gradient could be mostly driven by UVB intensity. 
Converging evidence supports the hypothesis that insufficient outdoor activity during 





 in Tasmania of 136 MS patients and 272 healthy control subjects 
found that sufficient summer sun exposure (> 2-3 h/day during weekends and 
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holidays) during childhood and adolescence was associated with a decreased risk of 
MS (OR: 0.31, 95% CI: 0.16-0.59) in a dose-dependent manner. Using objective 
measurement of sun exposure, this study also found a significant association between 
higher actinic damage and lower MS risk (OR: 0.32, 95% CI: 0.11-0.88). In line with 
these results, a subsequent multinational case-control study
115
 including 1,660 MS 
patients and 3,550 control subjects found that insufficient sun exposure in summer 
was associated with an increased risk of MS, and this association was strongest when 
sun exposure was measured during adolescence. A large multi-centre study
119
 in 
Australia including 1,524 MS cases found that low maternal exposure to UVR in the 
first trimester was associated with a higher risk of MS in the offspring [highest 
category vs. lowest category, incidence rate ratio (IRR): 1.67, 95% CI: 1.18-2.37]. 
This study also found that the association between month of birth and MS onset was 
totally driven by insufficient exposure to UVR. Possible mechanisms underlying the 
association include important role of first trimester vitamin D concentrations in the 
development of the CNS
120
 and immune tolerance
121
.  
For most individuals, skin exposure to UVR is the primary source of vitamin D
116
, 
and many have believed that the effect of sun exposure on MS was through its effect 
on vitamin D levels
122
. However, UVR has additional effects on the body, 
independent of vitamin D. Indeed, findings in animal models
123
 have suggested that 
the protective effect of UVR on MS pathology are independent of the status of 25-
hydroxyvitamin D [25(OH)D], because observations from experimental autoimmune 
encephalomyelitis (EAE) found that continuous exposure to UVR could suppress the 
clinical signs of MS, and this process occurred independent the elevation of 25(OH)D 
levels in serum. In agreement with these animal models, the Ausimmune Study
117
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[216 first demyelinating event (FDE) cases and 395 healthy controls] found that 
insufficient sun exposure and low vitamin D levels were two independent risk factors 
for FDE development (OR: 0.39, 95% CI: 0.17-0.92; OR: 0.93, 95% CI: 0.86-1.00, 
respectively) in a multivariable model. 
Vitamin D is a steroid hormone, and the pleiotropic effects have been demonstrated, 
as well as its effect on immune system modulation in MS pathology
124 125
. There are 
two forms of vitamin D: cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2). 
After metabolism in the liver, 25(OH)D is synthesised, and it is this form that is used 
to measure vitamin D levels in serum
126
. Through the regulation of local and systemic 
immune systems, low 25(OH)D levels have been regarded as an established risk 
factor for MS development (reviewed by van der Mei
127
).  
Genetic studies also support that vitamin D levels can modulate the susceptibility to 
MS. The enzyme 25(OH)D-1a-hydroxylase, which is needed for vitamin D activation, 
is encoded by the CYP27B1 gene. Ramagopalan et al
128
 found that mutations in the 
CYP27B1 gene were associated with an increased risk of MS. A vitamin D response 
element has been found in the promoter region in HLA-DR15, which suggests that an 
interaction between vitamin D and HLA-DR15 may modulate the onset of MS
129
. 
Some other genes associated with vitamin D metabolism were also found to contain 
single nucleotide polymorphisms (SNPs) related with MS onset
130 131
.All these studies 
provide additional support in favour of a role for vitamin D levels in the determination 
of MS risk. 
As previously discussed, not all MS patients need to be vitamin D insufficient, though 
this can be a component leading to MS. The Bradford-Hill criteria could be used to 
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support the association between insufficient levels of vitamin D and MS onset: 1) 
Strength: The strength of the association between decreased vitamin D levels and MS 
onset was strong
19
. In a nested case-control study with 192 MS patients with blood 
samples collected prior to disease onset and 384 controls, the authors found that 
higher levels of Vitamin D was associated with a decreased risk of MS (OR 0.39, 
95% CI 0.16-0.98); 2) Consistency: The association between vitamin D insufficiency 
and MS onset was consistent across multiple study settings and in different 
populations
20
; 3) Specificity: In contemporary epidemiological view, specificity dose 
not mean that insufficient levels of 25(OH)D could only cause MS but no other 
diseases. We should view specificity more generally, the effects of immunological 
regulation allows vitamin D to be relevant to many other diseases. However, we 
should notice that vitamin D was not associated with diseases randomly: it was 
associated with MS but not many other neurological diseases such as schizophrenia or 
brain cancer; 4) Temporality: Prospective cohort studies have demonstrated that 
insufficient vitamin D and related parameters like vitamin D intake and historical sun 
exposure prior to MS onset were associated with subsequent MS risk and clinical 
course
19
; 5) Biological gradient: Evidence supports a dose–response relationship 
between vitamin D levels and MS risk arises from a range of cohort and case-control 
studies. Studies collecting serum 25(OH)D before and at the time of MS onset both 
supported a dose–response relationship between vitamin D insufficiency and MS risk. 
One prospective cohort study with 25(OH)D collecting prior to MS onset showed that 
every 50 nmol/l increase in 25(OH)D was associated with a decreased odds of MS 
onset (OR 0.59 ,95% CI 0.36-0.97)
19
; 6) Biological plausibility: vitamin D encourages 
a more efficient and specific immune response, both adaptive and innate, and 
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encourages an anti-inflammatory and more tolerogenic state. Given MS is an 
autoimmune disease, these effects line up with the observed inverse associations 
between 25(OH)D and MS; 7) Coherence: studies in humans and animal models and 
cell culture line up, including the aforementioned studies of UV in EAE all supported 
a protective effect of higher 25(OH)D levels on MS onset; 8) Experiment: The criteria 
of experiment is somewhat difficult to be satisfied, as it is an essential nutrient for the 
general populations and it is obviously unethical to withhold vitamin D from the 
placebo group. Thus, current experimental evidence mostly comes from the effect of 
vitamin D supplementation in decreasing of disease activity. Including 49 MS 
patients, an unblinded randomized trial with a follow-up of 52 weeks found that 
treatment group patients had a reduction of T-cell proliferation and fewer relapses
21
; 
9) Analogy: The causal roles of vitamin D have been supported by Hill‘s criteria in 
several other diseases, such as overall cancer risk
22





. Thus, the analogy criterion was met. 
Table 2 shows some key studies assessing the association between 25(OH)D levels 
and MS clinical course. With the prospective cohort design of 145 RRMS patients, 
our group
135
 found that higher 25(OH)D levels were associated with reduced hazard 
of  relapses (HR: 0.90, p=0.016). All patients in this study were recruited in southern 
Tasmania from 2002 to 2005 and diagnosed using the 2001 McDonald criteria. This, 
along with the prospective cohort design, repeated measurement of 25(OH)D and 
sophisticated statistical methods provide strong support for the association between 
levels of 25(OH)D and relapses. Another prospective study
136
 with 469 MS patients 
found a significant association between 25(OH)D levels and MRI activity and 
disability progression, but found no association between vitamin D levels and risk of 
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relapses. As only white participants with relapsing-onset MS were included in this 
study, results in this study may not be generalisable to the entire population. However, 
repeated measurement of 25(OH)D and prospective study designs still supported the 
beneficial effects of 25(OH)D in MS disease activity. Martinelli el al
137
 conducted a 
prospective study of 100 CIS patients and found that decreased levels of baseline 
25(OH)D were associated with an elevated hazard of conversion to MS in a dose-
dependent manner. With a prospective design of 178 MS patients, Stewart and 
colleagues
138
 found a significant interaction between 25(OH) levels and interferon-β 
on hazard of relapses (pinteraction=0.003), with association of elevated 25(OH)D and 
lower hazard of relapses being found significant in patients with interferon-β 
administration. Other prospective cohort studies further supported the protective role 
of high 25(OH)D levels on MS clinical course
139-141
. In conclusion, a number of high-
quality prospective cohort studies supported the beneficial effects of increased 
25(OH)D on MS disease activity. However, the effects of 25(OH)D on long-term 
disability progression have been less definitely established. 
A number of prospective cohort study have shown that patients with MS had a 
decreased level of 25(OH)D since adolescence, the temporal relationship with 
exposures prior to outcomes indicated that the possibility that 25(OH)D is a negative 
acute phase reactant is low. Given the protective associations of vitamin D with MS 
onset and progression, it was hypothesised that vitamin D supplementation can reduce 
MS disease activity
142-145
.  Soilu-Hanninen and colleagues conducted a randomised 
trial including 66 RRMS patients using IFNB-1b use, showing no significant 
association between vitamin D supplementation and T2 burden of disease (p=0.105), 
new T2 lesions (p=0.29), and disability accumulation (p=0.07)
142
. A subsequent meta-





 including 5 RCT studies also showed that vitamin D supplementation did 
not reduce the odds of relapse (OR: 0.98, 95% CI: 0.45-2.16). Although current 
evidence from RCTs does not support therapeutic effects of vitamin D on MS 
development, firm conclusions are not yet possible due to limitations such as small 
sample sizes, heterogeneity of administered dosing, and distinct outcome measures in 
the current literature.  














145 MS patients 
Inverse association between deseasonalised vitamin D and 







469 MS patients 
Association between each 10 ng/mL increase in higher 25(OH)D 
and:  
Risk of a new T2 lesion (IRR: 0.85, 95% CI: 0.76-0.95, 
p=0.004);  
Risk of a gadolinium-enhancing lesion (IRR: 0.68, 95% CI: 
0.53-0.87, p=0.002);  
Subsequent EDSS (β: -0.047, 95% CI: -0.091to -0.003, 
p=0.037);  







100 CIS patients 
Association between 25(OH)D levels and conversion to MS:  
Patients with very low (< 10th percentile) (HR: 3.34, 95% CI: 
1.32-8.45) 








178 MS patients 
Association between 25(OH)D and relapse risk:  
IFN-β treated group (HR: 0.75, 95% CI: 0.66-0.84)  
Non-IFN-β treated group (HR: 0.97, 95% CI: 0.84-1.12);  









Every 10 nmol/L increase in 25(OH)D was associated with a 







73 MS patients 
Higher 25(OH)D levels were associated with a decreased relapse 







465 MS patients 
Each 20-ng/mL increment in 25(OH)D levels was associated 
with:  
57% lower rate of new active lesions (P < 0.001)  
57% lower relapse rate (P=0.03) 
25% lower yearly increase in T2 lesion volume (P <0 .001) 
0.41% lower yearly loss in brain volume (P=0.07)  
25(OH)D ≥50 nmol/L was associated with a decreased 
accumulation of EDSS (β: -0.17; P=0.004)  










Patients in the vitamin D group showed:  






Lower number of new/enlarging T2 lesions (p=0.286) 
Less decrease in number of T1 enhancing lesions (p=0.004) 
Reduced disability accumulation (p=0.071) 
Improved timed tandem walk (p=0.076) 







No association between high-dose vitamin D supplementation 
and risk of relapse  







170 MS patients 
After vitamin D supplementation, each 1 nmol/L increase in 
25(OH)D was associated with 
−0.014 (95% CI: -0.026 to -0.003,  p=0.02) decrease in ARR 
IRR, incidence rate ratio; ARR, annualised relapse rate; OR, odds ratio; HR, hazard ratio; CI, 
confidence interval 
2.5.3 Offspring number 
The sex ratio (female/male) of relapsing-onset MS patients increased from 2:1 to 3:1 
during the last two decades, and the continuously increasing incidence has been 
mostly driven by females
146 147
. Increasing sex ratio by year of birth was demonstrated 
by one longitudinal population-based study in Canada (r=0.84, p<0.001)
148
. Women 
of childbearing age are more susceptible to MS, which led to the hypothesis that 
reproductive factors—especially pregnancy—are associated with MS.  
The relationship between pregnancy and MS has been debated over the past 50 years. 
Relapse rate decreases significantly during pregnancy, especially in the third trimester, 
when compared to relapse rate prior to pregnancy; however, in the first 3 months 
postpartum, the relapse rate increases significantly (p<0.001), and then returned to the 
rates before pregnancy
149-152
. Decreases of relapse rate during pregnancy have been 
hypothesised to result from the increase of oestrogens levels. Previous in vivo 
research has found that oestrogen could modulate the profile of T helper (Th) cells, 
increasing levels of Th2 cells (which produce anti-inflammatory cytokines) and 
decreasing levels of Th1 cells (which produce pro-inflammatory cytokines)
153
.  
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However, the relationship between pregnancy prior to MS onset and risk of 
subsequent MS development is still a matter of controversy. A population-based 
national study
154
 of 4.4 million people who were born before 1989, and offspring 
number prior to MS onset, found that 6332 women and 3426 men were diagnosed 
with MS. The risk of MS for women with at least one child decreased approximately 
24% when compared with nulliparous women. With additional children, the risk of 
MS decreased further (RR: 0.87, 95% CI: 0.71-0.82). A similar association was also 
seen in men: cases with no less than one child before onset had a lower risk of MS 
when compared with men who had no children (RR: 0.89, 95% CI: 0.80-0.98). This 
study suggested that biological factors were not responsible for the protective role of 
pregnancy on MS onset. However, a case-control study
155
 conducted by our group 
found that giving birth to a child before onset was solely associated with reduced MS 
risk in women, whereas no association between offspring number and MS risk was 
seen in men. More well-powered prospective cohort studies are needed to confirm the 
link between pregnancy/offspring prior to MS onset and risk of MS development, 
especially whether higher offspring numbers confer a protective effect on men, and if 
so, the underlying mechanisms are definitely worth exploring.  
The long-term effects of pregnancy and childbirth on MS clinical course are not 
clearly defined. A retrospective cohort study
156
 including 675 relapsing-onset and 298 
progressive-onset patients found that a higher number of pregnancies was associated 
with lower hazard of sustained EDSS 6 (two or more pregnancies vs. never pregnant; 
HR: 0.66, 95% CI: 0.46-0.96) in relapsing-onset patients, whereas no association was 
seen in progressive-onset patients after controlling for age at onset and 
immunomodulatory treatment. This study also showed that a later age at menarche 
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(≥13) was associated with a lower hazard (HR: 0.61, 95% CI: 0.44-0.85) of disability 
progression in progressive-onset patients, but no association was seen in relapsing-
onset patients. Thus, the internal consistency of this study was poor. With the 
measurement of pregnancies after MS onset, another retrospective cohort study
157
 
with 445 women also found that parous women had a decreased hazard of reaching 
EDSS 4 and 6 (HR: 0.55, 95% CI: 0.36-0.86, p=0.008, and HR: 0.42, 95% CI: 0.22-
0.82, p=0.012, respectively). Ramagopalan and colleagues
158
 found that the 
association between having children after MS onset and decreased hazard of reaching 
EDSS 6 could be fully accounted for by age of MS onset. Another hospital-based 
retrospective cohort study
159
 with 277 women with MS found that the number of 
children was not associated with the hazard of progression to SPMS (OR: 0.93, 95% 
CI: 0.50-1.72, p=0.81). Including 254 pregnant and 423 non-pregnant women, Karp 
and colleagues
160
 found that pregnancy did not have a long-term effect on MS clinical 
course. Several limitations in these studies limited the ability to make conclusions 





, and the possibility of reverse causality between pregnancy 
and disability progression
138 
 (i.e., those with greater disability may have less 
children). Therefore, prospective cohort studies are needed to identify the association 
between preceding parity and subsequent disease activity and disability progression.  
2.5.4 Stressful life events 
Psychological comorbidity such as depression and anxiety is common in patients with 
MS
161





. Evidence about the association of SLEs and MS development is still 
sparse and controversial
163-169
. Some large cohort studies have tested the hypothesis 
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that SLEs in childhood and adulthood predispose to an increased risk of MS. Riise et 
al conducted a large prospective cohort study
165
 with two cohorts of female nurses (n 
= 121700; n = 116671), finding that general stressors at home or work during 
adulthood were not associated with the onset of MS (HR: 0.85, 95% CI: 0.32-2.26). 
This study also found that severe stressors such as physical and sexual abuse in 
childhood were also not related with MS development. With the follow-up time of 
approximately 63 million person-years in 3 million cases, another population-based 
cohort study
166
found that negative events prior to age 18 years (parental divorce, 
parental death, or death of a sibling) were associated with a higher risk of MS (RR: 
1.10, 95% CI: 1.03-1.20). However, this significant association was solely driven by 
parental divorce (RR: 1.13, 95% CI: 1.04-1.23), whereas parental death or death of a 
sibling showed no association with MS development. A nationwide population-based 
cohort study
167
in Denmark found a higher hazard of MS onset (HR: 1.56; 95% CI: 
1.05-2.31) in patients who lost a child unexpectedly. Higher exposure to adverse 
events in childhood was also found to be associated with an earlier onset in patients 
with MS (r=-0.3, p=0.04)
170
. However, the aforementioned studies did not control for 
possible confounders such as tobacco smoking or vitamin D levels, which may limit 
the validity of the results. Due to the inconsistent results and design deficits, no firm 
conclusions can be made from these studies. Current research does not support a 
major role of SLEs in MS development.  
Mounting evidence has suggested that SLEs, especially negative SLEs, may play a 
role in MS exacerbations. Most patients believed that stressors were responsible for 




 in 2003 including 14 studies 
demonstrated that previous SLEs were associated with a higher risk of subsequent 
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exacerbation (p<0.0001). A subsequent systematic review
173
 found that most research 
showed predisposed SLEs were associated with a higher risk of MS onset or 
exacerbations. Due to the diversity of SLE measurement, MS diagnosis, study design, 
and patients recruited, meta-analysis was not suitable to perform and no firm 
conclusion could be drawn from the included studies.  
The link between MS and altered regulation of the hypothalamic-pituitary-adrenal 
(HPA) axis
174
 supports the hypothesis that the psychobiological stress system interacts 
with the pathological process in MS natural history. Elevated glucocorticoid 
responsivity
175
 in patients with MS also supports this pathological process. Research 
has also shown that impairment of the HPA axis is associated with disability 
progression
176
 and brain atrophy
177
 in MS patients. 
Based on the findings that negative SLEs may induce MS exacerbations, some trials 
have explored the effects of psychiatric interventions in MS clinical course. Mohr and 
colleagues performed a randomised trial
178
 including 121 relapsing-onset patients, 
finding that a stress management programme could reduce the MRI activity during the 
treatment period (24 weeks), whereas in the post-intervention period (24 weeks), the 
effects were not detectable. This study also found no difference in the clinical 
exacerbation or disability progression between the treatment group and the control 
group. Failure to maintain the behavioural interventions after the treatment session
179
 
may limit the internal validity of this study, but the association between behavioural 
intervention and MS clinical course is still uncertain. 
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2.5.5 Genetic factors 
MS is caused by an interplay of environmental and genetic factors. Data on familial 
recurrence rates of multiple sclerosis support the aetiological roles of risk genes. A 
population-based study
11
 in Sweden with 28,396 MS patients demonstrated the 
existence of parent-of-origin effect, however, the significantly increased relative risk 
was only observed among paternal relations but not maternal relations. The authors 
assumed that the ―carter effect‖ may lead to this phenomenon, which means that male 
patients need more risk genes to develop disease. Collecting three cohorts of patients 
with MS in Australia, O‘Gorman et al
12
 found that the age-adjusted relative risk for 





to a similar overall genetic susceptibility between Australia and the northern 
hemisphere, this study suggests that environmental factors may explain the difference. 
All these studies demonstrated the phenomenon of familial aggregation in patients 
with MS. 
The association between genes encoding the major histocompatibility complex 
(MHC) and susceptibility of MS has been discussed extensively. With the genome-
wide association study (GWAS) approach, 6 loci in human leucocyte antigen (HLA) 
and 110 established variants outside the HLA have been confirmed to be associated 
with the onset of MS
127 184-186
. Among all suspected genetic variants, HLA-
DRB1*15:01 showed the single strongest association with MS onset
187






  have evaluated the relationship between specific genetic risk 
alleles and MS clinical characteristics. A cross-sectional study
190
 with 180 MS 
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patients in Japan found that the presence of HLA-DRB1*04:05 genotype was 
associated with increased IgG index and oligoclonal IgG bands in CSF, whereas no 
association was seen between HLA-DRB15 genotype and CSF findings. Using a 
GWAS approach, another large cross-sectional study
189
 with 5142 MS patients also 
found that HLA-DRB1*04 alleles were associated with the presence of oligoclonal 
bands in CSF. HLA-DRB1*15 alleles in this study were associated with the status of 
oligoclonal bands.  
With respect to the analysis of genetic factors in ASO, mounting studies showed that 
presence of HLA-DRB1*1501 risk allele was associated with earlier onset
127 191 192
. 
With 154 patients available for genetic data, Bove et al
193
 showed that patients with at 
least one HLA-DRB1*1501 risk allele showed a 3.4-years earlier onset (95% CI: 
26.42-20.37, p=0.028). Other genotypes such as HLA-DRB1*0801
194
 also showed 
some effects on delaying the onset of first symptom for approximately 5 years 
(p=0.01). With the calculation of a genetic risk score of 107 established genetic 
variants, a subsequent study
195
 found a significant interaction (p=0.014) between 
genetic risk score and phenotypes of MS on age at onset: a higher genetic risk score 
was associated with an earlier onset in relapsing-onset patients (r=-0.1, p=0.005) and 
a delayed onset in progressive-onset patients (r=0.07, p=0.15).  
However, the association between genetic variation and MS clinical course is still 
uncertain
196
. When adding 61 established MS-associated SNPs to a MS genetic 
burden score, a cross-sectional study
197
 with 1997 MS patients found that a higher 
score was associated with an earlier age at onset (p=2.65 × 10
-4
). However, this study 
found no relationship between the MS genetic burden score and MSSS. A prospective 





 following 141 RRMS patients for an average of 2.3 years found that 
five MS risk-associated SNPs were associated with relapses, whereas no SNPs were 
associated with annualised change in disability. The study had limited power, and the 
associations were non-significant after adjusting for multiple comparisons. A 
subsequent study
40
 with 127 participants with a diagnosis of a first demyelinating 
event at study entry found that seven non-HLA SNPs were associated with the 
hazards of conversion to MS and of relapses, and another seven non-HLA SNPs were 
associated with annualised change in disability as measured by EDSS. For this study, 
small sample size may limit the significance, as all associations became non-
significant after multiple comparisons; however, dose dependency, internal validity, 
and positive results of cumulative genetic risk score assessment supported a potential 
relationship between genetic risk factors and MS disability progression. 
2.6 Diagnosis of MS 
Although in most cases, clinical symptoms and MRI signs are sufficient for the 
diagnosis of MS, differentiating it from other neurological demyelination diseases 
such as neuromyelitis optic spectrum disorder and acute disseminated 
encephalomyelitis is still difficult in atypical MS patients. Accuracy has been 
considerably increased due to advances in MRI and other examinations such as 
serological and genetic testing, but misdiagnosis still occurs. Since most therapies are 
only effective in patients in the relapsing-remitting phase, early diagnosis of MS is 
essential.  
The first episode of demyelinating dysfunction with no evidence suggesting previous 
symptoms is referred to as CIS
1
. The definition of CIS is an episode of neurological 
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dysfunction (acute or subacute) that lasts more than 24 hours, without evidence of 
fever, infection, or encephalopathy. Spontaneous remission after the attack is the most 
essential clinical feature, whereas other signs such as onset at younger age and 
maximum deficit occurring at approximately 4 weeks after onset can further support 
the diagnosis
199
. The most common clinical symptoms for people with CIS are brain 
stem dysfunctions, partial myelitis, and unilateral optic neuritis
200
.  Even with long-
term follow-up, approximately one third of patients show a monophasic course and 
never convert to MS
70 201
. Slowly progressive symptoms that last over a period of 
months may suggest the diagnosis of primary progressive MS, and clinical signs such 




Due to its high sensitivity, reproducibility, and non-invasiveness, MRI has been 
commonly implemented as a diagnostic tool. Standardised protocols (e.g., 
MAGNIMS) aid in the diagnosis of MS
203
. Abnormal MRIs are present in nearly all 
MS patients
204
 and more than 80% of CIS patients
70
. Typical multifocal T2-weighted 
signs are mostly located at periventricular, juxtacortical, and infratentorial regions
205
. 
T1-weighted lesions mostly appear hypointense while being enhanced after the 
administration of gadolinium. Following 121 CIS patients for more than 5 years, 
Sombekkeet al
206
 found the odds of conversion to MS (OR 3.53, 95% CI 1.52-8.17) 
was significantly higher when compared patients with focal lesions in spinal cord to 
patients who did not have. Recruitment of participants was from one tertiary referral 
centre may influence the generalisation of the results. 
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For patients with typical clinical symptoms and findings on MRI, the CSFtest is not 
necessary, but it still could provide supportive evidence for the diagnosis of MS. 
More than 90% of MS patients and 68.6% CIS patients
207
show elevated IgG 
oligoclonal bands in the CSF that are absent in serum
208
. Abnormal CSF results could 
also be found in some other inflammatory diseases of the CSF; thus, the chance of a 
false-positive result should be considered. Evoked potential is another method for a 
supported MS diagnosis, and it could identify the clinically silent lesions in the 
CNS
209
 and dissemination of lesions in space. A test of aquaporin 4 IgG in serum can 
assist in the differentiation between MS and neuromyelitis optica spectrum disorder, 
which is now confirmed to be a different disease
210
.  
2.6.1 McDonald Criteria 
Dissemination of lesions in space and time are essential for an MS diagnosis. 
Alternative diagnoses should be considered and excluded. In the past, the diagnosis of 
MS
211
 was based on clinical grounds alone: two separate attacks from two or more 
lesions. However, with the developments in MRI, new criteria are not based on the 
clinical findings alone.  
For the diagnosis of RRMS, dissemination in space requires one or more lesions in at 
least two of four locations: periventricular, juxtacortical, infratentorial, and spinal 
cord. Symptomatic lesions at the brain stem and spinal cord are not included. 
Dissemination in time from MRI scans could be presented as new lesions that emerge 
on follow-up scans or the simultaneous presence of asymptomatic gadolinium-
enhancing and non-enhancing lesions. It was shown that the diagnosis of MS could be 
made approximately 17 months earlier when the updated diagnostic criteria were 





; and, with the implementation of MRI, one third of patients can be 
diagnosed with MS during the first relapse. 
Due to slow disease progression, the diagnosis of PPMS can be confirmed only after 1 
year from disease onset. To satisfy the diagnostic standard of dissemination in space, 
two of the three requirements should be met: one or more T2-weighted lesion at three 
characteristic regions (periventricular, juxtacortical, and infratentorial), two or more 
lesions at the spinal cord, and positive findings in CSF.   
Fulfilment of MRI criteria can also be found in patients with other CNS conditions, 
such as other inflammatory diseases, small vessel cerebrovascular disease, and even 
in healthy individuals
213 214
. Therefore, the application of MRI criteria is only suitable 
for patients with clinical symptoms suggestive of MS
199
. 
The previous discussion was based on the 2010 version of McDonald criteria. To 
facilitate an earlier diagnosis, some changes have been made in the 2017 version
1
. In 
summary: 1) for patients with a typical CIS, a dissemination in space (supported by 
clinical or MRI demonstration) and the positive test of CSF-specific oligoclonal bands 
allows the diagnosis of MS
2 3
; 2) for patients with supratentorial and infratentorial 
lesions or spinal cord syndrome, symptomatic lesions could be used to demonstrate 
dissemination in space or time
4 5




The diagnostic criteria has been evolved over the years. Some researchers have 
argued that the improvement in the sensitivity of diagnostic criteria may influence the 
risk of conversion. Recently, a prospective cohort study
7
 (published in JAMA 
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neurology) following 229 patients for 65 months showed that the updated diagnostic 
criteria (2017) had an increased sensitivity (68% vs. 36%, p<0.001) and a decreased 
specificity (61% vs. 85%, p<0.001) compared to criteria 2010. Since no patient had a 
neuropathological confirmation of MS, using sensitivity and specify to evaluate the 
diagnostic criteria is somewhat problematic. Another cohort study following 131 
patients presenting with symptoms suspicious for MS for 2 years found that 64% of 
the patients fulfilling McDonald 2010 criteria did not convert to CDMS
225
. Some 
limitations such as the registry-based design, insufficient time of follow-up, and 
higher rate of missing cases during follow-up may bias the results. However, some 
other studies
4 5
 have suggested that inclusion of symptomatic lesions would not 
influence the specificity of the new diagnostic criteria. Following 1,107 CIS patients 
prospectively, Tintore et al
5
 found that risk of second relapse was similar between 
patients with single asymptomatic lesion on MRI and patients with a symptomatic 
lesion. Following 30 patients‘ conversion from CIS to CDMS, another small study
4
 
with 30 patients found that the inclusion of symptomatic lesion led to the increase of 
sensitivity (80% to 87%) but the specificity remained stable (77% to 80%). In 
summary, the updated could obviously diagnose more MS patients with minor 
symptoms, however, some evidence still suggested that clinicians should bear in mind 
that the specificity may decrease when the new diagnostic criteria is applied, 
especially when early DMTs were administered. 
2.7 Treatment of MS 
2.7.1 Treatment for relapsing-remitting MS 
Therapeutic options for RRMS have expanded markedly since the first drug 
(interferon-beta) was approved on 1993
221
. More than 10 disease modifying drugs 
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have been approved for the modulation of disease activity in MS patients at the 
relapsing stage. Although the growing number of RCTs has confirmed that disease 
modifying therapy can influence the accumulation of irreversible nerve damage, their 
long-term effects are still suboptimal. People with MS respond differently to the same 
treatment; therefore, personalised therapy is necessary. Unsatisfactory response calls 
for a prompt shift of the treatment, but side effects of the treatment should be 
evaluated carefully. Escalation therapy should be considered in patients who do not 
respond, whereas in the case of adverse effects, another lower risk drug should be 
tried.   
Previous research focused primarily on the reduction of relapse frequency and 
disability accumulation. However, with the emergence of increasingly effective 
therapeutic options, researchers have shifted the goals of therapy towards the concept 
of ―no evidence of disease activity‖
222 223
, complete prevention of relapses, MRI 
activity, and disability accumulation. The treatment for RRMS patients should be 
administered at an early stage to facilitate better control of the aberrant immune 
system
224 225
. A prospective cohort study
226
 following 215 patients for a minimum of 7 
years found that sustaining no disease activity for 2 years was associated with a better 
prognosis, as 78.3% did not have disability progression (EDSS change <0.5) after 7 
years. However, 46% of patients could maintain no evidence of disease activity status 
for 1 year; however, the proportion decreased significantly to 27.5% during the 
second year and only 7.9% after 7 years. This study indicated that sustaining long-
term no evidence of disease activity was a difficult target to achieve in clinical 
practice, although it could predict a reduced disability accrual. To monitor the 
treatment effects closely, serial MRI scans are critical. For patients with no response 
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to their current treatment, MRI scans should be acquired every 12 months or more 
frequently
227
.   
Following we will discuss some therapeutic options for RRMS, and several key 
studies are listed in Table 3. As a naturally occurring cytokine, interferon-β was the 
first drug approved for RRMS. The major effect of interferon-β is anti-
inflammation
228
. A number of RCTs have supported that interferon-β could reduce the 
relapse rate and disability progression for patients diagnosed with RRMS
229-232
. Via 
the induction of the proliferation of glatiramer-acetate-specific lymphocytes, which 
can cross the blood-brain barrier, glatiramer acetate also has anti-inflammatory 




As a sphingosine 1-phosphate (S1P) receptor modulator in vivo, fingolimod could 
limit autoreactive lymphocytes in lymph nodes to inhibit their infiltration into the 
CNS. Fingolimod was ineffective in the MS animal model (experimental autoimmune 
encephalomyelitis, EAE) that was selectively deficient for S1P1 on astrocytes, which 
suggested that fingolimod had direct effects in the CNS. A 24-month RCT trial
234
 
with 1033 RRMS patients found that the annualised relapse rate decreased from 0.4 to 
0.18 when compared with the placebo group. Patients treated with fingolimod were 
also superior to the placebo group with regard to other endpoints such as disability 
progression and disease activity on MRI.  
Teriflunomide
235
 inhibits the proliferation of autoreactive B and T lymphocytes and 
induces the proliferation of anti-inflammation cytokine profiles. Three RCTs
235-237
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have been conducted and have found that the efficacy of teriflunomide was similar to 
that of interferon-β. 
Ocrelizumab is a monoclonal antibody that could inhibit CD20+ B cells. Conducting 
an RCT with 1656 RRMS patients
238
, ocrelizumab significantly reduced the relapse 
rate by approximately 50%, and compared with interferon-β, it reduced the disability 
progression by 40%. 
2.7.2 Treatment for progressive MS 
Compared with treatment for RRMS, therapies for PPMS are limited. As shown in 
Table 3, although two studies
239 240
 have shown a beneficial effect of interferon-β on 
PPMS patients, other studies all showed negative results
241-244
. A subsequent 
combined analysis
245
 found that the divergent results of interferon-β on progressive 
MS patients resulted from the degree of disease activity of the chosen samples, and 
that samples enriched with patients with high relapse rates and MRI lesion activity 
were associated with positive findings. As discussed previously, fingolimod could 
directly enter the CNS, so it was hypothesised that it may slow the disability 
progression in patients with PPMS. However, a recent RCT
246
 study found that there 
was no effect of fingolimod administration on disability progression. All these studies 
suggested that anti-inflammatory therapy could not slow disability progression in 
patients with PPMS. Based on the theory that B cells play an essential role in the 
pathogenesis of PPMS, one RCT study
247
 with 439 PPMS patients found that the 
volume of T2 lesions significantly decreased (p<0.001), although the progression of 
confirmed disability was not slowed. However, a subgroup analysis restricted to 
patients aged less than 51 years showed a significant association between rituximab 
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use and delayed time to confirmed disability progression (HR: 0.52, p=0.010). 
According to these results, another phase 3 RCT study
248
 recruiting participants with 
relatively younger age and shorter disease duration found that 12-week/24-week 
confirmed disability progression was delayed in patients with ocrelizumab use when 
compared to a placebo group (HR: 0.76, 95% CI: 0.59-0.98, p=0.03; HR: 0.75, 95% 
CI: 0.58-0.98, p=0.04). Secondary endpoints such as volume of T2 lesions and total 
brain volume loss were also significantly different between the ocrelizumab group 
and the placebo group. Disparity in the results between two anti-CD20+ B cell 













RCT, test association 
between  interferon-β 
and disease activity in 
RRMS patients 
dose 22 μg n = 
189 
dose 44 μg  n = 
184 
Placebo n = 187 
Time to confirmed disability 





RCT, test association 
between  daclizumab 
and disease activity in 
RRMS patients 
daclizumab n = 
919 
interferon-β n = 
922 
Daclizumab vs.  interferon β 
ARR (0.22 vs. 0.39, p<0.001) 
New or enlarged T2 lesions (4.2 vs. 
9.4, p<0.001) 
confirmed disability progression (16% 





RCT, test association 
between  fingolimod  
and disease activity in 
RRMS patients 
dose 1.25 mg n = 
429 
dose 0.50 mg n = 
425 
Placebo      n = 
418 
Fingolimod 1.25 mg ARR: 0.16 (0.13-
0.19); EDSS: –0.03 ± 0.88 
Fingolimod 0.5 mg ARR: 0.18 (0.15-
0.22); EDSS: 0.00 ± 0.88 
Placebo ARR: 0.40 (0.34-0.47); 
EDSS: 0.13 ± 0.94 
European 




RCT, test association 
between  interferon-β 
and disability  in SPMS 
patients 
Interferon-β n = 
360 
Placebo n = 358 
Time to confirmed disability 






RCT, test association 
between  interferon-β 
and disability  in SPMS 
patients 
Interferon-β n = 
217 
Placebo n = 219 
MSFC Z-score change was reduced 





RCT, test association 
between  interferon-β 
and disability  in SPMS 
dose 22 μg  n = 
209 
dose 44 μg  n = 
Time to confirmed disability 
progression: (interferon-β 44 mg vs. 
placebo: HR: 0.83, 95% CI: 0.65-1.07; 










RCT, test association 
between  interferon-β 








 n = 
314 
Placebo n = 308 
Time to confirmed disability 






RCT, test association 
between  interferon-β 
and disability in SPMS 
patients 
Interferon-β n = 
186 
Placebo      n = 
178 
Time to confirmed disability 






RCT, test association 
between  Glatiramer 
and disability in PPMS 
patients 
Glatiramer n = 
627 
Placebo n = 316 
Time to confirmed disability 






RCT, test association 
between fingolimod 
and disability in PPMS 
patients 
Fingolimod n = 
336 
Placebo n = 487 
Time to confirmed disability 






RCT, test association 
between rituximab 
and disability in PPMS 
patients 
Rituximab  n = 
336 
Placebo n = 487 
Time to confirmed disease 
progression: (38.5% placebo, 





RCT, test association 
between ocrelizumab 
and disability in PPMS 
patients 
Ocrelizumab n = 
488 
Placebo n = 244 
Time to confirmed disability 
progression: (HR: 0.76, 95% CI: 0.59-
0.98; p=0.03) 
RCT, randomised controlled trial; RRMS, relapsing-remitting MS; SPMS, secondary progressive MS; 
PPMS, primary progressive MS; HR, hazard ratio; CI, confidence interval; OR, odds ratio; EDSS, 
expanded disability status scale; ARR, annualised relapse rate; MSFC, MS functional composite. 
 
2.7.3 Complementary and alternative treatments 
In conjunction with pharmacological treatments, complementary and alternative 
treatments (CAMs) such as cannabis, diet, exercise, and psychological approaches are 
commonly applied to ease the symptoms in patients with MS. During the clinical 
course, almost every patient with MS reports having tried CAMs
251
.  
Some RCT studies showed that cannabis extract such as Sativex or 









 in patients with MS. While the literature is still 
limited, current studies favour the beneficial effects of cannabis administration. The 
effects of vitamin D on patients with MS have been discussed previously. Here we 
Chapter 2: Literature review of multiple sclerosis 
57 
 
will discuss another dietary extract: polyunsaturated fatty acid (PUFA). Torkildsen et 
al
257
 conducted a RCT study with 92 patients with MS, and they found that PUFA 
supplementation was not associated with relapse rate or disability progression. They 
also found no difference in fatigue and quality of life between the PUFA 
supplementation group and the control group. With more than 80% follow-up, this 
study was classified as class-II RCT according to Evidence-Based Spine- Care 
Journal (2013)‘s standard
258
. Another RCT study found that additional 
supplementation of PUFA was associated with decreased relapse rate and disability 
level, however, small sample size (n=65), great loss of follow-up (35%) and not using 
a rigorous statistical method made it difficult to interpreter the results
259
.Current 
studies could not conclude the association between diet and MS clinical course, 
however, converging evidence did not support a beneficial effect of dietary 
supplementation (vitamin D or PUFA) in patients with MS. 
A number of studies showed that exercise could improve the ability of mobility
260
 







patients with MS. A meta-analysis
267
 with 600 MS patients found that exercise 
training improved walking mobility among MS patients with the effect size of 0.19 
(95% CI: 0.09-0.28). Some studies also showed a significant association between 
exercise and the improvement of psychological status
262 263
. However, an association 
between exercise and MS clinical course is still less certain, although some studies 





. Short duration of follow-up
270
 and absence of a correct 
temporal relationship
271
 still hinder the reliability of current evidence.  
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A number of RCT studies showed that cognitive-behavioural therapy (CBT), which  











 in patients with MS. 
However, like exercise studies, the current literature does not provide a robust 
evidence supporting the beneficial effects of psychological intervention on MS 
clinical course. As previous discussed, the RCT study conducted by Mohr et al
178
 
showed the reduction of enhancing lesions (p=0.04) in patients with stress 
management therapy could last only 24 weeks post-treatment.   
Overall, the current treatments can partly prevent the occurrence of disease activity, 
whereas for disability progression and conversion to progressive disease, none of the 
treatments were effective. Effects of CAMs should be considered rigorously based on 
current studies. Therefore, the prevention of MS progression from other perspectives 
such as the modification of environmental/behavioural factors is needed. Also, the use 
of lifestyle interventions that could complement existing treatment is appealing for 
patients, as they generally have no side effects and result in an increased level of 
perceived control over the disease.   
2.8 Summary 
MS is a demyelinating disease of the CNS, and according to the pattern of relapses 
and disability progression, it can be divided into relapsing-onset disease and 
progressive-onset disease. Inflammation is responsible for the disease activity, 
whereas disability progression is largely due to neurodegeneration. Environmental 
risk factors such as smoking, low vitamin D levels, low exposure to UVR, and high 
immune response to EBV infection increased the risk of MS at the population level. 
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However, their role in MS disease activity and disability progression is less certain. 
Translating the findings to intervention and prevention of MS is still immature. 
Dissemination of lesions in time and space is the core to the diagnostic criteria of MS. 
Current treatments can partly prevent disease activity for patients with RRMS, and a 
phase 3 trial supported the effects of ocrelizumab on patients with PPMS. 
2.9 Postscript 
This chapter provided some key information, which will aid in the understanding of 
the rest of the thesis. However, this chapter has not discussed the association between 
viral infections and MS development and progression, which will be discussed in the 
next chapter. 
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Chapter 3 Review of the association between human 
herpesvirus & human endogenous retrovirus and MS onset 
& progression 
3.1 Preface 
In this chapter, we will review the role of viral infections on MS development and 
progression, and some assumptions about the mechanisms underlying these 
associations. This chapter has been published in the Journal of the Neurological 
Sciences, (2017) vol 372, page 239-249. The typeset version of the manuscript as it 
appeared in the journal is in Appendix.  
3.2 Abstract 
This review discusses the role of EBV, HHV6 and human endogenous retroviruses 
(HERVs) in the onset and progression of MS. Although EBV has been established as 
one of the causal factors in MS onset, its role in MS progression is still uncertain. 
Moreover, interactions between EBV and other risk factor on MS development still 
need more investment. With less consistent evidence than EBV, HHV6 has also been 
implicated in the pathogenesis of MS; moreover, it showed a closer connection with 
the disease activity. Recent studies found that HERVs were associated with the 
development and progression of MS. Some antiviral treatments have shown promise 
for clinical interventions in the future. Future studies are yet needed to fully clarify 
the role of these agents in MS onset and disease course and the modes by which they 
realise these effects. 
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Multiple sclerosis (MS) is a chronic and progressive inflammatory disease, causing 
demyelination, axonal loss and atrophy of the central nervous system. The aetiology 
of MS is due to interplay between genetic and environmental/behaviouralfactors
1 2
. 
For genetic factors, associations between the HLA-DR locus and MS have been 
consistently demonstrated, with the strongest of these being HLA-DRB1*1501
3 4
. As 
previously discussed in Chapter 2, a number of environmental and behavioural 




,are now viewed as causal factors. In 
addition to these, viral agents, particularly Epstein-Barr virus (EBV), human 
herpesvirus 6 (HHV6)
7
 and human endogenous retroviruses (HERVs)
8
, are thought to 
have an involvement in MS onset and progression.  
This review discusses the role of EBV, HHV6 and HERVs in the onset and 
progression of MS. It focuses on the key epidemiological studies investigating the 
role of these viruses in disease, as well as interactions between these viruses and other 
risk factors, and the potential mechanisms underlying these associations. Finally, the 
potential of interventions targeting these agents and their modes of effect in the 
prevention and treatment of MS will be discussed.  
3.4 Epstein-Barr virus 
3.4.1 What is Epstein-Barr virus? 
EBV is a member of the human herpesvirus family and mainly infects B lymphocytes 
and epithelial cells. Viral parameters including Epstein-Barr nuclear antigen (EBNA) 
complex, which includes EBNA-1, 2, 3a, 3b, 3c and leader protein, viral capsid 
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antigen (VCA), early antigen (EA) and EBV DNA (used to define viral load) are 
often used in EBV research. EA is observed at the early phase of EBV infection and 
only expressed during the lytic stage (active replication). EBV DNA can be found in 
serum at initial infection or during reactivation from the latent phase. In a clinical and 
research setting, initial infection is characterised by the rise of IgM antibodies against 
VCA, while at and after convalescence, these anti-VCA IgM antibodies decrease 
while IgG against VCA and EBNA-1 emerge and increase 
9
. EBNA-2 antibodies 
appear in the acute phase of EBV infection and decline during convalescence, 




Infected B-cells are immortalised and remain infected for life. Most infected B-cells 
are removed from circulation after the attack of cytotoxic T lymphocytes, while some 
remaining infected B-cells survive and enter the latent phase. EBV genomes exist as 
episomes residing in roughly one per million B-cells at this stage
11
. According to the 
variation of genetic expression in different cell lines, the latent stage is divided into 
three programs: type I is characterised by the multiplication of EBV genomes while 
B-cells are dividing, while B-cell differentiation and activation of naive B-cells are 
the feature of type II and type III, respectively. EBV genomes exist as episomes 
residing in one in a million B cells at this stage
11
. However, while other mechanism of 
reactivation may exist, subsequent infections of the EBV-infected B-cells may induce 
stimulation and activation of the B-cell from the latent phase (reviewed in reference
12
). 
In addition to the constant expression of EBNA-1 in all three latency stages, other 
EBNAs and LMPs are only expressed in the second and/or third latency stage. During 
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the latency stage, persistent EBV-infected B-cells are under control by cell-mediated 
immunity
13
; however, in conditions of lowered immunocompetency, EBV infection is 
associated with higher risk of malignancies
14
. 
EBV infection during childhood is usually asymptomatic, infection at or after 
adolescence manifests as a symptomatic infection termed infectious mononucleosis 
(IM) or glandular fever.  
3.4.2 Prevalence of EBV infection 
The marked difference in seropositivity between MS patients and healthy controls 
was one of the earliest findings implicating EBV as a risk factor in MS. While EBV is 
ubiquitous in the general population (~90%), in MS patients this approaches 100%
15 16
. 
This being so, EBV infection is thought to be a necessary component of MS aetiology, 
and it has recently been suggested that EBV would be detected in every MS patient if 
detection techniques were sufficiently sensitive
17
. A meta-analysis reported that when 




3.4.3 Infectious mononucleosis and MS risk  
It has been consistently demonstrated that a history of IM has a positive relationship 




 demonstrating a 
relative risk for MS greater than 2.0. The effect of IM on subsequent MS risk is long-
lasting
21
. A direct relationship between latitude and variation in winter ambient UV 
has led to the hypothesis
22 23
 that differences in winter ambient UV underlies the oft-
cited latitudinal gradient in MS prevalence and incidence
24 25
. However, others have 
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suggested that different frequencies of exposure to EBV - particularly infections after 
childhood leading to IM
18 26
 - may also contribute to this variability by latitude. Both 
IM and MS exhibit a positive latitudinal gradient of prevalence in temperate latitudes 
but are rare at tropical latitudes, and have a positive association with socioeconomic 
status
27
. However, no consideration of some important confounders such as ethnicity, 
socioeconomic status, and environmental/behavioural factors may have influenced the 
validity of the findings. Certainly, however, EBV, UV and other factors are not 
mutually exclusive, and may even interact with one another
28 29
.  
3.4.4 EBV biomarkers and MS onset 
The association between a history of infection and the risk of MS onset has been 
evaluated by many case-control studies and pooled analyses
15 30 31
, all which showed a 
strong relationship between EBV seropositivity and MS risk. Also supportive of a true 
association is the very strong and dose-dependent associations observed for anti-EBV 
serological parameters, with the strongest associations seen for anti-EBNA (anti-
EBNA complex, anti-EBNA 1 and anti-EBNA2 all showed significant association 
with MS risk) 
32-35
. Moreover, the evidence supporting the temporal relationship has 




Direct detection of EBV DNA, referred to as viral load, in cerebrospinal fluid (CSF) 
or peripheral blood suggests a role for EBV reactivation in MS clinical course. In the 
absence of a molecular mimicry mode of action (discussed later), such reactivation is 
the most obvious direct mechanism by which the virus could modulate disease risk 
and particularly disease course later in life. However, the frequency of EBV DNA 
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positivity in CSF or peripheral blood has generally shown no clear differences 
between MS patients and controls
37-40
. Assessing EBV DNA in both latent and lytic 
phases through examining the viral load from peripheral blood mononuclear cells 
(PBMCs) and serum also found a no difference when comparing 55 MS patients with 
51 matched other neurological disease patients
37
. Actually, EBV DNA has been 
infrequently detected in any body fluid at any stage of MS
41
. Detection of antibodies 
to EA also indicates EBV reactivation, but as for EBV viral load, most studies could 
not find an association between anti-EA Ig and MS risk: a recent meta-analysis 
including 14 studies showed no association
31
. These results suggest there is no strong 
link between EBV reactivation and MS risk. 
3.4.5 EBV biomarkers and MS clinical course 
The links found between EBV infection and MS risk led naturally to investigations 
for a role for EBV in MS clinical course, including relapse, disability progression and 
magnetic resonance imaging (MRI)-detected disease activity. Most studies, although 
not all
42
, have found that EBV reactivation (anti-EA IgG or EBV DNA) is infrequent 
during the progression of MS, and not associated with disease activity
41 43-45
. 
Following 19 MS patients for 1 year, IgA, IgM and serum DNA to EBV were found 
only in patients during exacerbations
42
. Although the study design was a prospective 
cohort study, the 19 patients were selected from 108 hospital-based CDMS patients 
caused the selection bias and decreased the external validity of the results. Another 
study found that levels of EBV-specific CD8
+
 T-cells were more common during 
active disease compared to remission (19% vs. 39%, p=0.05)
46
, suggesting that the 
ability to control EBV infection was associated with disease activity. Perhaps 
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supporting this finding, a single SPMS case study wherein supplementation with 
autologous anti-EBV CD8
+
 T-cells produced measurable clinical benefits
47
.  
Anti-EBNA IgG is the parameter most frequently used to analyse immune response to 
EBV and its association with MS disease activity. Current studies have suggested that 
anti-EBNA is stable during MS course
34
, one study even finding that anti-EBNA 
remained stable after the use of disease modifying therapy
48
. In a prospective study of 
147 clinically isolated syndrome patients, elevated anti-EBNA1-IgG titres were 
associated with higher hazard of conversion to MS (McDonald Criteria
49
) during 
seven years of follow-up (HR=2.2, 95% CI:1.2-4.3; p=0.003)
50
, but adjustment for 
other covariates attenuated the association and rendered it nonsignificant (HR=1.6, 95% 
CI: 0.9-3.0; p=0.13).A recent prospective cohort study
51
 also found no association 
between baseline anti-EBNA1 levels and subsequent conversion to CDMS, and our 
study
52
 also found no association with relapse in prevalent cases. A paediatric study 
found a stronger effect between EBV seropositivity and subsequent CDMS risk in 247 
patients (HR 3.58, 95% CI 1.62-7.91)
53




 with 5 and 7 years of follow-up, respectively, showed a 
positive association between anti-EBNA1 IgG titres and increase in EDSS. Anti-
EBNA1 IgG titres were significantly correlated with change in EDSS (r
2
=0.3, 
p=0.004), while another study found baseline anti-EBNA1 IgG titres were associated 
with EDSS in the first and fifth year of follow-up, respectively (r=0.21; p=0.015 & 
r=0.25; p=0.01). Associations between anti-EBV immune response with subclinical 
MRI-detected pathological changes, including lesion metrics and atrophy, were 
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another method to evaluate the relationship with clinical course. For instance, lesion 
volume or number measured by MRI has been associated with anti-EBNA1 IgG titre
45 
50 54
. Anti-VCA IgG was also found to be associated with MRI-detected total brain 
atrophy and increased lesion volume
55
.  
Overall, the association between EBV biomarkers and MS activity is less consistent 
than that seen for onset. Evidence tends to support a relationship between anti-EBV 
level and MRI activity or disability progression, but is less convincing for relapse or 
conversion to CDMS. If a significant relationship between EBV infection and MS 
clinical course exists, the impact on MS pathology may not be substantial enough to 
alter clinical symptoms as the observation interval of most studies was less than five 
years. Longer observation periods are required to better understand the relationship, if 
any, with clinical course. 
3.4.6 Association between EBV and other risk factors on MS risk 
Beyond direct associations of EBV infection and clinical outcomes, EBV has been 
shown to interact with other risk factors in predicting MS onset.  
EBV & genetic risk factors 
A number of studies
56-61
 (Table) demonstrated a significant interaction between EBV 
infection and HLA-DR15 on MS risk. A significant additive interaction between 
history of IM and HLA-DR15 genotype (Synergy index, 3.78; p=0.03), indicating that 
the combined effect of IM andHLA-DR15 was larger than expected based on the sum 
of their individual effects, was found using a multicentre case-control study
56
 with 
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282 cases with a first clinical diagnosis of demyelination. Another case-control 
study
57
 also found a significant additive interaction, with synergy index 2.09. 
Multiplicative interaction between IM and HLA-DR15 was not significant in most 
studies, however
56 57 62
. In terms of levels of immune response to EBV, most studies
56 
62-65
 have found no significant interaction between anti-EBNA IgG and HLA-DR15. 
One genome-wide association study
66
 (n=1,956) in Mexican-American population 
found that genetic variation in the HLA region (nearest gene: HLA-DRB1, SNP 
rs2516049) was associated with the levels of anti-EBNA1-IgG (p=1.4x10
-15
), and this 
association was specific to anti-EBNA as no association was observed for 12 other 
pathogens. A subsequent study
67
 in an Australian twin cohort (n=3,599) further 
supported this significant association (p=4.11x10-9), moreover, a positive relationship 
between 3 of the 110 non-HLA SNPs associated with MS risk  and anti-EBNA1-IgG 
was found in this study when combined in a meta-analysis with the previous dataset. 
The genes found included EVI5, which is an important mediator of viral incorporation 
and EOMES, again associated with host response to viral infections. These genes 
have a biologically plausible association with host responses to viral infections and 
are associated with increased MS risk. 
EBV & vitamin D/sun exposure 
Of great interest is the potential interaction of EBV parameters with other major 
environmental risk factors, such as vitamin D and sun exposure. The most direct 
association between EBV infection and vitamin D on MS risk is that EBNA3 can bind 
to the vitamin D receptor (VDR)
68
 and may attenuate vitamin D-related 
immunoregulatory functions
69
. Therefore, the higher immune response to EBV may 
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hinder the protective role of vitamin D on MS onset. However, given the established 
association between EBNA1 and MS onset, epidemiological research has focused 
mostly on this component. Also, EBNA3 comprises a small proportion of total EBNA, 
with EBNA1 comprising the majority. No significant correlation was found between 
25(OH)D3 and EBV load (r=0.10, p=0.33) or anti-EBNA1 IgG (r=0.11, p=0.43) in a 
cross-sectional study with 196 healthy participants.
70
A recent randomised-control 
study
71
 with 68 RRMS patients found that levels of antibody targeting a region of 
EBNA-1 (amino acids 385-420) significantly decreased as a result of vitamin D 
supplementation (20,000 IU/week) after 48 weeks, although the effect was reduced 
and non-significant after 96 weeks. 
Our case-control study
56
 demonstrated that neither additive and multiplicative 
interaction between low 25(OH)D and EBV infection (history of IM & anti-EBNA 
level) reached significance. In support of this finding, another case-control study
72
 
also showed no interaction between low 25(OH)D and higher anti-EBNA. 
EBV & smoking 
The epidemiological evidence in support of an interaction between EBV and smoking 
is conflicting. As in Table, a pooled analysis of 442 patients and 865 controls found a 
significant interaction with the association between EBNA1 and MS stronger among 
ever smokers compared to never smokers (test for interaction p<0.001)
64
. Three other 
case-control studies failed to show any significant interaction
56 61 73
. Design of studies, 
sources of the cases, and timing at which samples were collected may be responsible 
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for the mixed and conflicting findings, but current evidence does not support a 
significant interaction between EBV infection and tobacco smoking on MS onset.
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Table 3.1 Key studies for the interaction between EBV infection & other risk factors on MS onset 









Case-control, 282 FCD & 558 
controls 
EBV infection & other risk 
factors  
1.Additive interaction: 
IM &HLA-DR15 was significant (SI 3.78, p=0.03) 
IM & Low 25(OH)D was not significant (p=0.54)  
IM & smoking was not significant (p=0.62)  
anti-EBNA IgG &HLA-DR15 was not significant 
(p=0.41)  
anti-EBNA IgG Low 25(OH)D & was not significant 
(p=0.69)  
anti-EBNA IgG & smoking was not significant (p=0.63) 
2.Multiplicative interaction: 
IM &HLA-DR15 was not significant (p=0.15) 
IM & Low 25(OH)D was not significant (p=0.25) 
IM & smoking was not significant (p=0.97) 
anti-EBNA IgG &HLA-DR15 was not significant 
(p=0.95) 
anti-EBNA IgG & Low 25(OH)D was not significant 
(p=0.37) 








Case-control, 733 MS & 1089 
controls 
IM & DR15 1.Multiplicative interaction between HLA-DR15& IM 
was not significant (p=0.27) 
2.Additive interaction between HLA-DR15& IM was 








Case-control, 512 MS & 672 
controls 
EBV infection & HLA 1. Additive interaction between HLA-DR15& IM was 
significant (AP 0.34, 95%CI 0.01-0.68; p=0.05) 
2. Additive interaction between HLA-A2 & IM was not 
significant  
3.Additive interaction between HLA-DR15& anti-
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EBNA1 IgG (domain 385-420) was significant ( p=0.05)  
4. Additive interaction between HLA-A2 & anti-EBNA1 








Cohort study, 148 female MS & 
296 controls 
EBV infection & DR15 Multiplicative interaction between HLA-DR15& anti-








Pool data from 3 studies, 442 
MS & 865 controls 
EBV infection & DR15 Multiplicative interaction between HLA-DR15& anti-
EBNA was not significant (p=0.95) 
Multiplicative interaction between anti-EBNA IgG and 
smoking was significant (p=0.001) 
Estimates of OR of MS for increasing EBNA1 IgG titre: 
Never smokers: OR 1.8, 95% CI: 1.4-2.3; p<0.001 









Case-control, 192 MS & 384 
controls 
 
EBV infection & Low 25(OH)D Interaction between low 25(OH)D & anti-EBNA IgG 








Case-control, 552 MS & 625 
controls 
EBV & smoking Multiplicative interaction between anti-EBNA1 IgG and 
smoking was not significant (p=0.41) 
Estimates of OR of MS for increasing anti-EBNA1 IgG: 
Never smokers: OR 1.97, 95% CI: 1.39-2.80; p=2x10
-4
 










Case-control, 192 MS & 384 
controls 
EBV & smoking Multiplicative interaction between anti-EBNA1 IgG and 
cotinine was not significant (p=0.72) 
Estimates of OR of MS for increasing anti-EBNA1 IgG: 
Low cotinine group: OR 1.9, 95% CI: 1.2-3.0 
High cotinine group: OR 2.1, 95% CI: 1.2-3.7 
Abbreviations: FCD, first clinical diagnosis of central nervous system demyelination; SI, synergy index; AP, attributable proportion; MS, 
multiple sclerosis; IM, infectious mononucleosis; AP, attributable proportion; CI, confidence interval. 
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a population-based incident cases (diagnosed with McDonald criteria) and matched controls from the general population, a number of potential 
and established risk factors were analysed 
b pooled data from two case-control studies, sufficient sample size. Rothman‘s causation model was used and supported the causal relationship 
between IM, HLA-DR15 and MS onset 
c all incident patients were diagnosed with McDonald criteria, and recruited from 35 hospitals from 2005-2008 
d prospective cohort study, sufficient sample size, patients were diagnosed with the Poser criteria 
e pooled analysis from three investigations 
f/h incident cases, samples were collected before disease onset 
g clinic-based incident cases and matched controls from the general population, sufficient sample size 
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3.4.7 EBV and MS pathology 
In general, evidence of EBV in the brains of MS patients could be strongly indicative 
of the involvement of EBV in the pathogenesis of MS. EBV-encoded small nuclear 
mRNA (EBER) has been found in brain of MS patients, particularly in areas of active 
disease, but was not detected in samples from other neurological patients
74
. In 
addition, the frequency of EBV-infected B-cells was associated with higher 






cells in MS brains. However, 
conflicting results were found in other studies wherein EBV markers could not be 
detected in post-mortem brain tissues from MS patients
75-78
. A previous review
79
 
discussed the contradiction of the results and suggested that the lack of sensitivity and 
specificity in EBV detection method was responsible for the discrepancies between 
studies. A more sensitive radioactive in-situ hybridisation technique with EBV-
encoded small RNAs probes was utilised to mitigate these methodological limitations, 
confirming the existence of EBV-infected B-cells in MS lesions
80
. Higher expression 
of interferon-α and EBERs were found in active lesions of MS patients but not in 
inactive lesions or normal white matter, which suggested that activation of an innate 
immune response through latent EBV infection may contribute to the pathogenesis of 
MS. EBERs were also found in CNS lymphoma and stroke cases, which suggested a 
generalised association of EBV infection and CNS inflammation
81
.  
3.4.8 Mechanisms underlying EBV in MS 
Various mechanisms have been proposed for the link between EBV and MS. Of these, 
perhaps the most plausible is molecular mimicry, where antigenic similarities between 
viral peptides and host epitopes could lead to autoimmune attack on host cells and 
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components. In support of this hypothesis, cross-reactivity between EBV antigens and 
myelin protein by cytotoxic T-lymphocytes has been demonstrated
82 83
. The property 
of cross-reactivity by T-lymphocytes also indicated that MS pathogenesis may include 
a T-cell-mediated autoimmune response in the central nervous system. However, 
aggregations of B-cells in the meninges of MS patients has challenged the idea that 
MS is solely a T-cell-mediated disease
74
. In comparing cerebrospinal fluid and serum 
samples from MS patients with tissues from patients with other neurological diseases, 
significantly higher concentrations of B-cells, but not T-cells, were found
84
. Based on 
these data, it was suggested that a dysfunctional reaction to EBV-infected B-cells by 
cytotoxic T lymphocytes leads to an EBV-infected B-cell expansion. Supporting this 
T and B-cell interrelationship in disease aetiology, Serafini and colleagues 
demonstrated that EBV-specific cytotoxic T-cells were increased along with increased 
numbers of B-cells in the brains of MS patients
74
. Pender and colleagues
85
 found a 
decreasing frequency of CD8
+
 T-cells reactive to EBV antigens in MS patients when 
compared to healthy controls. These results support the hypothesis
86
 that a genetically 
determined deficiency of cytotoxic CD8
+
 T-cells (responsible genes are located in the 
HLA complex
87
) could be responsible for an inability to control/suppress  EBV-
infected B-cells. These infected B-cells could then move into the CNS and produce 
pathogenic autoantibodies, as well as co-stimulatory survival signals that could inhibit 
the apoptosis of autoreactive T-cells. 
3.4.9 Assessing the evidence for a relationship between EBV infection 
and MS: the Bradford-Hill criteria 
When studying infectious agents that are specific to humans or which are difficult to 
culture in the laboratory, applying Koch‘s postulates to explore the causal relationship 
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is difficult. Therefore, Sir Austin Bradford-Hill‘s criteria would be adopted to 
examine the role of EBV on MS onset
88
. These criteria comprise 9 elements: 1) 
Strength – the strength of the association between EBV infection and MS onset was 
appreciable and clinically meaningful, MS patients showed a higher seropositivity of 
immune response to EBNA (OR=4.5; p<0.001), VCA (OR=4.5; p<0.001) and IM 
(OR=2.17; p<0.001) than controls
20 31
; 2) Consistency - the association between EBV 
infection and MS onset was constant across variable settings and in different 
populations. Using different biomarkers of EBV infection (EBNA or VCA) and EBV 
dependent IM both strongly supported the consistency of the association between 
EBV and MS. Sero-positivity of EBNA1 was associated with an increased risk of MS 
in different ethnic groups (whites, blacks and Hispanics)
89
; 3) Specificity –As 
previous discussion, contemporary view of specificity allows EBV to be the cause of 
MS and some other diseases like infectious mononucleosis and Hodgkin‘s lymphoma. 
The potential causal role of EBV in systemic lupus erythematosus
90
 has opened the 
plausibility for another situation: considering specificity as to the induction of 
inflammation or unregulated immunological recognition, an argument for specificity 
between EBV infection status and MS (as a representative of autoimmune response) 
can be made. EBV was not associated with other diseases randomly, it was associated 
with MS but not other neurological dysfunction like stroke or Alzheimer; 4) 
Temporality - prospective cohort studies have demonstrated that higher immune 
response to EBV could be tested prior to MS onset. These studies, using differing 
methods in different populations and regions strongly inferred an important 
contribution of timing of aberrant immune response to EBV and subsequent risk; 5) 
Biological gradient - evidence to support a dose–response relationship between 
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immune response to EBV and MS risk arises from a range of cohort or case-control 
studies evaluating EBNA or VCA concentrations prior to and at the time of clinical 
onset of MS; 6) Plausibility - several theories have explained the potential causal 
mechanisms of EBV on MS, such as the molecular mimicry hypothesis, direct 
infection hypothesis, and the immune dysregulation hypothesis; 7) Coherence - in line 
with the epidemiological findings, a more predominant MS-like pathological features 
occurred when experimental autoimmune encephalomyelitis (EAE) model was 
infected with the murine homolog to EBV (γ-herpesvirus 68)
91
.8) Experiment – no 
available method to prevent EBV infection is available to date, however, some 
treatment targeting the B-cells implied the role of EBV infection in MS onset as EBV 
could regulate the differentiation and function of memory B cells
92-94
. 9) Analogy – 
the causal role of EBV in Hodgkin lymphoma has been confirmed, and some research 
has discovered a genetic overlap between the EBV-related Hodgkin lymphoma and 
MS
95 96
. Thus, the analogy criterion was somewhat met.‖ 
Notably, causal role of EBV infection does not need all MS patients to be 
seropositive, because EBV could be one underlying cause in only a subset of cases. 
Association between the hepatitis B virus and liver cancer could support this 
statement: as patients without hepatitis B virus infection could also suffer from liver 
cancer, but the risk of liver cancer increased 50- to 100-fold when compared patients 
with and without infection
97
. It would be easier to interpret with the Rothman‘s pie 
model: onset of MS requires a complex interaction of many risk factor, but to 
complete an intact pie does not mean the occurrence of all risk factor. Therefore, 
some patients did not a show a higher immune response to EBV infection.  
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3.4.10 Conclusions regarding EBV & MS 
Current epidemiology research has determined the aetiological role for EBV in MS 
onset; a prerequisite for developing MS with almost all cases of MS, and laboratory 
studies also support this conclusion. However, the association between immune 
responses to EBV and MS progression has not yet been confirmed.   
3.5 Human Herpesvirus 6 
3.5.1 What is human herpesvirus 6? 
Another member of the herpesvirus family with a strong association with MS is 
human herpesvirus 6. HHV6 was first discovered in 1986
98
, and the primary infection 
is generally asymptomatic. HHV6 is also a double-stranded DNA virus and can stay 
latent after the initial infection. Like EBV, anti-HHV6 IgG indicates a history of 
HHV6 infection, while anti-HHV6 IgM and HHV6 DNA are indicative of ongoing 
infection. Unlike EBV, HHV6 is comprised of two serotypes, HHV6A and HHV6B, 
each of which has distinct biological and immunological features
99
. Both types of 
HHV6 are neurotropic; however, a greater neurotropism by HHV6A than HHV6B
100
 
results may indicate a closer link between HHV6A and MS
101 102
. As with EBV, 
HHV6 infection is ubiquitous in most populations, suggesting interplay between 
HHV6 and other risk factors to modulate susceptibility to MS.  
3.5.2 HHV6 biomarkers and MS risk 
Some studies have demonstrated significantly higher frequencies of positivity and 
higher anti-HHV6 Ig titres in serum from MS patients than controls
103-105
. However, 
similarity of the serum anti-HHV6 antibody levels between MS patients and matched 
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controls in other studies has led to difficulty in determining the role of HHV6 in MS 
onset
106-110
. Moreover, unlike EBV, no researcher has designed prospective studies to 
demonstrate whether anti-HHV6 immune response increased prior to MS onset, 
which would support the temporality of the association. Direct detection of anti-
HHV6-IgG in cerebrospinal fluid is strong evidence of HHV6‘s involvement in MS 
aetiology, and a higher prevalence of anti-HHV6 CSF IgG detection in MS patients 
when compared to other neurological disease patients (34% vs. 12%, p=0.05) has 
been demonstrated
110
. This study did not account for possible confounders and the 
sample size was low, but the comparison between MS patients (28 RRMS &10 
progressive-MS) and patients with other neurological diseases (n=5) or inflammatory 
neurological diseases (n=21) still supported the association between HHV6 and MS 
pathogenesis. Because anti-HHV6 IgG could also cross react with other viruses, this 
finding could not exclude the impact of polyspecific B-cell reactions. A recent 
study
111
 found that 10 peptides (eluted from CSF IgG columns) from 3/8 PPMS and 
1/7 RRMS were in perfect homology with the major capsid protein of HHV6A, 
supporting the effect of HHV6 on MS pathology from the perspective of molecular 
mimicry. Small sample size and recruitment of all patients from one single centre 
could have influenced the validity and generalisability of the evidence. 
In addition to anti-HHV6 IgG, anti-HHV6 IgM has been investigated for its 
association with MS aetiology, but again, the results have been inconsistent 
106 112
. For 
example, using a rapid culture assay in serum, active HHV6 infection was present in 
22 of 41 MS patients and none of 61 healthy controls (p<0.001)
113
, while another 
study
106
 found anti-HHV6-IgM was negative in CSF of all MS patients and only one 
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patient was positive in serum. Differences in results between studies may be due to 
different sample sizes, techniques used, or thresholds defining a positive result
108 114
.  
Detection of HHV6 DNA by PCR is a way to quantify latent virus in cells and free 
virus in serum or CSF. One case-control study with 78 MS patients and 123 healthy 
controls found a higher positivity of cell-free virus in MS patients than healthy 
controls
115
 (60.2% vs. 14.6%; p<0.001). However, two other studies did not detect 
HHV6 DNA in serum, leading to their concluding that HHV6 DNA is not correlated 
with risk of MS
116 117
. A limitation of DNA detection method is that two samples from 
the same individual could exhibit different outcomes, given as viral reactivation could 
be occurring in the CNS but not the peripheral circulation, or vice versa, or latent 
virus could be present at quantifiable levels in one but not the other of these sites. 
This may explain why HHV6 DNA detection results have been inconsistent. The 
conflicting epidemiological research outcomes of the association between HHV6 and 
MS risk could indicate that there is no direct causal link between HHV6 infection and 
MS risk, or it may be that indirect mechanisms as seen with EBV may be involved, 
for example by gene-environment interaction.  
3.5.3 HHV6 biomarkers and MS clinical course 
Using data from a longitudinal study in Tasmania, our group previously found a 
strongly dose-dependent association (p=0.001) between anti-HHV6 IgG titre and 
subsequent risk of relapse
52
. HHV6 reactivation, as measured by anti-HHV6 IgM and 
HHV6 DNA, was rare, however, with anti-HHV6 IgM being detectable in only six 
samples from one individual out of 1,050 samples collected over nearly three years, 
and no association was observed between HHV6 DNA detection and either relapse or 
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. A higher positivity of HHV6 DNA was detected at time of relapse when 
compared to remission (p=0.008)
118
, reported from another longitudinal study 
following 59 participants for five months. When testing HHV6 DNA in CSF, 
increasing load was associated with elevated numbers of contrast-enhancing lesions 
on MRI
119
. A recent study demonstrated that anti-HHV6-IgG titre reached its highest 
levels approximately two weeks prior to relapse (p=0.01), this interval increasing to 
one month for anti-HHV6 IgM (p=0.03)
120
. This finding supported the association of 
anti-HHV6 and disease activity from temporal relationship. Current research suggests 
that immunological reaction against HHV6, either directly or indirectly, should be 
regarded as a potential risk factor in the progression of MS.  
3.5.4 HHV6 and MS pathology 
Detecting HHV6 directly in the brains of patients is strong evidence for the 
involvement of HHV6 in the pathogenesis of MS. With the assay of post-mortem 
samples in 7 MS patients and 3 patients with other disorders, using a fluorescent in-
situ hybridisation technique, a higher level of HHV6 gene transcription was detected 
in MS patients, as well as in demyelinating lesions compared with normal-appearing 
white matter in samples from MS patients
121
. Another important finding in this study 
was that HHV6 gene transcription was restricted to oligodendrocytes, the myelin-
producing glial cells of the CNS. Similar studies also found the frequency of HHV6 
DNA was higher in lesions from MS patients than in normal-appearing white 
matter
113 122
. In contrast, another study found no difference in HHV6 detection in 
brains between MS patients and healthy donors
123
.  
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3.5.5 Potential mechanisms of HHV6 association with MS 
Molecular mimicry between HHV6 and host myelin components has been 
hypothesised to contribute to the pathology of MS. Another study found that seven 
residues were identical between myelin basic protein (MBP) and U24, a protein 
produced by HHV6
124
. Moreover, more than 50% of T-cells recognising MBP 
epitopes could be activated by HHV6 U24. This cross-reactivity was subsequently 
confirmed to be higher in MS patients than healthy controls or patients with other 
neurological diseases
125
. Another study found that HHV6 was capable of infecting 
glial precursor cells, resulting in alteration of cell morphology and impairment of cell 
replication
126
. This finding demonstrated that HHV6 has the potential to impact the 
production of myelin directly.  
3.5.6 Conclusions regarding HHV6 & MS 
The role of HHV6 in MS onset is elusive, with conflicting results from multiple case-
control and cohort studies
41 127 128
. Additional longitudinal cohort studies, ideally 
measuring both serological and viral load parameters in both CSF and peripheral 
circulation, are needed to determine whether a true association exists. The role of 
abnormal immune response to HHV6 in the disease activity of MS has been supported 
by an increasing number of cohort and laboratory studies. Interestingly, the effect of 
HHV6 in MS is at least partly in contrast to EBV, where most research has 
demonstrated the essential role in MS onset other than disease activity. The 
association between HHV-6 and multiple sclerosis primarily relied on pathological 
studies, observational studies were scarce and could not provide sufficient evidence 
from the epidemiological perspective. To prove causation, diverse research 
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methodologies are required. Notably, publication bias may influence our 
interpretation of the results, and sample size of current research was still small. 
Therefore, conclusions about the role of HHV6 on MS clinical course are not yet able 
to be drawn. 
3.6 Human endogenous retroviruses and MS 
Although this thesis did not perform the analysis between HERVs and clinical course 
of MS, mounting evidence suggested that HERVs are associated with MS onset and 
progression. Therefore, we will briefly review the roles of HERVs in MS. 
3.6.1 What are human endogenous retroviruses and multiple 
sclerosis-associated retrovirus? 
Endogenous retroviruses originate from ancestral exogenous infecting viruses which 
were incorporated into the host genome and entered the germ line during evolution. 
Endogenous retroviruses make up nearly 8% of the human genome
129
. While through 
the process of evolution most endogenous retroviruses have become incomplete and 
lost their function, open reading frames still exist in some HERVs which encode 
functional proteins. While no longer capable of replication and lysis of host cells, 
some viral components, including gap, pro, pol, and env genes, are still 
transcriptionally active. Some of these have become useful in host function; for 
instance, the HERV-derived synctin-1 protein is produced in the placenta and plays a 
role in placental implantation
130
. However, neurotoxic effects of some HERV-
produced proteins expressed in the CNS led to the hypothesis that they have a role in 
MS onset. Of the various HERVs, one, aptly called Multiple Sclerosis-associated 
Retrovirus (MSRV), is of particular interest in MS. MSRV was first discovered within 
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leptomeningeal cells isolated from the CSF of MS patients and found to possess 
reverse-transcriptase activity
131
. Evaluation of the sequence of MSRV showed close 
relatedness with the HERV-W family. Frequent detection of MSRV in the brains of 
MS patients has supported its potential role in MS aetiology
132
.  
3.6.2 HERV biomarkers and MS risk 
Measurement of DNA copy number or transcription levels or expression of HERVs 
env or pol genes in MS patients could aid in understanding the association between 
HERVs and MS. Several case-control studies have demonstrated a higher positivity of 
MSRV RNA in serum of MS patients than healthy controls
133 134
. For instance, a 
multicentre study with 149 MS patients and 153 controls found that the positivity of 
MSRV pol gene was 71.4% in MS patients, compared to only 17.3% in healthy 
controls
135
. Using fluorescence in-situ hybridisation (FISH) and PCR, DNA copies of 
MSRV pol were found to be higher in PBMCs of 16 MS patients when compared 
with 10 healthy controls
136
. Notably, the quality of the evidence in this study were 
influenced by 1) all cases were prevalent with the durations of disease ranged from 2 
to 174 months, and all controls were healthy individuals with no information about 
the match degree; 2) not controlled for possible confounders; 3) sample size was low. 
Garcia-Montojo and colleagues
137
 found higher levels of MSRV transcription in 
PBMCs from MS patients than controls. Moreover, the MSRV RNA level was higher 
in SPMS patients than RRMS. The same group also found that the copy number of 





HERV-Fc1 belongs to the HERV H/F family, and MS patients have increased levels 
of HERV-F gap or env expression in PBMCs compared with controls
139 140
. The 
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HERV-Fc1 RNA load was four-fold higher in plasma from MS patients compared 
with those from healthy controls
139
. SNP rs3802981, located in the first intron of the 
restriction gene TRIM5, is able to control the transcription of HERV-Fc. An inverse 
association
141
 was found between the T-allele of SNP rs3802981and MS risk 
(OR=0.59, p=0.002). This study also found that C-allele of SNP rs391745 (near 
HERV-Fc1) was more common in MS patients (OR=1.54, p=1.3x10
-5
). A subsequent 
study showed that C-allele of rs391745 was more common among MS patients with 
relapse-onset than progressive-onset
142
. This association was supported by a pooled 
analysis, yielding an OR of 1.27 (95% CI: 1.11-1.45)
143
.  Other HERVs such as 
HERV-k
144 145
, have shown inconsistent associations with MS onset, however. 
3.6.3 HERV biomarkers and MS clinical course 
Studies investigating the association between HERVs and MS clinical course have 
been few and inconsistent. One study (n=112) demonstrated that the level of HERV-
W transcription was significantly associated with the Multiple Sclerosis Severity 
Score (MSSS) in female patients (r=0.34, p=0.017), as well as showing a weaker and 
non-significant trend (r=0.22, p=0.16) in males
137
. In addition, the number of DNA 
copies of HERV-W on chromosome Xq22.3 and the polymorphisms of rs6622189, 
located in the env region of HERV-W, were associated with MSSS score in women. 
Since this gene is located on the X chromosome, to some extent this may be relevant 
in the well-known female preponderance in MS
146
. Using RT-qPCR, one case-control 
study with 178 MS patients found that a higher DNA copy number of MSRV in 
PBMCs was associated with an increasing EDSS (4.92 vs. 2.83; p=0.032) and MSSS 
(6.40 vs. 3.92; p=0.044) in women
138
. In this study, patients and control were not 1:1 
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matched (124 controls) and some important confounders were not controlled for, 
which may influence the validity of the findings. One six-year prospective study with 
18 MS patients found that, despite a similar disability and relapse rate at early stages 
of follow-up, those with detectable MSRV in their CSF at baseline had significantly 
higher EDSS scores (4.3 vs. 2.2; p=0.004) and annual relapse rate (0.5 vs. 0.3; 
p=0.01)
147
 by the end of follow-up. Overall, although the data is insufficient at this 
stage to conclude that a higher HERV copy number or transcription rate is associated 
with disease progression, HERV biomarkers should be regarded as potential risk 
factors predicting the progression of MS.  
3.6.4 HERV and MS pathology 
Repeated isolation of MSRV from the leptomeninges or choroid plexus
131 132
 has 
indicated the role of HERVs in MS pathogenesis. Concentrations of several HERV 
markers were higher in lesions of MS patients when compared to non-lesion samples 
from the same patients or from brain tissues of matched controls. RNA levels of 
HERV-W were higher in lesions of MS patients than in lesions of other neurological 
diseases or white matter of healthy controls
123 148
. Testing 8 MS patients, env 
immunoreactivity was found in activated lesions but absent in normal-appearing white 
matter
149
. In keeping with this study, antibodies to the env protein of HERV-W could 
only be detected in lesions of MS patients
123
. Similarly, accumulation of gag antigens 
from HERV-W were detected in axonal lesions in MS patients
150
 when compared to 
non-MS control brains. However, using RT-PCR one study found no significant 
difference in HERV-W transcription levels in white matter between MS patients and 
healthy controls
151
. Methodological difference may explain the conflicting findings; 
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however, most studies to date demonstrated a higher frequency of HERVs 
transcription or expression in lesions of MS patients, which suggested the potential 
association between HERVs and MS pathology.  
In addition to a direct impact of HERV products, some studies have investigated 
whether MSRV-env protein could directly modulate the secretion of cytokines. An 
increasing frequency of interferon-γ and tumour necrosis factor-α (TNF-α) and 
decreased frequency of interleukin-10 from MSRV-env simulated PBMCs have been 
shown when compared 13 MS patients in relapse with 17 MS patients in remission
152
. 
A similar study found an increased secretion of IL-6 and TNF-α by MSRV-env 
simulated PBMCs when cultured in-vitro
153
. In addition, animal experiments 
demonstrated that env protein from MSRV could induce the synthesis of 
proinflammatory cytokines such as interferon-γ and TNF-α 
154
. The study‘s cross-
sectional design using prevalent MS patients may decrease the validity of the 
findings; however, HERVs tests are costly at the present stage, meaning studies with 
large sample size are logistically challenging. Prospective study designs are less 
important for HERVs studies due to its genetic nature. All these results suggest that 
MSRV env particles could work as a superantigen, affecting T-cells and causing 
overexpression of proinflammatory cytokines. With similar characteristics to a 





 also suggested that 
MSRV env can activate toll-like receptor 4 which can lead to the secretion of 
proinflammatory cytokines. 
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Despite its utility in the placenta, studies have demonstrated increased levels of 
synctin-1 in MS lesions, especially in glial cells
157
. Endoplasmic reticulum stress 
could be induced by synctin-1
158
 and one of the chaperones, old astrocyte specifically 
induced substance (OASIS), was capable of strengthening the expression of inducible 
nitric oxide synthase (iNOS), resulting in an overexpression of free radicals. This may 
be relevant to MS pathogenesis, particularly as oligodendrocytes are especially 
vulnerable to damage mediated by free radicals.  
Env protein of HERV-k18 is regarded as a superantigen that can stimulate T-cells and 
elicit a powerful immune response. EBV-infected B lymphocytes are capable of 
transactivating the env gene of HERV-k18
159
, and subsequent studies
160
 have revealed 
that latent membrane protein (LMP) plays an essential role in the induction of the 
transactivation. Experiments using murine B lymphocytes has demonstrated that 
immunoreceptor tyrosine-based activation motif (ITAM) of LMP-2A was capable of 
initiating a signalling cascade and induction of HERV-k18 env
161
.  
3.6.5 Conclusions regarding HERV/MSRV & MS 
Through the consistent detection of HERV biomarkers, the evidence for HERVs in 
MS onset is appreciable. However, without evidence from prospective cohort studies, 
particularly the transcription or expression level of HERVs prior to MS onset is less 
clear. Also, a clear pathway for biological plausibility has yet to be fully elucidated. 
Further work is required to clearly demonstrate that HERVs may influence MS onset 
or clinical course. These will require both epidemiological associations in cohort 
studies and basic science experiments.  
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3.7 Potential therapies that could influence the immune response to 
EBV/HHV6/HERVs in MS patients 
Given the diverse evidence from epidemiology and laboratory research implicating 
the role of human herpesvirus infection(s) in MS, it has been assumed that efforts to 
prevent viral infection by vaccination or other prophylactic interventions could reduce 
MS risk or moderate its clinical course. Despite the tremendous potential for this point 
of intervention in MS prevention and treatment, relatively few studies aimed at 
treating MS from the perspective of viral infection have been conducted. To date, the 
most notable experiments were three phase-3 clinical trials (OPERA I, OPERA II and 
ORATORIO study) of ocrelizumab, a humanised anti-CD20 antibody, which 
selectively removes mature B-cells based on the hypothesis that dysregulated B-
lymphocytes are involved in MS pathogenesis. These studies demonstrated patients 
administered with therapy showed a lower relapse rate and recovery from relapses in 
RRMS and moderate but still statistically significant effects on PPMS progression. 
The period of follow-up was still too short to conclude its effects on long-term 
disability progression, but these trials suggested the significant role of removing 
CD20-positive B-cells on the reduction of the number of EBV-infected B-cells, and 
may be one of the mechanisms by which this medication affects MS clinical course. 




 are nucleoside-based medications 
that inhibit the function of viral DNA polymerase and block lytic replication after 
being taken up by the infected B-cells. These have been tested in clinical trials but 
neither reached statistical significance in reducing exacerbation rate or number of new 
active MRI-detected lesions. However, as shown above, there is little evidence that 
viral replication and cell lysis are the drivers of MS onset or progression. If in fact 
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another mechanism is at play, including potential transactivation of HERVs or 
molecular mimicry-induced autoimmune response, then the impacts of these viruses 
on MS will not be influenced by these antiviral drugs.  
Some novel forms of clinical research have also been tested. For example, according 
to the theory that exhaustion of EBV-specific CD8+ T-cells are associated with MS 
pathogenesis, supplementation of EBV-specific CD8+ T-cells was performed in one 
SPMS patient and this patient showed decreased clinical activity on MRI and reduced 
intrathecal immunoglobulin production
47
. Natalizumab, is a humanised anti α4-
integrin monoclonal antibody therapy that prevents leukocyte migration into the 
central nervous system
164
 and could interfere with immunoglobulin synthesis
165
, was 
tested for its influence on antibodies‘ level to human herpesvirus infection. Recently, 
a two-year follow-up longitudinal study showed a decreased level of anti-HHV6-
IgM/IgG in natalizumab-treated patients and a correlation between the variation of 
antibodies and the clinical response to treatment
120
. This study also found that patients 
with interferon-βand glatiramer acetate showing no significant reduction of anti-
HHV6 IgG. This indicates the potential to influence MS disease course, which aligns 
with the studies that observed an association between anti-HHV6-IgG and relapse. 
Another prospective study with 21 months follow-up in 21 MS patients found that 
anti-EBNA1 was stable during the treatment period
48
, which may suggest that inactive 
EBV was not associated with MS clinical course. 
Anantti-EBV vaccine to prevent EBV infection has not been developed for market yet. 
Some research has attempted to develop a vaccine targeting viral glycoprotein 350, 
which is the main antigen targeted by the immune system. Unfortunately, the vaccine 
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was not effective at preventing EBV infection
166
. Moreover, some research has 
indicated that EBV infection during childhood is protective, so we could not exclude 
the possibility that being infected with EBV is developing other forms of immune 
tolerance. 
GNbAC1, a humanised monoclonal antibody targeted at HERV-env has been tested in 
a phase II clinical trial and showed a significant reduction of HERV transcripts in the 
treated group
167
. Conclusions about the clinical benefits could not be drawn yet since 
the observation period was only six months, but only one SPMS patient developed a 
new lesion on MRI and the other 9 patients were clinically stable. Some laboratory 
data also demonstrated that GNbAC1 could prevent MSRV-env mediated 





A large number of epidemiological studies have ascertained the association between 
EBV and MS risk. The evidence for causality is well-supported within the present 
methodological framework to the extent that observational epidemiological outcomes 
can ascribe causality. Discrepancies in post-mortem and laboratory investigations of 
the role of EBV in MS patients are probably due to the diversity of sample quality and 
detection techniques, with most research inclined to support this association.  
Owing to the lack of well-powered prospective cohort study, evidence for HHV6‘s 
role in MS risk is not as robust as that for EBV. However, an increasing number of 
studies support a potential role in MS clinical course. HHV6 can be regarded as a 
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potential risk factor for MS progression, but clearly there is more work required to 
confirm the link. Interesting, the role of EBV and HHV6 are somewhat opposed to 
each other: EBV is strongly associated with the onset of MS while there is more 
evidence that HHV6 is associated with disease activity. However, the insignificant 
association between EBV infection and MS disease activity in current 
epidemiological studies may suggest that biomarkers like anti-EBNA or anti-VCA are 
not suitable for studies of MS clinical course (Figure). Future studies focusing on 
novel biomarkers may reveal a closer connection to the immune response to EBV. 
Moreover, future studies should clarify the variation of anti-EBV after the use disease 
modifying therapy in MS patients.  
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In terms of HERVs, the neurotoxic role and mechanisms of MSRV-env were 
supported by laboratory findings and some clinical pilot trials have been performed 
from this perspective. Epidemiologically, while there is some preliminary evidence 
from case-control studies linking HERV to MS onset and clinical course, further 
prospective cohort studies are needed to substantiate these results and exclude the 
possibility of reverse causality.  
If viral infection, principally EBV infection, was an essential part of MS pathogenesis, 
prevention of EBV infection by vaccination could be a feasible approach. Similarly, 
novel studies assessing the role of immunomodulation of the complex EBV induced 
changes within the MS patient may provide another avenue for treatment. The 
exciting finding of the success of B-cell depletion in RRMS and PPMS adds further 
weight to the role of B-cell dysregulation possibly from HHV infection as a major 
driver of MS clinical course. Future studies aimed at understanding the mechanism 
and role of viral infection on the MS onset and progression will hopefully identify 
advanced methods for the prevention and treatment of MS. 
3.9 Postscript 
This chapter demonstrated the role of viral infection on MS onset and progression, 
and we found that EBV was associated with MS onset but the effects on MS 
progression were uncertain. In contrast, a number of studies demonstrated that higher 
immune response to HHV6 infection were associated with clinical course in MS 
patients. The next chapter is about the association between latitude and age at onset. 
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Chapter 4 Higher latitude is significantly associated with an 
earlier age of disease onset in multiple sclerosis 
4.1 Preface 
In this chapter, we address aim 1 of the thesis - the examination of the association 
between latitude and age of symptom onset and to what extent ultraviolet radiation 
levels may underlie such an association. This chapter has been published in journal of 
neurology, neursurgery& psychiatry, year 2016, volume 87, page 1343-1349.  The 
manuscript presented in this chapter has been published. The typeset version of the 
manuscript as it appeared in the journal is in Appendix. The text of this chapter is the 
same as the published version. 
4.2 Abstract 
Background: Age at onset (AAO) in multiple sclerosis (MS) is an important marker 
of disease severity and may have prognostic significance. Understanding what factors 
can influence AAO may shed light on the aetiology of this complex disease, and have 
applications in the diagnostic process. 
Methods: The study cohort of 22,162 eligible patients from 21 countries was 
extracted from the MSBase Registry. Only MS patients aged  16 years were 
included. To reduce heterogeneity, only centres of largely European descent were 
included for analysis. AAO was defined as the year of the first symptom suggestive of 
inflammatory central nervous system demyelination. Predictors of AAO were 
evaluated by linear regression. 
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Results: Compared with those living in lower latitudes (19.0-39.9°), onset of 
symptoms was 1.9 years earlier for those at higher latitudes (50.0-56.0°) (p=3.83x10
-
23
). A reciprocal relationship was seen for ambient UVR (ultraviolet radiation), with a 
significantly increasing age at onset for MS patients per each quartile increment of 
ambient UVR (p=1.56x10
-17
). We found that the AAO of female patients was 
approximately 5 months earlier than male patients (p=0.002). AAO of progressive-




Conclusion: An earlier AAO in higher latitude regions was found in this worldwide 
European-descent cohort and correlated inversely with variation in latitudinal UVR. 
These results suggest that environmental factors which act at the population level may 
significantly influence disease severity characteristics in genetically susceptible 
populations. 
4.3 Introduction 
Multiple sclerosis (MS) is a complex autoimmune disorder of the central nervous 
system characterised by inflammatory demyelination on a background of progressive 
neurodegeneration. The aetiology of MS is still uncertain
1
; however, a complex 
interplay between genetic and environmental factors likely contributes to disease 
onset. Of the environmental risk factors linked to MS, the robust latitudinal gradients 
of prevalence
2
 and incidence rate
3
 have been among the most consistent and striking 
findings in MS epidemiology
4
. Indeed, we previously showed a positive association 
between latitude and MS prevalence with a 1.04 change in prevalence per degree-
latitude (p<0.001)
2
, while Alonso & Hernán
3
 demonstrated that MS incidence 
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increased 30% in women and 50% in men per each ten-degree increment of latitude. 
The explanations of this geographic variation have largely been considered to reflect 
changes in ambient UVR (ultraviolet radiation) and/or concomitant variations in 
vitamin D sufficiency
5
 although this is by no means the only potential explanation
6 7
.
Using space-time cluster analysis, studies have demonstrated a high degree of 
clustering of residence was associated with a lower age at onset (AAO) of MS
8 9
.
From these studies, it is reasonable to assume that there may exist an association 
between latitude and AAO for MS patients. However, little data is available on 
whether a higher latitude or lower ambient UVR is associated with a lower AAO. 
The latitudinal gradient has been shown to be present largely in populations of 
European descent
2
 and also to vary by MS phenotype
10
. It is unclear whether the
latitudinal gradient of MS also affects clinical characteristics, although some recent 
studies
11 12
 have demonstrated a significant relationship between latitude and
positivity for cerebrospinal fluid (CSF) oligoclonal bands (OCBs). A recent study in 
Japan has also confirmed this relationship between latitude and abnormal CSF 
findings, with a significant association of positive CSF findings (OR=4.08) and OCB 
positivity (OR=2.57) when comparing northern to southern Japan
13
 in 180 MS
patients diagnosed with the 2010 McDonald criteria
14
.
The association between AAO and the prognosis of MS patients is complicated. A 
prospective population-based cohort in southeast Wales
15
 indicated that complete
recovery from the onset event varied in different age groups, with full recovery more 
common (87.4%) in the youngest group (less than 18 years old), compared to only 
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68% in the oldest (greater than 44 years old). Another cohort study also found that an 
older AAO could accelerate the accumulation of disability in MS
16
, and this 
association was independent of disease duration and early relapse frequencies. 
However, despite the fact that early onset MS patients manifest a comparatively 
moderate clinical course, the younger onset was associated with a younger attainment 
of disability milestones
17
. While these studies have been consistent in their 
determination that AAO is a determinant of the progression of MS, less is known 
about the factors that influence the age of symptom onset in MS, with studies 




In the present study, we sought to evaluate whether there was any evidence of a 
latitudinal variation in the age of symptom onset of MS and if so, whether such 
variation could be ascribed to a similar UV-based mechanism or if other factors were 
at play.  
4.4 Methods 
4.4.1 The MSBase Registry 
The MSBase Registry is an international collaboration that has established a 
prospective longitudinal dataset of MS patients‘ neurological records from a number 
of sites worldwide. Presently, the Registry has 59 centres in 26 countries in Europe, 
North America, South America, Asia Minor, South Asia and Australia. Participating 
centres enter data in or near real-time using a secure internet-based database. 
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The MSBase Registry was approved by the Melbourne Health Human Research 
Ethics Committee, and local ethics committees in all participating centres gave 
regional approval for participation in the MSBase Registry. Written informed consent 
was obtained from all participants who provided data to the Registry. 
4.4.2 Criteria for data extraction 
All patients fulfilled either the 2005 or 2010 McDonald criteria
14 21
 for diagnosis of 
MS, with the data being extracted and edited on 31
st
 May 2014, a total of 30,415 
participants were included (Figure 1). 
4.4.3 Participant inclusion criteria 
Our dataset was restricted to patients with clinically diagnosed MS as per the 
McDonald criteria 2010
14
 and to adult-onset MS (excluding patients with AAO less 
than 16 years old
22 23
).The Atlas of MS
24
 has demonstrated that the prevalence for MS 
between Asian and European populations varies significantly, from 1/100,000 to 
>180/100,000. In the present sample, other characteristics like the populations mean 
age and the sex ratio of the source populations also differed significantly between 
sites. For example, sex ratio of source population (female/male) was 0.94 in non-
European-descent centres (Isfahan, Iran; Kuwait City, Kuwait; Mumbai, India) while 
it was 1.06 in other centres, a significant difference (p=2.74x10
-6
). Likewise, the mean 
age of the source population differed significantly, with mean age of 33.39 years in 
non-European-descent centres compared to 39.33 years in European-descent centres 
(p=8.34x10
-6
). This marked variation in population characteristics and the 
heterogeneity of main effects between the two centre subsets led to our excluding 
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these three centres from our analysis (Figure 1).These exclusion left a total of 22,162 
patients from 52 centres in 21 countries. 
Figure 4.1 Flow chart showing inclusion criteria of the sample for the present 
analysis. CDMS: clinically diagnosed MS; CIS: clinically isolated syndrome. 
4.4.4 Factors of interest 
Participant birthdate, sex, first recorded MS type (relapsing-onset, progressive-onset) 
and date of symptom onset, and current MS types, as well as the location of the 
registered MSBase centre (city, country) were recorded for every participant. 
Age at onset 
Age at onset was defined as the age of the first validated symptom(s) consistent with 
multiple sclerosis. 
Latitude 
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The latitude of each study centre was derived from Google maps 
(https://www.google.com.au/maps/). For our purposes, latitudes were recoded to all 
be positive, though we retained information on the hemisphere of the study centre to 
allow for evaluation of differences by hemisphere. For a better presentation of the 
latitudinal gradient and according to the sample distribution in our study, latitude was 






. Using other cut points such a s 
quartiles or 10 degree increments did not significantly alter the data. 
Solar radiation values 
We created a UVB variable for each MSBase participant based on the latitude and 
longitude of each treatment centre. UVB (wavelengths 280-320nm) was our focus in 
this study, since only shorter-wavelength UVB radiation can induce the cutaneous 
synthesis of vitamin D. UV data were collected from the Solar Radiation Database 
(SoDa) service. Hourly values for clear sky were calculated and summed to daily or 
monthly values. UVB intensity was defined as radiation received per area, expressed 
as Wh/m
2
 (watt hour per square meter). Mean monthly values from December to 
March were used to calculate the winter mean UVB for the Northern Hemisphere and 
from June to August for the Southern Hemisphere. Research
25
 has demonstrated that 
UVR can modulate the immune response independent of the effect of vitamin D, 
however all UV measurements are highly correlated e.g. erythemally weighted UVR 
and UVB (r=0.99, p<0.001) therefore there was no difference in outcomes when using 
any measure of UVR. 
4.4.5 Potential confounding variables 
Population mean age 
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It was reasonable to assume that a higher mean age in the source population could 
impact on the number of cases available for study, given the average age of prevalent 
cases being in early-mid adulthood. In terms of our dataset, we found a positive 
association between population mean age and AAO (r=0.06, p<0.001) and latitude 
(p=0.49, r<0.001), therefore population average age was included in the multivariable 
model. Low variance inflate factor allows the inclusion of both variables in the 
multivariable model. We obtained the mean age of the source population in each 
treatment centre from the most recent national demographic statistics available for 
each country.  
Sex ratio in each treatment centre 
Since female patients exhibit an earlier AAO, and there was a negative association 
between sex ratio (female/male) and latitude (r=-0.29, p<0.001), this was added to the 
multivariable model. From the sex distribution of MS patients in each treatment 
centre we calculated the sex ratio (female/males). 
MS type ratio in each treatment centre 
AAO in relapsing-onset patients is typically earlier than progressive-onset patients, 
and we found a positive association between the ratio of MS type (progressive-
onset/relapsing-onset) at each centre and latitude (r=0.38, p<0.001), therefore MS 
type ratio in each treatment centre was added to the multivariable model. 
4.4.6 Statistical analysis 
This study was analysed with cox proportional analysis and linear analysis initially, 
which showing a similar direction and statistical significance. For an easier 
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interpretation and clinical application (beta coefficient), linear regression was used to 
assess potential predictors of AAO. Since we excluded all patients less than 16 years 
old, the distribution of AAO in our dataset was left-skewed. Log-transformation was 
applied to reduce heteroskedasticity and thus satisfy the requirements of linear 
regression. All coefficients were back-transformed to present on the original scale at 
the mean of model covariates, however, to facilitate interpretation of results. Due to 
the significant heterogeneity of the sample size in each treatment centre, all analyses 
were weighted by the square root of the sample size in each treatment centre. 
To assess the seasonality of the AAO, we fitted a sinusoidal model to data on AAO 
and the month (t) when the patient was born: AAO=β0+β1sin(2πt/12) +β2cos(2πt/12). 
The ANOVA F-test was used to decide whether there was significant seasonal 
variation. 
All statistical analyses were undertaken using Stata/SE 12.1 (College Park, TX). 
4.5 Results 
4.5.1 Participant characteristics 
Our analysis dataset included a total of 22,162 patients from 52 centres in 21 
countries (Table 1). In keeping with known MS distributions, most patients were 
female (70.4%) and of relapsing-remitting course (91.5%). The distribution of the 
cohort was such that most patients were from the Northern Hemisphere (81.4%), 
particularly Europe (67.2%), while participants from Australia also contributed a large 
proportion (15.7%). The mean AAO in this cohort was 32.3 years. Supplemental 
Table 1 shows the characteristics of the total cohort, overall and by centre. 
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Table 4.1 List of countries included in our primary analysis 










Mexico 69 (0.31) 1 19.4ºN 14.3 
Cuba 134 (0.60) 1 23.1 ºN 11.8 
Israel 83 (0.37) 1 31.9 ºN 6.3 
Argentina 643 (2.90) 2 33.0 ºS 6.5 
Australia 3,470 (15.66) 8 35.0 ºS 5.7 
Malta 87 (0.39) 1 35.9 ºN 5.0 
Spain 2,571 (11.60) 6 40.6 ºN 3.8 
United States 80 (0.36) 1 40.7 ºN 3.6 
Turkey 1,166 (5.26) 2 41.1 ºN 3.2 
Portugal 254 (1.15) 1 41.2 ºN 3.9 
Macedonia 23 (0.10) 1 42.0 ºN 3.2 
Italy 5,090 (22.97) 9 43.0 ºN 2.9 
Romania 17 (0.08) 1 44.4 ºN 2.7 
Canada 2,866 (12.93) 2 46.1 ºN 2.0 
Hungary 96 (0.43) 4 47.7 ºN 1.6 
France 80 (0.36) 1 48.9 ºN 2.2 
Czech 
Republic 
1,787 (8.06) 1 50.1 ºN 1.4 
Belgium 417 (1.88) 1 50.9 ºN 1.3 
Netherlands 2,568 (11.59) 5 51.6 ºN 1.2 
Northern 
Ireland 
236 (1.06) 2 54.5 ºN 1.0 
Denmark 425 (1.92) 1 55.7 ºN 0.8 
Total 22,162 (100) 52   
Wh/m2=watt per square meter; Mean latitude: average of latitudes of centres in the 
same country.  
Mean winter UVB: Mean monthly values from December to March were used to 
calculate the winter mean UVB for northern hemisphere and from June to August 
were used for southern hemisphere.  
Values of mean latitude of study centres and mean winter UVB described the average 
values of latitude and winter UVB in each country, the values here would not be used 
in the statistical analysis. 
4.5.2 Factors associated with AAO 
Latitude and UVB 
Our primary factor of interest for AAO was study centre latitude. In the univariable 
analysis, latitude as a continuous linear factor was significantly negatively associated 
with AAO (p=0.01), every 10-degree increment of latitude associated with a 0.3-year 
earlier onset. Evaluating this as a categorical term in Table 2, we found a clear dose-
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dependent response. On adjustment for relevant covariates, this association became 
much more dose-dependent, with those of the highest latitude stratum having nearly 
1.9-years earlier age at onset than those of the lowest (Figure 2). When we evaluated 
latitude as a continuous variable in the multivariable analysis, a 10
o 
increase in 
latitude was associated with a 0.82-year earlier onset (p<0.001). We did not include 
UV in our multivariable analysis, due to the significant collinearity between the level 
of UV and latitude. Restricting to relapsing-onset patients, every 10-degree increment 
of latitude was associated with a 0.76-year earlier onset (p<0.001). In supplementary 
Table 2, we show the stepwise process of the adjustment used in our multivariable 
model. 
The results for the association between AAO and winter UVB were similar to the 
latitudinal ones, and the results were predictably of high correlation (r=-0.96, 
p<0.001) between latitude and UVB. In the univariable analysis, no strong dose-
response relationship was observed, but the association and dose-dependency were 
enhanced after adjustment for confounders. A clear dose-dependent association 
(p<0.001) appeared with those of the lowest UVB level having nearly 2 years earlier 
AAO than those of the highest UVB category in the multivariable analysis (Figure 3). 
Using summer UVB and winter erythemally weighted UV, the positive relationship 
between higher sun exposure and later AAO persisted (p<0.001).  
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Figure 4.2Adjusted age at onset in each latitude category. 
Figure 4.3Adjusted age at onset in each winter ultraviolet B category. 
Sex 
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Female patients‘ AAO were on average 0.88 years (95% CI: 0.60-1.17; p<0.001) 
younger than male patients in our univariable analysis. After adjustment for other 
relevant variables, this magnitude reduced to 0.43 years (95% CI: 0.15-0.70; 
p=0.002). Restricting to relapsing-onset patients, female patients still showed 0.58 
years earlier onset than male patients (p<0.001). The latitudinal gradient of AAO was 
not significantly different between males and females (p=0.10 for interaction). 
MS type 
Progressive-onset patients exhibited a much later age at onset than relapsing-onset 
MS patients (β: 9.29; 95% CI: 8.74-9.84; p<0.001) (Table 2). This association was 
quite robust to adjustment (β: 8.90; 95% CI: 8.35-9.45; p<0.001). The latitudinal 
gradient of AAO was not significantly different between relapsing-onset and 
progressive-onset cases (p=0.36 for interaction). Subgroup analysis of the association 
between latitude and ASO were significant in both relapsing-onset (p<0.001) and 
progressive-onset (p=0.002) patients.  
Season of Birth  
Birth dates were relatively evenly distributed in the four seasons. We explored season 
of birth (Figure 4) and its association with age at onset using a sinusoidal model, 
finding no seasonal pattern (F=0.66, p=0.52).  
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Figure 4.4Mean age at symptom onset by month of birth. All southern 
hemisphere birth dates were moved 6 months forward to sync with northern 
hemisphere seasons. 
 
Table 4.2 Univariable and multivariable analysis of factors associated with MS 
age at onset 
 Univariable Multivariable 
 N (%) β (95% CI) P β (95% CI) P 
Degree of latitude a      
 19.0-39.9 5,850 (26.40) 31.47 (31.21,31.72)  31.65 (31.40, 31.91)  
 40.0-49.9 10,879 (49.09) -0.88 (-1.19,-0.56) <0.001 -1.01 (-1.32, -0.69) <0.001 
 50.0-56.0 5,433 (24.51) -1.22 (-1.58,-0.86) <0.001 -1.86 (-2.22, -1.49) <0.001 
 Trend   <0.001  <0.001 
Winter UV ( Wh/m2) b      
 5.07-14.3 2,626 (11.85) 31.97 (31.59,32.36)  31.98 (31.57, 32.38)  
 3.27-5.07 6,429 (29.01) -1.53 (-1.98,-1.08) <0.001 -0.95 (-1.44, -0.46) <0.001 
 2.13-3.27 6,865 (30.98) -1.10 (-1.55,-0.65) <0.001 -1.35 (-1.81, -0.89) <0.001 
 0.8-2.13 6,242 (28.17) -1.50 (-1.96,-1.05) <0.001 -1.96 (-2.44, -1.49) <0.001 
 Trend   0.001  <0.001 
Sex a      
 Male 6,550 (29.56) 31.35 (31.11,31.59)  31.00 (30.77, 31.23)  
 Female 15,612 (70.44) -0.88 (-1.17,-0.60) <0.001 -0.43 (-0.70, -0.15) 0.002 
MS type a      
 Relapsing-onset 20,277 (91.49) 30.02 (29.89,30.15)  30.03 (29.90, 30.16)  
 Progressive-onset 1,885 (8.51) +9.29 (8.74,9.84) <0.001 +8.90 (8.35, 9.45) <0.001 
Season of birth a      
 Spring 5,483 (24.74) 30.51(30.25,30.77)  30.51(30.26, 30.75)  
 Summer 6,131 (27.66) +0.24 (-0.12, 0.60) 0.18 +0.20(-0.14, 0.55) 0.25 
 Autumn 5,025 (22.67) +0.25 (-0.13, 0.62) 0.19 +0.21(-0.15, 0.57) 0.24 
 Winter 5,523 (24.92) +0.37 (0.00, 0.73) 0.05 +0.36(0.00,0.71) 0.05 
Relapsing-onset: relapsing-remitting MS and secondary progressive MS;  
Progressive-onset: primary progressive MS and progressive relapsing MS 
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Each model with the factor of interest was adjusted for sex, latitude, MS type, average population age 
of each centre, sex ratio of each centre and MS type ratio of each centre; b: adjusted for sex, MS type, 
sex ratio of each centre and MS type ratio of each centre. 
4.6 Discussion 
Using one of the largest cohorts to date with 22,162 patients from 21 countries, we 
evaluated the role of latitude and age of MS symptom onset in adult, European-
descent patients. We found evidence that those living at a higher latitude had a 
significantly younger AAO, with every 10
°
 increase in latitude associated with around 
a ten month earlier AAO. The results were consistent when latitude was analysed as a 
categorical variable, demonstrating a strong inverse association between latitude and 
AAO, such that those in the highest latitudinal range had a nearly 2-years earlier onset 
than those in the lowest latitudinal range. Accordingly, we found a positive 
association between a lower winter ambient UV level and an earlier age at onset, 
these results neatly in harmony due to the known relationship between UV levels and 
latitude. Sex and MS type showed expected differences in AAO; however, we found 
no difference in AAO by season/month of birth.   
In line with our results, one previous study
26
 also found that latitude was negatively 
associated with AAO in RRMS patients, although this association was not significant 
(p=0.10). However, the magnitude of the latitudinal association observed in that study 
(1.3 years change in per 10º latitude) is greater than the findings in our study, the 
absence of significance simply reflecting their smaller sample size of 987 patients. 
The difference in those findings to the present work likely reflects the difference in 
study samples (mostly Caucasian US military veterans vs. a worldwide collaborative 
patient records database).  
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Variation of ambient winter UV is a possible but not the only explanation for this 
latitudinal variation in AAO, in line with previous research indicating associations 
between vitamin D/UV in MS onset and progression
27 28
. We utilised mean winter UV 
intensity in different centres as a predicted variable to analyse the association with 
AAO. Due to the close relationship between latitude and UVB radiation (r=-0.96, 
p<0.001 in our study), we were unable to extricate the individual effects to determine 
which was the more potent driver of effect. This likely reflects the less sensitive mode 
of assessing latitude or UV, by utilising surrogate latitude or ambient UV levels at the 
study centre rather than assessing individual participant exposure. However, the 
similarity of the two models also suggested UV radiation is the main factor 
underlying the association of latitude and onset age. Notably, other factors such as 
socioeconomicstatus and EBV infection may also contribute to the latitudinal gradient 
of ASO.  
A recent study in Japan demonstrated that latitude had a more significant impact on 
prevalence of MS than UVB
29
, and some studies have proposed that factors other than 
UVR may lead to the latitudinal gradient
7
. The latitudinal gradient of Epstein-Barr 
virus (EBV) infection prevalence may also partly explain the earlier onset at high 
latitudinal regions. A recent meta-analysis demonstrated that an increased rate of EBV 





 found a similar geographical distribution between 
infectious mononucleosis and MS that may also contribute to the latitudinal gradient 
in prevalence and also potentially age at onset. However, an ecological study
31
 
performed in Australia showed a closer relationship between ambient ultraviolet 
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radiation and MS prevalence (r=-0.91, p=0.01) when compared with the relationship 
of latitudes (r=0.89, p=0.02). Another study conducted by our group including 136 
MS patients found that increasing exposure to sun in adolescence was not associated 
with AAO
32
. However, this study found that skin phenotype was associated with 
AAO, which may be driven by the differential ability of skin types to absorb UV and 
synthesise vitamin D. A recent study
33
 with a larger sample size (n=540) suggested 
that cumulative sun exposure (more than 16 weeks) in fall/winter in the 9 to 15 years 
age group was associated with 2.1 years later AAO (p=0.02), persisting on adjustment 
for sunscreen use, cod liver oil intake, sex and skin type. Genetic variation is another 
potential factor that may account for the latitudinal gradient of AAO, our previous 
study
2
 demonstrated enhancement of the association between latitude and prevalence 
of MS by genotype particularly HLA-DRB1, another study
34
 showed that HLA-DRB1 
genotype could account for up to 52% of the latitudinal gradient of prevalence 
We also showed that women exhibit an earlier AAO than men and this relationship 
has been supported by many other studies. One study
15
 with 1,424 patients conducted 
in southeast Wales showed a significant difference of AAO between sexes (male 31.2, 
female 29.3, p=0.002). This difference is in the same direction as our results, but the 
magnitude was larger than ours. Likely the difference in magnitude reflects the 
different populations assessed. It may be that latitudinal or sex effects may be 
appreciably greater or lesser in local regions, but in a multicentre database-based 
study like ours, such regional differences may average out to yield a reduced 
magnitude of difference. Earlier puberty in females may be a candidate explanation 
for the earlier onset in females, as a study has found a positive association between 
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age of menarche and AAO
35
. Progressive-onset patients showed approximately 9 
years later onset than relapsing-onset patients. Some research has also shown a 





 within the Lyon Multiple sclerosis Cohort showed a similar 
magnitude to our study with their mean age at onset in PPMS and RRMS being 40.6 
and 29.4-years, respectively.  
Studies in a number of countries with a high prevalence of MS have demonstrated that 





 including 11,415 patients from 15 countries has shown that this 
seasonal association existed but did not correlate with variation in UVR exposure 
(p=0.086). A multicentre longitudinal study
39
 conducted in Australia also 
demonstrated a higher risk of MS for those born in November-December when 
compared to those born in May-June (p<0.01). Our study showed that there was no 
clear association with month or season of birth and AAO. This is in keeping with the 
finding that the association between MS risk and month of birth was debatable when 
enough variables were included in the analysis
40
 (especially those variables associated 
with regional and temporal variation).  
We made the assumption that patients generally were born and lived in the same 
latitude where the study centres were located. We found no evidence to indicated that 
MS patients were more likely to move to other areas after disease onset. This is not an 
unreasonable expectation; however, our inability to exclude patients who fell outside 
this assumption may affect our results. However, we believe that this misclassification 
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error should be evenly distributed and would not impact the association of latitude 
and AAO. 
In MSBase study, cases were diagnosed with Poser, Polman or McDonald‘s criteria, 
which may lead to some difference in the diagnosis of MS. We have adjusted for the 
ratio of MS type and sex to account for the different mixture of patients in each study 
centre. Moreover, the primary aim of the study was to analyse the association between 
latitude and age at onset, and no evidence of the significantly differential diagnosis by 
latitude was seen. We therefore believed that the potential spectrum effect would not 
influence the results materially. 
Our analysis had remarkable statistical power provided by 22,162 patients from an 
international clinic-based and private practice-based study. Accordingly, while we 
have noted statistical significance, we were appropriately focused on magnitudes of 
difference in AAO. Our study does have some limitations, however. Firstly, we had 
no individual information on diet, dietary supplementation (particularly with vitamin 
D), and likewise individual genetic characteristics was not available. The lack of 
personal information leads to a lower explainable variance in our study and 
insufficient control of the confounding bias. Secondly, despite the similarity in 
demographic data between MSBase and other observational studies, our sample could 
be somewhat skewed because it included patients from clinics and private practices 
from developed countries with a universal health cover, and excluded those who did 
not attend those clinics (e.g. severely disabled). It is difficult to predict how that 
would have affected the association between latitude and ASO. In order to control for 
some selection bias, all joined MS Base centres agreed to database all available 
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. We also weighted by the count of patients in each centre in our study, 
which decreased such inter-centre variation. However, we did not have data about the 
total number of MS patients in each centre or the proportion of patients enrolled in 
MSBase study in each centre. It would be hard to predict whether any sampling error 
would be differential by age of onset. As a result, it is not possible to predict whether 
it affected our main associations of interest and in which direction. Another limitation 
in this study was the potential measurement error of ASO. ASO of some cases could 
be inaccurate especially when the onset was progressive, which could have reduced 
our associations towards the null. However, no evidence was seen that the potential 
measurement error of ASO was differential in different latitudinal region. Moreover, 
when restricting to relapsing-onset cases, the association between latitude and ASO 
was still significant. Finally, birth cohort effect could influence the association 
between latitude and ASO materially especially when different generations of cases 
were included in multi-centres with unknown period of recruitment. However, the 
sensitivity analysis according to the date of birth (1920-1940, 1941-1950, 1951-1960, 
1961-1970, 1971-1980, 1981-1997) all showed a significant association between 
increased latitude and decreased ASO. Therefore, it was reasonable to consider that 
birth cohort effect would not influence the result materially. 
In conclusion, this study confirms the presence of a significant inverse latitudinal 
gradient in the onset age in multiple sclerosis; such that each 10º increased latitude 
was associated with a 0.8 years earlier onset. Our results also supported that variation 
of UVR exposure may play a role in the latitudinal gradient, although other factors 
like differential timing of EBV infection and genetic background may also have a 
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role. No difference in onset age by season or month of birth was seen, however, 
suggesting that while such in-utero effects may modulate MS risk, the onset age may 
be determined by latitudinally varying exposures occurring after birth. The increased 
likelihood of patients living in high latitude areas to suffer an earlier onset of MS may 
lead to improved understanding of MS aetiopathogenesis. 
4.7 Postscript 
This chapter demonstrated the latitudinal gradient of age at onset in patients with MS, 
and UVR is the possible candidate underlying this phenomenon. The next chapter 
investigates the role of a range of individual variables on age of symptom onset in 
patients with first demyelinating event. 
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Table 4.3List of centres 
 Number of 
patients (%) 
Mean age of 
onset 




Centres     
 Huixquilucan 69 (0.27) 31.31 28.90 19.41 ºN 
 Havana 134 (0.53) 33.67 39.89 23.05 ºN 
 Brisbane 162 (0.64) 32.49 36.25 27.47 ºS 
 Cordoba 17 (0.07) 32.44 34.72 31.40 ºS 
 Be'er Ya'akov 83 (0.33) 31.39 31.33 31.94 ºN 
 Perth 71 (0.28) 33.73 36.84 31.95 ºS 
 Newcastle 462 (1.83) 33.84 38.64 32.93 ºS 
 Sydney 745 (2.95) 34.10 37.21 33.87 ºS 
 Buenos Aires 626 (2.48) 32.37 34.43 34.60 ºS 
 Adelaide 257 (1.02) 34.31 39.00 34.93 ºS 
 Msida 87 (0.34) 32.40 41.50 35.90 ºN 
 Sevilla 216 (0.85) 31.73 39.12 37.39 ºN 
 Macarena 1,408 (5.57) 31.99 39.12 37.67 ºN 
 Melbourne 1,415 (5.6) 33.27 37.28 37.81 ºS 
 Geelong 98 (0.39) 33.11 39.55 38.15 ºS 
 Madrid 516 (2.04) 32.21 40.06 40.42 ºN 
 Salerno 445 (1.76) 31.61 41.92 40.68 ºN 
 New York 80 (0.32) 34.46 36.39 40.71 ºN 
 Avellino 246 (0.97) 33.03 42.96 40.91 ºN 
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Trabzon 646 (2.56) 30.59 29.05 41.00 ºN 
Bari 1,370 (5.42) 29.76 42.08 41.12 ºN 
Porto 254 (1.00) 32.27 40.05 41.16 ºN 
Samsun 520 (2.06) 29.67 28.69 41.29 ºN 
Barcelona 294 (1.16) 33.19 41.34 41.39 ºN 
Skopje 23 (0.09) 31.84 35.48 42.00 ºN 
Chieti 1,412 (5.59) 32.08 44.61 42.35 ºN 
Hobart 260 (1.03) 35.14 39.10 42.88 ºS 
Vizcaya 114 (0.45) 34.70 44.22 43.22 ºN 
Macerata 379 (1.50) 29.89 44.71 43.30 ºN 
San Sebastian 23 (0.09) 35.62 43.05 43.32 ºN 
Florence 245 (0.97) 33.77 45.54 43.77 ºN 
Bucharest 17 (0.07) 29.07 38.09 44.43 ºN 
Modena 400 (1.58) 33.75 43.70 44.65 ºN 
Parma 207 (0.82) 33.79 44.81 44.80 ºN 
Pavia 386 (1.53) 29.62 45.23 45.18 ºN 
Montreal 2,153 (8.52) 33.04 38.75 45.51 ºN 
Levis 713 (2.82) 34.11 37.57 46.74 ºN 
Budapest 68 (0.27) 28.41 42.04 47.50 ºN 
Debrecen 14 (0.06) 29.31 39.58 47.53 ºN 
Gyor 10 (0.04) 25.53 40.60 47.69 ºN 
Nyiregyhaza 4 (0.02) 25.80 38.74 47.95 ºN 
Paris 80 (0.32) 30.84 38.48 48.86 ºN 
Prague 1,787 (7.07) 29.22 40.00 50.08 ºN 
Brussels 417 (1.65) 31.38 37.80 50.85 ºN 
Sittard 598 (2.37) 33.98 40.62 51.00 ºN 
Roosendaal 136 (0.54) 36.68 40.62 51.54 ºN 
Den Bosch 382 (1.51) 34.48 40.62 51.70 ºN 
Nijmegen 1,181 (4.67) 33.97 40.62 51.81 ºN 
Gouda 271 (1.07) 35.94 40.62 52.01 ºN 
Craigavon 193 (0.76) 33.27 35.98 54.45 ºN 
Belfast 43 (0.17) 32.48 35.98 54.60 ºN 
Copenhagen 425 (1.68) 32.65 35.42 55.68 ºN 
Total 22,162 (100) 
Table 4.4 Stepwise analysis 
β (95% CI) P Adjustments & rationales 
Latitudea In this univariable analysis, we observed a dose-





-0.88 (-1.19,-0.56) 4.09x10-8 
50.0-
56.0 
-1.22 (-1.58,-0.86) 4.01x10-11 
Trend 3.68x10-11 
Latitudeb In this model, we adjusted for sex for each individual. 
Since female patients exhibited an earlier AAO, and the 
negative association between the count of female 
patients and latitude (r=-0.02, p=0.001), this 
adjustment was reasonable. However, the adjustment 
for sex did change the magnitude of latitude materially; 
19.0-
39.9 
31.46 (31.21, 31.72) 
40.0-
49.9 
-0.87 (-1.19, -0.56) 5.12x10-8 
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-1.22 (-1.58, -0.86) 4.25x10-11 
Trend 3.91x10-11 
Latitudec In this model, we adjusted for sex and MS type for each 
individual. Since PPMS patients exhibit a later AAO, 
and the positive association between the count of PPMS 
patients and latitude (r=0.09, p<0.001), this 
adjustment was reasonable. Moreover, adjustment for 




31.50 (31.25, 31.74) 
40.0-
49.9 
-0.86 (-1.16, -0.55) 3.75x10-8 
50.0-
56.0 
-1.41 (-1.76, -1.06) 2.49x10-15 
Trend 2.32x10-15 
Latituded In this model, we adjusted for sex and MS type for each 
individual and the average age of population in each 
centre. Since a positive association between population 
mean age and AAO (r=0.06, p<0.001) and latitude 
(p=0.49, r<0.001), it was reasonable to adjust for 
population average age.  
19.0-
39.9 
31.52 (31.26, 31.77) 
40.0-
49.9 
-0.89 (-1.21, -0.57) 4.18x10-8 
50.0-
56.0 
-1.44 (-1.79, -1.08) 2.76x10-15 
Trend 4.20x10-15 
Latitudee In this model, we adjusted for sex and MS type for each 
individual and the average age of population and sex 
ratio (F/M) of MS patients in each centre. Since female 
patients exhibit an earlier AAO, and the negative 
association between the ratio of female patients and 




31.58 (31.33, 31.84) 
40.0-
49.9 
-1.03 (-1.35, -0.72) 1.21x10-10 
50.0-
56.0 
-1.46 (-1.82, -1.11) 9.38x10-16 
Trend 2.14x10-15 
Latitudef In this model, we adjusted for sex and MS type for each 
individual and the average age of population, sex ratio 
(F/M) of MS patients and MS type ratio 
(POMS/ROMS) in each centre. Since RRMS patients 
exhibit an earlier AAO, and the positive association 
between the ratio of MS type and latitude (r=0.49, 
p<0.001), this adjustment was reasonable. The 
adjustment for the ratio of MS type enhanced the 
association between latitude and AAO, we could 
observe a clear dose-dependent association now. The 
proportion of PPMS patients were much higher in 
European nations than non-European nations 
(p<0.001), so this MS type ratio could modulate the 
magnitude and direction materially. 
19.0-
39.9 
31.65 (31.40, 31.91) 
40.0-
49.9 
-1.01 (-1.32, -0.69) 3.91x10-10 
50.0-
56.0 
-1.86 (-2.22, -1.49) 3.83x10-23 
Trend 3.78x10-23 
POMS: progressive onset MS; ROMS: relapsing-onset MS; AAO: age at onset 
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Chapter 5 Tobacco smoking, progressive-onset, cerebral 
dysfunction are associated with a delayed onset of multiple 
sclerosis and marijuana use with an earlier onset 
5.1 Preface 
The previous chapter investigated the associations between surrogate latitude and age 
at onset. This chapter will address aim 2 of the thesis - the effects of 
knowing/emerging risk factors on age of symptom onset using the AusImmune Study.  
5.2 Abstract 
Background: Age at symptom onset (ASO) is a prognostic factor that could affect 
disability development in patients with multiple sclerosis (MS). A number of factors 
are now known to influence the risk of MS, but their influence on the ASO is less 
well-investigated. 
Objective: Examine the associations between known or emerging MS risk factors and 
ASO.  
Methods: Multicentre study; cases (n=279) aged 18–59 years with a first clinical 
diagnosis of central nervous system demyelination, recruited at four Australian 
centres (latitudes 27°S to 43°S), from 1 November 2003 to 31 December 2006. 
Environmental/behavioural and initial symptoms variables were recorded at baseline 
interview through questionnaire and neurological review. Linear regression was used 
to assess the association between risk factors and ASO. 
Results: A history of tobacco smoking was associated with 3.05-years later ASO 
(p=0.002); a history of marijuana use was associated with 6.03-years earlier ASO 
(p<0.001); progressive-onset cases had 5.61-years later ASO (p=0.001); an initial 
presentation of bowel & bladder and cerebral functional impairment were associated 
with 3.39 (p=0.017) and 4.37-years (p=0.006) later ASO, respectively. Other factors, 
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including sex, offspring number, latitude of study site, history of infectious 
mononucleosis, HLA-DR15 &HLA-A2 genotype, 25(OH)D levels, and ultraviolet 
radiation exposure were not significantly associated with ASO.  
Conclusion: We found a novel association between a history of tobacco smoking and 
later onset, whereas marijuana use was associated with earlier onset. Behavioural 
factors might be important drivers of MS onset timing and may aid in our 
understanding of MS pathogenesis. 
5.3 Introduction 
Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the 




, lower vitamin D
3
 or 




, and evidence of past infection 
with Epstein-Barr virus
6
 are the main factors implicated in MS risk. Our group 
recently demonstrated that these risk factors could explain 63.8% of the attributable 
risk
7
, with 53.3% of that solely due to the environmental factors. Other factors such as 
HLA-A2 genotype
8
 (protective), offspring number
9
 (protective), and marijuana use
5
 
(detrimental), have some evidence of involvement in MS risk.  
While a number of studies have examined risk factors for the onset of MS, far fewer 
have tested associations with age at symptom onset (ASO), which is the age at which 
first symptoms suggestive of future MS occur. Some studies showed that lower sun 
exposure in adolescence was associated with earlier ASO
10 11
. One cohort study 
(n=895 cases) found no difference in ASO between never and ever smokers (32.29 
and 32.75 years, respectively)
12
. One study (n=816) found that cases with HLA-DR15 
risk genotype had roughly 2.5-years earlier onset
13
, a later pooled analysis (n=2,201) 
showed no association between HLA-DR15 genotype and ASO.
14
 The association 
between HLA-A2 genotype and ASO has also yielded inconsistent findings: Smestad 
and colleagues found a weak correlation between HLA-A2 genotype and a later ASO 
(p=0.07)
15
, but another study showed no association
16
. Regarding the onset type of 
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MS, our recent large study
17
 has found that primary-progressive MS (PPMS) patients 
had approximately 9 years later onset of initial symptoms than RRMS patients 
(p<0.001).   
In view of the conflicting evidence presented above, this paper examines the 
association between risk factors for MS onset and ASO in a cohort recruited soon 
after the first diagnosis of CNS demyelination (FCD). 
5.4 Methods 
The Ausimmune Study was an Australian multicentre case-control study
18
. 
Participants were aged 18-59 years and resident in a study region: Brisbane city 
(latitude 27 South), Newcastle city and surrounds (33S), Geelong city and the 
Western Districts of Victoria (37S), or the state of Tasmania (approximately 41-
43S). Incident cases (n=282) were referred to the study by medical specialists, 
following a first clinical diagnosis of CNS demyelination. A study neurologist 
confirmed the date and symptomatology of the demyelinating event(s) that led to 
study participation and conducted a full neurologic examination. In subsequent 
follow-up (AusLong study)
19
, three cases were found to have a non-MS condition, 
and 19 cases were confirmed as PPMS. Among all 279 cases, 219 had been diagnosed 
as MS at 5-year review. Among 260 relapsing-onset cases, 219 had their first ever 
symptom of CNS demyelination (FDE) during the study recruitment period (1 Nov 
2003 to 31 Dec 2006), with remaining cases having had a prior, previously 
unrecognised neurological event.   
The Ausimmune Study was approved by nine regional Human Research Ethics 
Committees. All participants gave written informed consent. 
5.4.1 Measurements 
Demographic, environmental, behavioural and neurological data were collected by 
self-reported questionnaire and face-to-face interview. Serum samples and biometric 
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measures were taken at face-to-face interview. Mean interval between study entry and 
date of FDE was 1.37 years. 
Clinical presentation was divided into seven categories (pyramid, cerebellar, 
brainstem, sensory, bowel & bladder, cerebral and visual) and confirmed by a 
neurologist via face-to-face interview at baseline. With in-person interview at study 
entry, questionnaire data collected included: a detailed smoking history of tobacco 
and marijuana use (ever smoked, current smoking status, age started/stopped 
smoking); history of infectious mononucleosis (―have you ever had glandular fever‖; 
those who did not know whether they had a history of IM were coded as not having 
had IM); number and age of all live births; and for females only, the age at menarche. 
Participants completed a life calendar from age 6 years noting, for each year of life, 
the location of residence, and leisure time in the sun in summer and winter. With the 
latitude and longitude of the location, average daily ambient erythemally weighted 
UVR was calculated for every year of life for each participant
4
. For each participant, 
UVR dose (kJ/m
2
) was summed in relevant periods of life by multiplication of the 
average hours per day in each season outside and average UVR for that season. 
Annual UVR exposure was assigned by adding the summer and winter UVR dose.  
Serum concentrations of 25(OH)D were measured using liquid chromatography dual 
mass spectrometry at study completion. Skin reflectance on the buttock (non-sun-
exposed site) was measured using a hand-held spectrophotometer (Minolta CM-
2500D) to estimate cutaneous melanin density
4
. The genotyping of HLA-DR15 (SNP 
rs9271366) was performed by the SNPline method (KBiosciences, HoddesdonHerts, 
UK). The genotyping of HLA-A2 (SNP rs2844821 on Illumina Custom MS Chip) was 
performed by the Hussman Institute for Human Genomics, University of Miami.  
5.4.2 Data analysis 
ASO was calculated by subtracting the date of birth from the date of first symptom 
onset (as determined by review of data by the study neurologist team). Where only the 
year of symptom onset was recorded, the onset date was assigned as 15
th
 of June of 
that year and if only the month was known it was assigned as the 15
th
 of the month 
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(month of FDE was not sure in 27 cases, but results were robust when these cases 
were dropped (data not shown)). 
Because 25(OH)D levels vary substantially by season, we deseasonalised 25(OH)D 
levels in each study centre using a sinusoidal function, as described previously
4
. The 
25(OH)D level was modelled as both a continuous and categorical variable (using 
commonly used cut-points, <50, 50-75, 76-100, >100 nmol/L). Measurement of body 
mass index was after study entry, so we did not adjust for it in the multivariable 
model.  
Logbinomial regression was used to assess the association between two categorical 
variables. Linear regression was used to assess the association between potential 
predictors and ASO. We mostly examined risk factors that occurred prior to the initial 
symptom onset to ensure proper temporality. 25(OH)D was measured at the baseline 
review. For variables that were inherently associated with age (e.g. smoking, sun 
exposure, offspring number), we summarized the information prior to a specific age 
and examined the associations with ASO after this age to obtain a less biased 
estimate. This ensured that the participants included in the analysis had an equal 
opportunity of exposure, but it substantially reduced the power (analysis restricting to 
those with a later ASO). It also assumes that there is nothing unusual about those with 
a later ASO. Where participants with an early onset were excluded from the study, the 
distribution was left skewed. Box-Cox power transformation was then applied to 
reduce heteroskedasticity and thus satisfy the requirements of linear regression. All 
coefficients presented in the results were back-transformed on the original scale of 
age.  
In preliminary analyses, participants in Tasmania had a later ASO than other study 
centres (mean difference between Tasmania and other centres: 3.19 years, 95% CI 
0.73-5.65, p=0.011). The higher ASO is likely to have been due to the higher average 
age of the Tasmanian population; however, due to collinearity between the population 
mean age and study centre (r=0.91, p<0.001), adjustment for population mean age 
was not possible. We therefore divided cases into five-year ASO groups (15-19 years, 
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20-24 years, 25-29 years, 30-34 years, 35-39 years, 40-44 years, 45-49 years, 50-54 
years, 55-59 years) in each study centre, and standardised the ASO to the age 
distribution in the whole Australian population. After standardisation, ASO (from 
highest to lowest latitude: 37.2, 37.6, 37.0 & 37.2 years, respectively) was similar in 
the four different study centres. 
In the basic multivariable model for each exposure of interest, we adjusted for sex and 
study centre, and MS onset type (relapsing vs progressive onset). For sun exposure 
analysis, we did not adjust for study centre due to collinearity (latitude and ambient 
UVR are strongly negatively correlated). We adjusted for buttock melanin density to 
take natural skin type into consideration. For smoking analyses, we further adjusted 
for tobacco or marijuana smoking, due to the significant positive correlation between 
them (r=0.40, p<0.001). 
After the univariable and multivariable analyses of each category of exposures, we 
built a mutually adjusted model including all significant exposures, and examined the 
total variance explained by these exposures. The relative contribution of each variable 
was calculated as the change of the residual sum of squares (SSs) when comparing the 
model without the variable with the full model.  
To examine whether our key findings were robust, we conducted a number of 
sensitivity analyses. First, a number of cases had their FDE before the recruitment 
period and the reliability of the symptom onset date was somewhat uncertain. 
Therefore, we conducted a sensitivity analysis restricted to cases with FDE during the 
recruitment period (all these patients were relapsing-onset). Second, as a small 
percentage of our cases may never convert to MS, we performed a separate analysis 
restricted to cases who had converted to MS by a 5-year follow-up
19
. Third, we were 
concerned that some associations were the result of an age effect or a cohort effect. To 
examine this we used the controls (n=545)and assigned the same ASO of the cases to 
their age and sex-matched controls. If association were also observed in controls, then 
that is likely due to an age or cohort effect.  
All statistical analyses were undertaken using Stata/SE 12.1 (College Park, TX). 
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The mean ASO for the total cohort was 37.3 years and 76.7% were females. ASO for 
those who had converted to MS at 5-year follow-up (n=217) was 37.0 years and for 
cases with FDE during the recruitment period (n=219) was 36.9 years.  
5.5.1 Sex, HLA-DR15, HLA-A2 and history of infectious 
mononucleosis 
We found no significant associations between ASO and sex, history of IM, HLA-
DR15 genotype, or HLA-A2 genotype (Table 1). 
5.5.2 Vitamin D and UVR dose 
We explored season of FDE and its association with AAO, finding no seasonal pattern 
(F=0.61, p=0.72). There was no association between deseasonalised 25(OH)D and 
ASO, either as a continuous (p=0.88) or categorical term (p=0.67) (Table 1). Time 
between FDE and 25(OH)D level being taken did not modify the association between 
25(OH)D and ASO (test for interaction p=0.38). Cumulative UVR dose (summer, 
winter, and combined) within 15 years prior to onset was not associated with ASO 
(Table 1). Different risk windows (e.g. 5 and 10 years) or UVR dose during 
adolescence (6-15 years) also showed no convincing associations with subsequent 
ASO (Supplementary Table 2).   
Table 5.1 Associations between sex, IM history, HLA-DR15 genotype, HLA-A2 
genotype, 25(OH)D, UV exposure and age of symptom onset 
  Univariable Multivariable 
 No. (%) β (95% CI) p β (95% CI) p 
Sex
 a
      
 Male 65 (23.30) 37.50 (35.17, 39.83) 
c
  37.21 (34.90, 39.52)
 c
  
 Female 214 (76.70) -0.28 (-2.94, 2.38) 0.842 +0.15 (-2.49, 2.80) 0.913 
Past history of IM 
a
      
 No 200 (72.99) 37.61 (36.30, 38.92)
 c
  37.7 (36.41, 39.00)
 c
  
 Yes 74 (27.01) -1.18 (-3.70, 1.34) 0.355 -1.33 (-3.83, 1.18) 0.302 
HLA-DR15 (rs9271366)
 a
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 AA 106 (43.80) 37.19 (35.38, 39.00)
 c
  36.89 (34.91, 38.86)
 c
  
 AG 123 (50.83) +0.40 (-2.07, 2.86) 0.748 +1.42 (-1.26, 4.09) 0.303 
 GG  13 (5.37) +3.18 (-2.26, 8.63) 0.254 +4.74 (-2.43, 11.91) 0.203 
 Trend    0.380  0.151 
HLA-A2 (rs2844821)
 a
      
 AA 117 (54.42) 36.93 (35.22, 38.64)
 c
  37.17 (35.43, 38.92)
 c
  
 AG 98 (45.58) +1.79 (-0.74, 4.31) 0.173 +1.38 (-1.24, 4.01) 0.298 
Season of FDE
b
      
 Spring 70 (25.09) 36.9 (34.47, 39.34) 
c
  37.2 (34.69, 39.7) 
c
  
 Summer 72 (25.81) +1.00 (-2.27, 4.26) 0.548 0.01 (-3.39, 3.42) 0.989 
 Autumn 61 (21.86) +0.05 (-3.28, 3.37) 0.978 -0.42 (-3.8, 2.97) 0.813 
 Winter  76 (27.24) +0.40 (-2.87, 3.66) 0.813 0.43 (-2.89, 3.76) 0.804 
Deseasonalised 25(OH)D,  
continuous  
(per 10 nmol/L increase)
 b
 
 -0.04 (-0.48, 0.40) 0.872 -0.03 (-0.48, 0.41) 0.880 
Deseasonalised 25(OH)D
 b
      
 < 50 nmol/L 33 (15.57) 36.95 (33.68, 40.22)
 c
  36.92 (33.64, 40.19)
 c
  
 50 - 75 nmol/L 70 (33.02) -0.19 (-4.16, 3.77) 0.923 -0.33 (-4.32, 3.65) 0.869 
 76 - 100 nmol/L 70 (33.02) -0.68 (-4.65, 3.28) 0.741 -0.75 (-4.72, 3.22) 0.713 
 > 100 nmol/L 39 (18.40) +1.26 (-3.18, 5.71) 0.579 +1.19 (-3.25, 5.64) 0.602 
 Trend    0.667  0.673 
Winter UV dose 




     




 64 (24.81) 39.62 (37.43, 41.81)
 c
  39.68 (37.47, 41.9)
 c
  




 65 (25.19) -3.05 (-6.12, 0.02) 0.053 -3.37 (-6.46, -0.28) 0.032 




 64 (24.81) -1.95 (-5.04, 1.14) 0.219 -2.06 (-5.22, 1.09) 0.203 




 65 (25.19) -1.43 (-4.51, 1.65) 0.358 -1.37 (-4.50, 1.76) 0.389 
 Trend   0.530  0.568 




     




 64 (24.71) 39.82 (37.66, 41.97)
 c
  39.54 (37.35, 41.73)
 c
  




 65 (25.10) -3.91 (-6.91, -0.91) 0.011 -3.75 (-6.77, -0.73) 0.015 




 65 (25.10) -3.95 (-6.95, -0.95) 0.010 -3.87 (-6.93, -0.81) 0.013 




 65 (25.10) +0.38 (-2.66, 3.42) 0.810 +1.07 (-2.15, 4.28) 0.523 
 Trend   0.812  0.649 
Annual UV dose in the  
15 years before onset
 b
 
     




 64 (24.81) 39.35 (37.18, 41.52)
 c
  39.09 (36.89, 41.3)
 c
  




 65 (25.19) -3.13 (-6.15, -0.10) 0.043 -3.01 (-6.07, 0.04) 0.053 




 64 (24.81) -3.42 (-6.45, -0.38) 0.027 -3.26 (-6.37, -0.15) 0.040 




 65 (25.19) +0.85 (-2.21, 3.91) 0.587 +1.41 (-1.79, 4.61) 0.386 
 Trend    0.643  0.482 
Statistical significance (p<0.05) was denoted in bold and italics. 
a: adjusted for sex, MS onset type and study centre; b: adjusted for sex, MS onset type and buttock melanin density;  
c: mean ASO of the reference group  
Abbreviations: MS, multiple sclerosis; IM, infectious mononucleosis; UV, ultraviolet; FDE, first demyelinating 
event. 
5.5.3 Onset type and initial symptoms 
We also explored the association between initial symptoms and ASO, and it was 
acknowledged that these initial symptoms with their preceding pathological process 
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occurred more or less simultaneously with ASO. However, we believed that these 
analyses may provide a valuable contribution the mechanisms underlying MS onset. 
ASO of progressive-onset patients was 5.61-years later than relapsing-onset patients 
(p=0.013) (Table 2). There was no association between the occurrence of pyramidal, 
brainstem, sensory, visual dysfunction and ASO (Table 2). Cases with bowel/bladder 
and cerebral function impairment had 3.49-years (p=0.017) and 4.37-years (p=0.006) 
later onset compared to those without these symptoms, respectively, persisting on 
restriction to relapsing-onset cases. 
Table 5.2Associations between onset type/initial symptoms and age of symptom 
onset 
  Univariable analysis  Multivariable analysis 
 No. (%) β (95% CI) p β (95% CI) p 
MS onset type      
 Relapsing-onset 258 (92.47) 36.99 (35.84, 38.15) b  36.95 (35.8, 38.09) b  
 Progressive-onset 21 (7.53) +4.86 (0.44, 9.28) 0.031 +5.61 (1.17, 10.05) 0.013 
Onset symptoms      
 Pyramid function-no  150 (58.37) 37.51 (35.98, 39.04) b  37.86 (36.33, 39.38) b  
 Pyramid function-yes 107 (41.63) +0.21 (-2.17, 2.58) 0.861 -0.52 (-2.94, 1.90) 0.672 
 Cerebellar function-no  185 (72.27) 36.89 (35.53, 38.26) b  37.01 (35.66, 38.37) b  
 Cerebellar function-yes  71 (27.73) +2.83 (0.24, 5.41) 0.032 +2.52 (-0.08, 5.12) 0.062 
 Brainstem function-no  192 (75.59) 37.43 (36.06, 38.79) b  37.4 (36.06, 38.75) b  
 Brainstem function-yes 62 (24.41) -0.13 (-2.90, 2.64) 0.931 0.15 (-2.59, 2.89) 0.920 
 Sensory function-no  114 (45.6) 37.6 (35.83, 39.37) b  37.56 (35.81, 39.3) b  
 Sensory function-yes 136 (54.4) -0.48 (-2.88, 1.92) 0.703 -0.33 (-2.70, 2.05) 0.791 
 Bowel & Bladder function-no  210 (79.55) 36.84 (35.56, 38.12) b  36.85 (35.58, 38.12) b  
 Bowel & Bladder function-yes 54 (20.45) +3.39 (0.57, 6.20) 0.019 +3.49 (0.63, 6.34) 0.017 
 Cerebral function-no  218 (83.52) 36.71 (35.47, 37.95) b  36.87 (35.64, 38.1) b  
 Cerebral function-yes 43 (16.48) +5.12 (2.08, 8.15) 0.001 +4.37 (1.28, 7.46) 0.006 
 Visual function-no  178 (70.92) 37.64 (36.25, 39.03) b  37.74 (36.38, 39.10) b  
 Visual function-yes 73 (29.08) -0.80 (-3.38, 1.77) 0.539 -1.00 (-3.54, 1.54) 0.439 
Onset symptoms in  
relapsing-onset cases 
     
 Pyramid function-no  147 (61.51) 37.22 (35.70, 38.75) b  37.35 (35.84, 38.86) b  
 Pyramid function-yes 92 (38.49) -0.09 (-2.55, 2.37) 0.942 -0.36 (-2.80, 2.09) 0.773 
 Cerebellar function-no  179 (74.27) 36.55 (35.18, 37.92) b  36.55 (35.19, 37.91) b  
 Cerebellar function-yes  62 (25.73) +2.82 (0.11, 5.52) 0.041 +2.91 (0.21, 5.60) 0.034 
 Brainstem function-no  179 (74.9) 36.79 (35.39, 38.18) b  36.78 (35.41, 38.16) b  
 Brainstem function-yes 60 (25.1) +1.06 (-1.72, 3.83) 0.452 +1.14 (-1.61, 3.90) 0.418 
 Sensory function-no  106 (45.3) 37.15 (35.34, 38.96) b  37.12 (35.33, 38.91) b  
 Sensory function-yes 128 (54.7) -0.29 (-2.73, 2.15) 0.809 -0.21 (-2.63, 2.21) 0.866 
 Bowel & Bladder function-no  201 (81.71) 36.52 (35.23, 37.81) b  36.43 (35.16, 37.71) b  
 Bowel & Bladder function-yes 45 (18.29) +3.33 (0.31, 6.34) 0.031 +3.90 (0.88, 6.93) 0.011 
 Cerebral function-no  205 (84.36) 36.35 (35.10, 37.61) b  36.47 (35.21, 37.72) b  
 Cerebral function-yes 38 (15.64) +5.20 (2.02, 8.39) 0.001 +4.54 (1.30, 7.78) 0.006 
 Visual function-no  166 (70.34) 37.10 (35.68, 38.51) b  37.23 (35.83, 38.63) b  
 Visual function-yes 70 (29.66) -0.24 (-2.84, 2.37) 0.859 -0.63 (-3.22, 1.96) 0.632 
Statistical significance (p<0.05) was denoted in bold and italics.                                                                                                        
a: adjusted for sex, MS type, and study centres; b: mean ASO of the reference group 
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5.5.4 Smoking of tobacco and marijuana 
Ever smokers had approximately 5.11-years later onset than those who never smoked 
(p<0.001) (Table 3). The magnitudes were similar between past smokers and current 
smokers. Cases with an earlier ASO might have had less opportunity to start smoking, 
so we tested this by only including cases with ASO ≥28 years (as 27 was the oldest 
age of taking up smoking in this cohort). While attenuating the magnitude, a history 
of smoking remained significantly associated with ASO (Table 3). To examine 
whether the results were due to an age or cohort effect, we repeated the analysis in the 
matched healthy controls. Each control was given the ASO of the matched cases. If 
the association was also observed in controls, then that is likely due to an age or 
cohort effect. We found no association between smoking status and  ASO (never 
smokers vs. ever smokers: adjusted β=+0.11 years, 95% CI -1.54 - 1.77, p=0.89), 
suggesting the significant association in cases was not due to an age or cohort effect. 
Among ever smokers, the ASO was similar whether the smoking was taken up early 
(<16 years) or later (pinteraction=0.26), or the duration was longer or shorter 
(pinteraction=0.94). 
Marijuana use was more common in male cases than in females (OR=0.50, p=0.020), 
and a history of marijuana use was positively associated with smoking (OR=8.05, 
p<0.001). A history of marijuana use was associated with a 6.03-years earlier ASO 
(Table 3). The magnitudes were similar between past users and current users. We next 
evaluated associations among cases with ASO ≥31 years (30 years was the oldest age 
of taking up marijuana in this cohort). Magnitudes were attenuated but still highly 
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significant: in this subgroup, current marijuana users had a 3.88-years earlier onset 
than cases without a marijuana history (Table 3).   
Table 5.3Associations between smoking behaviours and age of symptom at onset 
  Univariable  multivariable 
a
 
 No. (%) β (95% CI) P β (95% CI) P 
Smoking ever      
 No 103 (37.59) 35.6 (33.79, 37.41)
 b
  34.24 (32.41, 36.06)
 b
  
 Yes 171 (62.41) +2.71 (0.42, 5.00) 0.021 +5.11 (2.74, 7.48) <0.001 
Smoking ever 
 (ASO ≥ 28 years)  
     
 No 79 (35.59) 38.71 (37.2, 40.22)  37.89 (36.45, 39.34)  
 Yes 143 (64.41) +1.79 (-0.12, 3.71) 0.073 +3.05 (1.16, 4.95) 0.002 
Smoking status      
 Never smoked 103 (37.59) 35.6 (33.78, 37.41)
 b
  34.21 (32.38, 36.03)  
 Past smokers 101 (36.86) +2.62 (0.04, 5.20) 0.047 +4.80 (2.21, 7.38) <0.001 
 Current smokers  70 (25.55) +2.85 (-0.01, 5.70) 0.054 +5.66 (2.69, 8.64) <0.001 
 Trend    0.037  <0.001 
Smoking status 
 (ASO ≥ 28years)  
     
 Never smoked 79 (35.59) 38.71 (37.2, 40.22)  37.89 (36.44, 39.34)  
 Past smokers 83 (37.39) +2.12 (-0.05, 4.30) 0.062 +3.05 (0.95, 5.14) 0.004 
 Current smokers  60 (27.03) +1.34 (-1.01, 3.68) 0.273 +3.06 (0.65, 5.47) 0.013 
 Trend    0.219  0.010 
Age uptake smoking  
(ASO ≥ 28years)  
    
 ≥16 years 84 (58.74) 41.45 (39.85, 43.05)  41.21 (39.72, 42.7)  
 <16 years 59 (41.26) -1.77 (-4.22, 0.68) 0.162 -1.35 (-3.66, 0.97) 0.258 
Duration of smoking before 
age 27 (ASO ≥ 28years)  
    
 ≤ 10 years 55 (40.44) 40.97 (38.99, 42.95)  40.58 (38.67, 42.5)  
 >10 years 81 (59.56) -0.51 (-3.07, 2.04) 0.693 +0.10 (-2.40, 2.60) 0.942 
Marijuana ever      
 No 190 (69.6) 38.58 (37.26, 39.9)
 b
  39.23 (37.91, 40.55)
 b
  
 Yes 83 (30.4) -4.04 (-6.43, -1.64) 0.001 -6.03 (-8.62, -3.45) <0.001 
Marijuana ever 
 (ASO ≥ 31 years) 
     
 No 151 (74.02) 41.29 (40.24, 42.34)
 b
  41.5 (40.43, 42.57)
 b
  
 Yes 53 (25.98) -2.20 (-4.14, -0.27) 0.026 -2.80 (-4.89, -0.71) 0.009 
Marijuana status      
 Never  190 (69.6) 38.58 (37.26, 39.90)
 c
  38.56 (37.25, 39.87)
 b
  
 Past users  63 (23.08) -4.08 (-6.73, -1.43) 0.003 -3.98 (-6.63, -1.34) 0.003 
 Current users 20 (7.33) -3.92 (-8.20, 0.37) 0.070 -3.46 (-7.87, 0.94) 0.123 
 Trend    0.003  0.004 
Marijuana status 
 (ASO≥31 years) 
     
 Never  151 (74.02) 41.28 (40.24, 42.33)
 b
  41.25 (40.22, 42.28)
 b
  
 Past users  39 (19.12) -1.50 (-3.71, 0.70) 0.175 -1.35 (-3.58, 0.88) 0.238 
 Current users 14 (6.86) -4.06 (-7.16, -0.95) 0.010 -3.88 (-7.09, -0.66) 0.018 
 Trend    0.008  0.016 
Statistical significance (p<0.05) was denoted in bold and italics.                                                                                                        
a: adjusted for sex, MS type,  study centresand tobacco smoking status/marijuana use status ; b: mean ASO of the 
reference group 
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5.5.5 Offspring numbers and age at menarche 
Having children was strongly associated with a later ASO (Table 4). The magnitude 
was potentially biased since those with a later ASO may have had different 
opportunities to have children. We therefore chose a cut-off point of ASO that 
balanced sample size against the offspring number information, and by restricting to 
those with ASO≥31 years, we could include 204 cases and 56.9% of participant 
offspring. After restriction, a significant dose-dependent association remained, albeit 
with reduced magnitude; e.g. those with 1 child had, on average, a 1.39 year later 
onset, and those with ≥2 children had a 3.61-years later onset. This dose-dependent 
association was found in both male and female participants (test for interaction 
p=0.11), actually of greater magnitude in males than females. To examine whether the 
results were due to an age or cohort effect, we repeated the analyses in the healthy 
controls where the controls were assigned the same ASO as their matched cases. 
Having more children was also significantly associated with a later ASO in controls 
(0 vs. 1: β=4.55, p<0.001; 0 vs. ≥2: β=10.41, p<0.001; p for trend<0.001), and 
restricting to those with ASO≥31 years still showed a significant association (0 vs. 1: 
β=1.39, p=0.16; 0 vs. ≥2: β=3.48, p<0.001; p for trend<0.001). This suggests that the 
significant association of offspring number and ASO in cases was largely driven by 
an age or cohort effect. 
The age of the participant when having their first child (≤20, 21-25, 26-30, 31-35, 
≥36) was not associated with ASO; the average ASO was around 41 years for each 
child birth age group. There was no association between age of menarche and ASO 
(p=0.22), persisting after adjustment for MS onset type and study centre. 
Table 5.4Associations between offspring numbers/age at menarche and age of 
symptom onset 
  Univariable  multivariable  
 No. (%) β (95% CI) p β (95% CI) p 
Offspring number 
a
      
 0 111 (39.78) 31.16 (29.7, 32.63) 
c
  31.37 (29.9, 32.83) 
c
  
 1  39 (13.98) +5.97 (3.01, 8.92) <0.001 +5.51 (2.57, 8.44) <0.001 
 2 or more 129 (46.24) +11.12 (9.06, 13.18) <0.001 +10.88 (8.84, 12.93) <0.001 
 Trend    <0.001  <0.001 
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Offspring number  
(ASO ≥ 31 years) 
b
 
     
 0 89 (43.00) 39.25 (37.99, 40.5) 
c
  39.22 (37.99, 40.45) 
c
  
 1  37 (17.87) +1.67 (-0.74, 4.09) 0.182 +1.39 (-0.98, 3.77) 0.254 
 2 or more 81 (39.13) +3.42 (1.47, 5.36) 0.001 +3.61 (1.69, 5.54) <0.001 
 Trend    0.001  <0.001 
Age of menarche 
a
      
 8-12 years 98 (46.23) 37.07 (35.17, 38.97)
 c
  37.13 (35.24, 39.01)
 c
  
 13-14 years 87 (41.04) +1.13 (-1.64, 3.9) 0.432 +0.98 (-1.8, 3.75) 0.493 
 15-23 years 27 (12.74) -4.19 (-8.24, -0.15) 0.042 -3.72 (-7.76, 0.32) 0.068 
 Trend   0.221  0.269 
Statistical significance (p<0.05) was denoted in bold and italics.                                                                                 
a: adjusted for sex, MS type, and study centres; b: samples limited to those with ASO ≥ age 31 years and 
summarizing offspring number < age 31 years, adjusted for sex, MS type, and study centres. c: mean ASO of the 
reference group 
5.5.6 Mutually adjusted model 
We next built a combined model based on the significant findings (tobacco smoking, 
marijuana use, MS onset type, cerebral dysfunction, and bowel & bladder 
dysfunction). The final model explained approximately 12% of the total variance in 
ASO, with marijuana use and tobacco smoking having the largest relative 
contributions (Table 5). 
Table 5.5Mutually adjusted model including all 
factors associated with age of symptom at onset. 
 All cases (adjusted R
2 
=0.12) 
 β (95% CI) P  RC 
Smoking status   5.0% 
 Never smoking 35.14 (33.31, 36.98)   
 Past users +3.80 (1.21, 6.40) 0.004  
 Current users  +4.72 (1.74, 7.71) 0.002  
 Trend  0.001  
Marijuana history    9.2% 
 Never marijuana 39.47 (38.17, 40.78)   
 Past users  -5.49 (-8.29, -2.70) <0.001  
 Current users -7.23 (-11.75, -2.71) 0.002  
 Trend   <0.001  
MS onset type    0.6% 
 RRMS 37.58 (36.46, 38.69)   
 PPMS +2.23 (-2.05, 6.52) 0.313  
Cerebral function   5.9% 
 No 36.96 (35.78, 38.14)   
 Yes +4.58 (1.68, 7.48) 0.002  
Bowel & bladder function   1.2% 
 No 37.3 (36.09, 38.51)   
 Yes +2.13 (-0.61, 4.87) 0.130  
Statistical significance (p<0.05) was denoted in bold and italics.                                                                              
RC: relative contribution                                                                                                                                                 
a: mean ASO of the reference group 
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5.5.7 Sensitivity analyses 
Sensitivity analyses that restricted to cases with FDE during the study recruitment 
period or diagnosed MS cases did not materially alter the results (Supplementary 
Tables). 
5.6 Discussion 
In this comprehensive study, we systematically evaluated the association between 
ASO and established / emerging risk factors for MS onset. A model including all the 
significant factors explained 12% of the total variance. Of the individual risk factors, 
a history of tobacco smoking, progressive-onset type, and cerebral / bowel & bladder 
function impairment at onset were associated with a later onset, while marijuana use 
was associated with an earlier onset. HLA-A2 genotype, HLA-DR15 genotype, latitude 
of study site, past sun exposure, current 25(OH)D levels, history of IM, offspring 
number, age of menarche and sex were not associated with ASO.  
A strength of our study is the detailed information on exposure variables, as well as 
the study neurologist interview and review of medical records for optimal assessment 
of the ASO. Also, our findings showed a robustness when repeating the analysis 
among those with diagnosed MS by 5-year review (potentially excluding some cases 
who may yet convert to MS after this point), as well as restricting to cases with FDE 
during study recruitment period (excluding some whose ASO was slightly less certain 
as they had had a previously unrecognised event thought to now represent CNS 
demyelination). A challenge was that a number of exposures were intrinsically 
associated with ASO (i.e. those who had a later ASO would have greater opportunity 
to accumulate a higher level of exposure before onset simply as a function of time). 
To overcome this issue, we assessed the temporal relationship between exposures and 
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outcome through analysing some exposure variables before a specific age and 
analysing the association with ASO after this point. This, however, reduced the 
sample size for those analyses, and also assumed that there was nothing unusual about 
those with a later vs earlier onset. To examine whether some observed associations 
were due to an age or cohort effect, we tested the existence of an effect existed in the 
age and sex matched controls. Based on these analyses, we believe that the between 
offspring and ASO was not a true association. 
Another limitation was that some exposures such as IM and past exposure to sunlight 
happened years prior to study entry, and it was difficult for us to detect whether 
information about these variables was accurately recorded at baseline interview. IM 
was decoded into two ways (those who did not know whether they had an IM before 
was decoded as no history of IM and missing) to decrease the influence of the 
potential error of recall. We used lifetime calendar to measure the past exposure to 
sunlight, which has been suggested to be valid by some research with the 
polysulphone badge readings as the comparison method
41
. Influence of potential 
recall error was extremely difficult of be controlled for fully, however, there was no 
evidence that the potential recall error of these variables was systematically 
differential by age at onset, and the significant association between these exposures 
and MS onset/relapses suggested that the influence of the potential error of recall was 
minor on the results. 
Age at onset in Ausimmune study was measured and reviewed by experienced 
neurologists. However, we still could not determine that no measurement error existed 
in the study especially in the progressive-onset cases. We did some sensitivity 
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analysis in the relapsing-onset cases with date of FDE during recruitment period, 
which showed a similar association with our primary analysis. Moreover, there was 
no evidence that the potential measurement error of ASO was differential with the 
exposures of interest and a biased ASO would have reduced the association towards 
null. We therefore believed that the potential measurement error of ASO would not 
influence the results martially. 
In agreement with previous studies
17 20 21
, progressive-onset patients showed a later 
ASO than relapsing-onset patients. In this study, patients with initial presentation of 
cerebral or bowel & bladder function impairment showed a 4.4 and 3.5 years later 
ASO, respectively. This is partly in contrast to a previous study
22
, which found no 
association between psychiatric (p=0.31) or cognitive (p=0.93) symptoms and ASO, 
while a positive relationship between sphincteric symptoms and ASO was shown 
(p=0.012). Notably there were marked differences in the ASO between these studies – 
roughly 37 years in the current study compared to approximately 30 years – and this 
may account for the divergent findings.  
Despite tobacco smoking being typically shown to be a risk factor for FCD, including 
in the Ausimmune Study
5
, in this study tobacco smoking delayed the average ASO by 
4 years in our multivariable model. Two other studies have also shown a similar 
direction of the association with our study, magnitude 2.60 years (n=7,883)
23
 and 0.82 
years (n=540)
11
, respectively. A null association between tobacco smoking and ASO 
in controls supported that this association was not due to an age or cohort effect. A 





 is challenging. It could relate to the anti-inflammatory effects of nicotine 
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upon T-cells, B-cells and even dendritic cells
25
. It is possible that tobacco smoking 
more impact more on neurodegeneration rather than immune dysfunction
26
 and older 




Marijuana use was associated with a 6.0-years earlier ASO, despite our previous 
findings from the Ausimmune Study
5
 showing no association between marijuana use 
and MS risk (never vs. ever, adjusted OR 0.91 (0.84-1.54)). Other research has also 
demonstrated a detrimental effect of marijuana on the CNS. Two studies
28 29
 have 
showed that marijuana use was associated with poorer cognitive performance in MS 
patients. Thus there is some epidemiological evidence in support of potential 
deleterious impacts of marijuana use in MS, though the means by which this occurs 
and why its impact is deleterious but that of tobacco is not, requires further study.  
Consistent with previous research
10 11 15 30
, we found no association between sex, 
history of infectious mononucleosis, HLA-A2 or HLA-DR15 genotype and ASO. 
Latitude of study site, deseasonalised 25(OH)D levels and UVR exposures were not 
associated with ASO in the present study. Using the large MSBase global dataset 
(n=22,162), we had previously found an inverse association between latitude and 





. However, in line with the present study, subgroup analysis restricting 
to Australian participants showed a non-significant association. We were unclear why 
this latitudinal gradient was not found in Australia, and we assumed that some 
difference between Europe and Australia in temperature, culture/lifestyle, genetics
16
 
may underlie the disparate findings. Our previous study also found that increasing 
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UVR exposure from age 6-15 years or lifetime actinic damage was not associated 
with ASO
31
. Another cross-sectional study
10
 of 1,161 MS patients found that vitamin 
D-associated SNPs and vitamin D supplementation (multivitamin/vitamin D or fatty 
fish) were not associated with ASO.  
The disparate findings in different outcomes (ASO, risk of MS, and progression 
measures such as relapses) were not unexpected. While there might be an increased 
likelihood for a factor to be related with multiple outcomes, this should not be seen to 
be ―in contrast‖ with the literature, and therefore does not invalidate our findings. For 
example, EBV has been significantly associated with MS onset but no determined 
effect has been made with MS progression. We therefore prefer limit to the literature 
to factors associated with ASO. 
For a study with participants enrolled from different centres, the influence of 
spectrum effect was considered in the analysis. In Ausimmune study, all cases were 
diagnosed with a standardised protocol by experienced neurologists, and adjustment 
for study centre was performed in every multivariable model, so we believed that 
spectrum bias would not influence the results materially. 
While we identified some factors that were associated with ASO, we only explained 
12% of the total variance and thus leaving the majority unexplained. We 
demonstrated that marijuana use was associated with an earlier MS onset, in line with 
evidence indicating its deleterious impacts on the CNS, and that a history of tobacco 
smoking was associated with a later ASO. Further research is required to better 
understand these opposite effects and underlying pathways. These results, if 
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corroborated and supported in other studies, may aid in the understanding of MS and 
potentially contribute to delaying MS onset. 
5.7 Postscript 
Chapter 4 and 5 discussed association between environmental/behavioural factors and 
age of symptom onset in MS patients. The next chapter will investigate association 
between viral infections and MS clinical course.   
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5.9 Supplementary Tables 
 
Table 5.6 Sensitivity analysis of sex, IM history, HLA-DR15 genotype, HLA-A2 genotype of the total cohort in the AusImmune Study by 
restricting to cases with FDE during recruitment period and those with diagnosed MS before 5-year review 
 Primary analysis  Restricted to cases with FDE  
during recruitment period 
Restricted to MS 
 β (95% CI) p β (95% CI) p β (95% CI) p 
Sex        
 Male 37.21 (34.90, 39.52) a  37.16 (34.58, 39.74) a  37.00 (34.08, 39.93) a  
 Female +0.15 (-2.49, 2.80) 0.913 -0.52 (-3.48, 2.43) 0.725 -0.03 (-3.29, 3.24) 0.992 
Past history of IM        
 No 37.7 (36.41, 39.00) a  37.03 (35.60, 38.46) a  37.59 (36.09, 39.08) a  
 Yes -1.33 (-3.83, 1.18) 0.302 -1.07 (-3.85, 1.71) 0.449 -1.91 (-4.80, 0.98) 0.193 
HLA-DR15 (rs9271366)       
 AA 36.89 (34.91, 38.86) a  36.06 (33.93, 38.20) a  36.99 (34.60, 39.38) a  
 AG +1.42 (-1.26, 4.0 9) 0.303 +2.11 (-0.82, 5.03) 0.163 +0.53 (-2.65, 3.72) 0.739 
 GG  +4.74 (-2.43, 11.91) 0.202 +3.14 (-4.59, 10.87) 0.432 +4.55 (-2.94, 12.05) 0.225 
 Trend   0.151  0.144  0.376 
HLA-A2 (rs2844821)        
 AA 37.17 (35.43, 38.92) a  36.69 (34.78, 38.59) a  36.84 (34.85, 38.83) a  
 AG +1.38 (-1.24, 4.01) 0.298 +1.32 (-1.57, 4.20) 0.365 +1.52 (-1.55, 4.59) 0.332 
Statistical significance (p<0.05) was denoted in bold and italics.                                                                                                                                                    
adjusted for sex, MS type, and study centresa: mean ASO of the reference group 
 
Table 5.7 Sensitivity analysis of UV exposure of the total cohort in the AusImmune Study by restricting to cases with FDE during 
recruitment period and those with diagnosed MS before 5-year review 
 Primary analysis  Restricted to cases with FDE  
during recruitment period 
Restricted to MS 




 β (95% CI) p β (95% CI) p β (95% CI) p 
Winter UV dose within  
5 years before onset
 b
 





 38.06 (35.73, 40.40)
 a
  38.07 (35.5, 40.64)
 a

















 +0.17 (-3.13, 3.46) 0.923 -1.51 (-5.20, 2.18) 0.424 +0.86 (-2.80, 4.52) 0.649 
 Trend  0.974  0.478  0.718 
Winter UV dose within  












 38.36 (36.08, 40.64)
 a
  38.76 (36.2, 41.31)
 a
  38.21 (35.76, 40.65)
 a
  




 -2.07 (-5.29, 1.14) 0.205 -3.16 (-6.7, 0.38) 0.082 -3.42 (-7.05, 0.21) 0.073 




 -2.21 (-5.45, 1.03) 0.183 -2.62 (-6.24, 0.99) 0.155 -2.84 (-6.40, 0.72) 0.124 




 -0.28 (-3.51, 2.96) 0.868 -2.18 (-5.82, 1.46) 0.239 +0.38 (-3.25, 4.01) 0.843 
 Trend  0.848  0.305  0.919 
Winter UV dose within  












 39.68 (37.47, 41.9)
 c
  39.07 (36.6, 41.53)
 a
  38.88 (36.48, 41.27)
 a
  




 -3.37 (-6.46, -0.28) 0.032 -1.86 (-5.31, 1.58) 0.286 -3.79 (-7.21, -0.36) 0.033 




 -2.06 (-5.22, 1.09) 0.203 -2.95 (-6.39, 0.48) 0.092 -2.66 (-6.27, 0.94) 0.154 




 -1.37 (-4.50, 1.76) 0.389 -2.29 (-5.78, 1.2) 0.201 +0.14 (-3.35, 3.64) 0.939 
 Trend  0.568  0.153  0.847 
Summer UV dose within  












 37.08 (34.79, 39.38)
 a
  36.54 (33.85, 39.22)
 a
  36.93 (34.49, 39.37)
 a
  




 -0.69 (-3.90, 2.52) 0.681 -0.34 (-4.01, 3.33) 0.861 -0.66 (-4.18, 2.86) 0.713 




 -1.13 (-4.36, 2.09) 0.492 -1.30 (-4.90, 2.30) 0.476 -2.13 (-5.7, 1.45) 0.239 




 2.48 (-0.86, 5.83) 0.153 +2.49 (-1.32, 6.30) 0.202 2.83 (-0.98, 6.63) 0.148 
 Trend  0.208  0.303  0.365 




Summer UV dose within  












 38.40 (36.13, 40.67)
 a
  37.82 (35.18, 40.46)
 a
  38.60 (36.17, 41.03)
 a
  




 -3.27 (-6.44, -0.11) 0.043 -3.17 (-6.74, 0.39) 0.078 -3.88 (-7.35, -0.41) 0.028 




 -2.66 (-5.84, 0.52) 0.095 -2.72 (-6.34, 0.89) 0.142 -4.13 (-7.57, -0.68) 0.019 




 +1.36 (-1.97, 4.69) 0.423 +1.59 (-2.17, 5.35) 0.413 +1.80 (-2.04, 5.64) 0.363 
 Trend  0.454  0.382  0.762 
Summer UV dose within  
15 years before onset
 b
 





 39.82 (37.66, 41.97)
 c
  38.49 (35.91, 41.07)
 a
  39.49 (37.16, 41.82)
 a
  




 -3.91 (-6.91, -0.91) 0.011 -3.53 (-6.91, -0.16) 0.040 -4.40 (-7.72, -1.08) 0.009 




 -3.95 (-6.95, -0.95) 0.010 -3.43 (-6.86, 0.01) 0.050 -5.35 (-8.62, -2.09) 0.001 




 +0.38 (-2.66, 3.42) 0.810 +2.12 (-1.57, 5.80) 0.263 +2.45 (-1.25, 6.16) 0.187 
 Trend  0.812  0.262  0.729 













 37.07 (34.77, 39.37)
 a
  36.36 (33.70, 39.01)
 a
  36.89 (34.43, 39.34)
 a
  




 -0.95 (-4.17, 2.27) 0.562 -0.33 (-3.92, 3.27) 0.858 -1.25 (-4.83, 2.33) 0.503 




 -0.20 (-3.44, 3.04) 0.903 +0.18 (-3.50, 3.85) 0.929 -1.15 (-4.76, 2.45) 0.529 




 +1.82 (-1.54, 5.18) 0.286 +1.73 (-2.11, 5.56) 0.381 +2.14 (-1.63, 5.92) 0.268 
 Trend   0.265  0.369  0.359 













 37.74 (35.41, 40.08)
 a
  37.04 (34.30, 39.78)
 a
  37.61 (35.05, 40.16)
 a
  




 -2.49 (-5.68, 0.71) 0.132 -1.96 (-5.55, 1.63) 0.278 -2.56 (-6.10, 0.97) 0.158 




 -0.92 (-4.19, 2.34) 0.581 -0.38 (-4.11, 3.35) 0.839 -1.95 (-5.59, 1.70) 0.303 




 +1.49 (-1.87, 4.85) 0.387 +1.39 (-2.48, 5.27) 0.475 +1.76 (-2.09, 5.62) 0.372 
 Trend   0.265  0.318  0.429 
UV dose within 15 years        











 39.35 (37.18, 41.52)
 c
  38.70 (36.19, 41.20)
 a
  38.94 (36.54, 41.34)
 a
  




 -3.13 (-6.15, -0.10) 0.043 -3.99 (-7.32, -0.66) 0.019 -3.51 (-6.90, -0.13) 0.042 




 -3.42 (-6.45, -0.38) 0.027 -3.41 (-6.80, -0.02) 0.049 -4.14 (-7.67, -0.61) 0.021 




 +0.85 (-2.21, 3.91) 0.587 +1.80 (-1.84, 5.44) 0.333 +1.26 (-2.37, 4.90) 0.503 
 Trend   0.643  0.382  0.738 












 37.83 (35.53, 40.13)
 a
  37.53 (34.94, 40.12)
 a

















 -1.21 (-4.48, 2.05) 0.468 -1.92 (-5.54, 1.70) 0.296 -0.57 (-4.22, 3.09) 0.758 
 Trend  0.362  0.223  0.518 












 37.19 (34.9, 39.48)
 a
  35.81 (33.27, 38.36)
 a

















 -0.83 (-4.13, 2.47) 0.624 +0.06 (-3.63, 3.76) 0.968 -0.98 (-4.75, 2.79) 0.612 
 Trend  0.959  0.628  0.957 












 37.18 (34.88, 39.47)
 a
  36.51 (33.92, 39.10)
 a

















 +0.27 (-3.03, 3.56) 0.868 +0.33 (-3.34, 4.00) 0.864 +0.05 (-3.68, 3.78) 0.979 
 Trend  1.000  0.913  0.953 
Statistical significance (p<0.05) was denoted in bold and italics.                                                                                                                                                    
adjusted for sex, MS type, and  buttock melanin density                    a: mean ASO of the reference group 





Table 5.8 Sensitivity analysis of MS type/initial clinical symptoms of the total cohort in the AusImmune Study by restricting to cases 
with FDE during recruitment period and those with diagnosed MS before 5-year review 
 Multivariable analysis Restricted to cases with FDE  
during recruitment period 
Restricted to MS 
 β (95% CI) p β (95% CI) p β (95% CI) p 
MS onset type       
 Relapsing-onset 36.95 (35.8, 38.09) b    36.52 (35.18, 37.86) b  
 Progressive-onset +5.61 (1.17, 10.05) 0.013   +5.91 (1.34, 10.47) 0.011 
Onset symptoms       
 Pyramid function-no  37.86 (36.33, 39.38) b  37.15 (35.53, 38.77) b  37.82 (35.98, 39.67) b  
 Pyramid function-yes -0.52 (-2.94, 1.90) 0.672 -0.15 (-2.83, 2.52) 0.91 -0.89 (-3.66, 1.88) 0.534 
 Cerebellar function-no 37.01 (35.66, 38.37) b  36.38 (34.93, 37.83) b  36.86 (35.23, 38.48) b  
 Cerebellar function-yes +2.52 (-0.08, 5.12) 0.057 +3.45 (0.44, 6.45) 0.025 +1.99 (-0.91, 4.88) 0.178 
 Brainstem function-no  37.4 (36.06, 38.75) b  36.88 (35.38, 38.37) b  37.28 (35.69, 38.87) b  
 Brainstem function-yes 0.15 (-2.59, 2.89) 0.920 +0.16 (-2.86, 3.19) 0.92 -0.57 (-3.73, 2.60) 0.729 
 Sensory function-no  37.56 (35.81, 39.3) b  36.78 (34.89, 38.68) b  37.91 (35.85, 39.96) b  
 Sensory function-yes -0.33 (-2.70, 2.05) 0.791 +0.12 (-2.52, 2.75) 0.93 -1.35 (-4.12, 1.43) 0.337 
 Bowel & Bladder function-no  36.85 (35.58, 38.12) b  36.36 (34.98, 37.75) b  36.52 (35.02, 38.02) b  
 Bowel & Bladder function-yes +3.49 (0.63, 6.34) 0.017 +3.62 (0.33, 6.91) 0.031 +3.59 (0.27, 6.91) 0.034 
 Cerebral function-no  36.87 (35.64, 38.1) b  36.39 (35.03, 37.76) b  36.6 (35.16, 38.04) b  
 Cerebral function-yes +4.37 (1.28, 7.46) 0.006 +4.19 (0.69, 7.69) 0.019 +4.58 (1.10, 8.06) 0.010 
 Visual function-no  37.74 (36.38, 39.10) b  37.16 (35.62, 38.69) b  37.41 (35.85, 38.98) b  
 Visual function-yes -1.00 (-3.54, 1.54) 0.439 -0.61 (-3.37, 2.14) 0.66 -1.11 (-4.22, 2.00) 0.487 
Onset symptoms in  
relapsing-onset cases 
      
 Pyramid function-no  37.35 (35.84, 38.86) b    37.11 (35.27, 38.95) b  
 Pyramid function-yes -0.36 (-2.80, 2.09) 0.773   -0.65 (-3.47, 2.17) 0.652 
 Cerebellar function-yes  36.55 (35.19, 37.91) b    36.21 (34.56, 37.85) b  
 Cerebellar function-no  +2.91 (0.21, 5.60) 0.034   +2.42 (-0.61, 5.45) 0.123 
 Brainstem function-no  36.78 (35.41, 38.16) b    36.47 (34.82, 38.11) b  




 Brainstem function-yes +1.14 (-1.61, 3.90) 0.418   +0.62 (-2.58, 3.81) 0.714 
 Sensory function-no  37.12 (35.33, 38.91) b    37.37 (35.23, 39.5) b  
 Sensory function-yes -0.21 (-2.63, 2.21) 0.866   -1.27 (-4.14, 1.59) 0.378 
 Bowel & Bladder function-no  36.43 (35.16, 37.71) b    35.93 (34.41, 37.45) b  
 Bowel & Bladder function-yes +3.90 (0.88, 6.93) 0.011   +4.24 (0.62, 7.86) 0.022 
 Cerebral function-no  36.47 (35.21, 37.72) b    36.05 (34.56, 37.53) b  
 Cerebral function-yes +4.54 (1.30, 7.78) 0.006   +4.89 (1.20, 8.59) 0.009 
 Visual function-no  37.23 (35.83, 38.63) b    36.73 (35.1, 38.37) b  
 Visual function-yes -0.63 (-3.22, 1.96) 0.632   -0.65 (-3.86, 2.56) 0.686 
Statistical significance (p<0.05) was denoted in bold and italics.                                                                                                                                                   
a: adjusted for sex, MS type, and study centres; b: mean ASO of the reference group 
 
Table 5.9 Sensitivity analysis of smoking behaviours of the total cohort in the AusImmune Study by restricting to cases with FDE during 
recruitment period and those with diagnosed MS before 5-year review 
 Primary analysis  Restricted to cases with FDE  
during recruitment period 
Restricted to MS 
 β (95% CI) P   β (95% CI) P 
Smoking ever a       
 No 35.6 (33.79, 37.41) b  33.48 (31.48, 35.48) c  34.62 (32.46, 36.78) c  
 Yes +2.71 (0.42, 5.00) 0.021 +5.42 (2.80, 8.04) <0.001 +3.99 (1.17, 6.82) 0.005 
Smoking ever b       
 No 38.71 (37.2, 40.22)  37.1 (35.54, 38.66) c  39.1 (37.34, 40.86) c  
 Yes +1.79 (-0.12, 3.71) 0.073 +3.21 (1.14, 5.28) 0.002 +1.63 (-0.63, 3.90) 0.158 
Smoking status a       
 Never smoked 35.6 (33.78, 37.41) b  33.44 (31.44, 35.45) c  34.61 (32.44, 36.77) c  
 Past smokers +2.62 (0.04, 5.20) 0.047 +4.80 (1.91, 7.69) 0.001 +3.84 (0.77, 6.90) 0.014 
 Current smokers  +2.85 (-0.01, 5.70) 0.054 +6.36 (3.14, 9.58) <0.001 +4.28 (0.73, 7.84) 0.018 
 Trend   0.037  <0.001  0.013 
Smoking status b       




 Never smoked 38.71 (37.2, 40.22)  37.09 (35.53, 38.64) c  39.13 (37.37, 40.89) c  
 Past smokers +2.12 (-0.05, 4.30) 0.062 +2.85 (0.52, 5.17) 0.016 +1.94 (-0.54, 4.42) 0.133 
 Current smokers  +1.34 (-1.01, 3.68) 0.273 +3.73 (1.14, 6.31) 0.005 +1.09 (-1.75, 3.93) 0.451 
 Trend   0.219  0.005  0.392 
Age of smoking begin b       
 ≥16 41.45 (39.85, 43.05)  39.82 (38.18, 41.46) c  40.92 (39.24, 42.59) c  
 <16 -1.77 (-4.22, 0.68) 0.162 +0.22 (-2.36, 2.81) 0.873 -1.17 (-3.81, 1.48) 0.392 
Duration of smoking before 28 b       
 ≤ 10 years 40.97 (38.99, 42.95)  39.64 (37.47, 41.82) c  40.12 (37.96, 42.29) c  
 >10 -0.51 (-3.07, 2.04) 0.693 +0.37 (-2.42, 3.16) 0.803 +0.73 (-2.09, 3.55) 0.614 
Marijuana ever a       
 No 38.58 (37.26, 39.9) b  38.72 (37.27, 40.17) c  38.63 (37.11, 40.15) c  
 Yes -4.04 (-6.43, -1.64) 0.001 -5.79 (-8.52, -3.07) <0.001 -5.25 (-8.33, -2.18) 0.001 
Marijuana status a       
 Never  38.58 (37.26, 39.90) c  38.74 (37.28, 40.19) c  38.62 (37.09, 40.14) c  
 Past users  -4.08 (-6.73, -1.43) 0.003 -5.58 (-8.51, -2.65) <0.001 -5.43 (-8.74, -2.12) 0.001 
 Current users -3.92 (-8.20, 0.37) 0.070 -6.55 (-11.18, -1.92) 0.006 -4.58 (-10.09, 0.93) 0.102 
 Trend   0.003  <0.001  0.003 
Marijuana ever after 31        
 No 41.29 (40.24, 42.34) b  41.07 (39.9, 42.24) c  41.51 (40.32, 42.70) c  
 Yes -2.20 (-4.14, -0.27) 0.026 -3.33 (-5.46, -1.21) 0.002 -1.95 (-4.44, 0.53) 0.118 
Marijuana status after 31       
 Never  41.28 (40.24, 42.33) b  41.08 (39.91, 42.25) c  41.49 (40.31, 42.68) c  
 Past users  -1.50 (-3.71, 0.70) 0.175 -2.89 (-5.24, -0.54) 0.016 -1.09 (-3.87, 1.68) 0.439 
 Current users -4.06 (-7.16, -0.95) 0.010 -4.57 (-7.80, -1.34) 0.006 -4.30 (-8.14, -0.47) 0.028 
 Trend   0.008  0.001  0.041 
Statistical significance (p<0.05) was denoted in bold and italics.                                                                                                                         
a:adjusted for sex, MS type, study centres, and tobacco smoking status/marijuana use status; b:exclude those with ASO<28 years old, adjust for 
sex, MS type, study centres, and tobacco smoking status/marijuana use status.                                                                               c: mean ASO of 
the reference group 





Table 5.10 Sensitivity analysis of offspring number/age at menarche of the total cohort in the AusImmune Study by restricting to 
participants with FDE during recruitment period and those with diagnosed MS before 5-year review 
 Primary analysis  Restricted to cases with FDE  
during recruitment period 
Restricted to MS 
Offspring number a β (95% CI) p β (95% CI) p β (95% CI) p 
 0 31.37 (29.9, 32.83) d  31.57 (29.95, 33.19) d  31.07 (29.37, 32.77) d  
 1  +5.51 (2.57, 8.44) <0.001 +4.29 (1.01, 7.56) 0.010 +6.39 (3.06, 9.71) <0.001 
 2 or more +10.88 (8.84, 12.93) <0.001 +10.06 (7.74, 12.38) <0.001 +10.99 (8.58, 13.39) <0.001 
 Trend   <0.001  <0.001  <0.001 
Offspring number b       
 0 39.22 (37.99, 40.45) d  38.85 (37.54, 40.15) d  40.05 (38.59, 41.51) d  
 1  +1.39 (-0.98, 3.77) 0.254 +0.66 (-1.91, 3.22) 0.623 +1.51 (-1.36, 4.38) 0.298 
 2 or more +3.61 (1.69, 5.54) <0.001 +3.52 (1.37, 5.67) 0.001 +2.17 (-0.05, 4.39) 0.062 
 Trend   <0.001  0.002  0.062 
Age of menarche c       
 8-14  37.60 (36.24, 38.96) d  37.14 (35.60, 38.68) d  37.44 (35.92, 38.97) d  
 15-23 -4.16 (-8.00, -0.33) 0.033 -5.95 (-10.09, -1.81) 0.005 -5.03 (-9.46, -0.60) 0.026 
Statistical significance (p<0.05) was denoted in bold and italics.                                                                                                                      
a: adjusted for sex, MS type, study centres; b: restricted to those with ASO greater than 31 and summarizing offspring number before age 31, 
adjust for sex, MS type, study centres; c: adjust for MS type, study centres                                                                                               
d: mean ASO of the reference group
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Chapter 6: Associations between immune responses to 
Epstein-Barr virus and Human Herpes Virus 6 and multiple 
sclerosis clinical course 
6.1 Preface 
In this chapter, we will examine aim 3 of thesis - whether EBV/HHV6 infections 
could influence conversion to MS, time to relapse and disability with a prospective 
cohort of patients diagnosed as first clinical diagnosis of CNS demyelination. 
6.2 Abstract 
Background  
Infections with Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV6) have 
been implicated in multiple sclerosis (MS) onset. Few studies have evaluated the role 
of these viruses in MS clinical course. 
Objective 
We evaluated associations between markers of EBV and HHV6 infection and the 
hazard of subsequent conversion to MS, relapses and annualised change of Expanded 
Disability Status Scale (EDSS) following a first clinical diagnosis of demyelination 
(FCD). 
Method 
The study included 279 cases, followed prospectively for approximately 5 years post 
FCD. Markers of Epstein-Barr virus and Human Herpes Virus 6 and history of 
infectious mononucleosis (IM) were measured at the initial interview. Conversion to 
MS and relapses were assessed at annual reviews and via medical record review, and 
EDSS was assessed at 5-year review.  
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Elevated levels of anti-EAR (early antigen, restricted) IgG to EBV was associated 
with increased hazard of relapses (p=0.023). However, no associations were seen for 
other serological or viral load parameters of EBV exposure with any aspect of clinical 
course. History of IM was associated with an increased hazard of relapse (aHR 1.52, 
95% CI: 1.16-2.00; p=0.003); however, no association with conversion to MS was 
seen (p=0.54). Higher levels of anti-HHV6 IgG were associated with an increased 
annualised change in EDSS (p=0.044). No other associations were seen between 
HHV6 DNA, anti-HHV6 IgG or anti-HHV6 IgM and any clinical course outcome. 
Conclusion 
A history of IM and higher levels of anti-EAR IgG at baseline were associated with 
an increased hazard of relapse, and anti-HHV6 IgG was positively associated with 
disability progression. This is agreement with other evidence showing a lack of 
consistent associations between markers of active EBV/HHV6 infection and MS 
clinical course, and inconclusive results in relation to markers of latent infection.    
6.3 Introduction 
Multiple sclerosis (MS) is a complex autoimmune/neurodegenerative disorder of the 
central nervous system (CNS). The onset of MS has been ascribed to an interplay 
between environmental and genetic risk factors
1 2
. Amongst environmental risk 
factors, the role of infection with human herpesviruses, especially Epstein-Barr virus 
(EBV), is prominent. Recent meta-analyses support causal relationships between 
latent EBV infections and increased risk of developing MS, as MS patients showed a 
higher sero-positivity of immune response to Epstein-Barr nuclear antigen (EBNA, 
OR=4.5; p<0.001)
3
, viral capsid antigen (VCA, OR=4.5; p<0.001)
3
 and a past history 
of infectious mononucleosis (IM, OR=2.17; p<0.001)
4
. However, markers of active 
infection (increased EBV viral load (EBV-VL) or anti-early antigen (EA)) have not 
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been consistently associated with increased MS risk
3 5
. Human herpesvirus 6 (HHV6) 
infections were more prevalent in MS patients, although the evidence is less 
consistent than that seen with EBV, with some studies showing that anti-HHV6 IgG 
titres were higher in MS patients than matched controls
6




The issue of whether these viruses are involved in the clinical course of MS - 
including conversion from clinically isolated syndrome (CIS) to MS, and relapse and 
disability accumulation following MS diagnosis – is of considerable interest for 
possible early therapeutic intervention. A recent study
9
 involving 468 patients with 
clinically isolated syndrome (CIS) who were followed for 5 years, found no 
association between anti-EBV antibodies both baseline and serial and conversion to 
MS. However, some significant limitations in this study may influence the 
generalisability of the findings to the whole MS population: initial design of this study 
was RCT andall patients in this study were accepted interferon-beta. This is consistent 
with our 2.2 years of follow-up of 198 established MS cases in Tasmania
10
, where 
there was no association between anti-EBNA IgG titres and subsequent risk of 
relapse. Another prospective study, which followed 147 CIS patients for 7 years, 
found that a higher anti-EBNA IgG titre at baseline was not associated with the 
hazard of conversion to MS (p=0.13).
11
 However, other studies have shown an 
association between higher anti-EBNA1 IgG & anti-VCA IgGtitres and increased 
number of lesions on MRI and/or greater brain atrophy.12-15Other studies have 
demonstrated associations between higher anti-EBNA1 IgG and anti-VCA IgG titres 
and greater progression of disability, as measured by change in the Expanded 
Disability Status Scale (EDSS).
11 12 16
 
Few studies have examined the association between markers of HHV6 infection and 
MS clinical course. Following 198 patients with MS for approximate 2 years, our 
group previously demonstrated a robust dose-dependent positive association between 
anti-HHV6 IgG levels and subsequent hazard of relapse (p=0.003)
10
, while another 
prospective study
17
including 301 MS patients found that anti-HHV6 IgG titres peaked 
around two weeks prior to clinical relapse (p=0.01). Higher load of HHV6 DNA in 
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cerebrospinal fluid (CSF) has been linked with a greater number of contrast-
enhancing lesions on MRI
18
, in a small study of 37 MS patients.     
Here we examined the relationship between markers of EBV and HHV6 infection and 
clinical course (conversion to MS, relapse and change in disability) in early MS, using 
a multicentre longitudinal prospective cohort recruited soon after onset of CNS 
demyelination.We further examined that association between use of DMT and 
markers of viral infection. 
6.4 Methods 
6.4.1 Study design 
As described elsewhere
19
, the Ausimmune Study was a multicentre case-control study 
which recruited individuals at their first clinical diagnosis of CNS demyelination 
(FCD). Participating cases were aged 18 to 59 years old and resident in one of four 
study regions on the east coast of Australia. A subsequent longitudinal prospective 
cohort study, the Ausimmune Longitudinal (AusLong) Study has continued to follow 
the case participants of the Ausimmune Study with high retention (84.6%) to five 
years following their initial participation in the Ausimmune Study. More patients 
received disease modifying therapy from baseline interview (58/279) to 5-year review 
(127/236). At study entry, 21% (58/279) patients accepted DMTs and most of them 
(51/58) used interferon-beta, while in the 5-year review, the proportion of patients 
accepted DMTs increased to 54% (127/236) and only 60% (74/127) used interferon-
beta, with 23 (18%) and 12 (9%) used copaxone and natalizumab, respectively.  
Of the 282 cases considered to be eligible as having a FCD, three cases were 
subsequently diagnosed with a non-MS disorder (one neuromyelitis optica, one 
Susac‘s Syndrome, and one a pineal germinoma). Of the remaining 279 cases, review 
of notes at 5 years led to 260 cases now considered to have a relapse-onset and 19 had 
progressive-onset disease. Amongst the relapse-onset cases, 219 had their FDE within 
the study recruitment period. Here we report on the data collected during the first 5 
years of follow up.  
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6.4.2 Data collection 
Participants completed questionnaires prior to, and during, a face to face interview 
with a study nurse on entry to the Ausimmune Study. History of IM (‗have you ever 
had glandular fever?‘) at baseline. Use (yes/no) of disease-modifying therapy (DMT) 
were reported at annual review. Since only baseline DMTs were associated with viral 
biomarkers, we used baseline DMTs as the covariate in the primary multivariable 
model. However, longitudinal DMTs had a closer relationship with the clinical 
course, so a sensitivity analysis with longitudinal DMTs were performed. We found 
that associations between viral biomarkers and clinical course did not change 
materially when longitudinal DMTs were used (data not shown).Blood was taken by 
venepuncture; aliquots of serum and whole blood were stored at -80ºC until 
completion of the Ausimmune Study. 
Measurement of EBV/HHV6 variables 
As previously described
5
, serological EBV and HHV6 parameters were measured in 
blood taken at the initial interview for the Ausimmune Study in a subset of 205 cases, 
with 167 having their FDE during recruitment period. A comparison of the data 
between those patients who did and those who did not have the data of viral 
biomarkers showed that the two groups were very similar (supplementaltable 1). As a 
result, our sample is likely representative of the entire AusLong population. 
Quantitative IgG antibody titres to EBV viral capsid antigen (VCA) were measured 
by automated enzyme immunoassay (Star Corp, Stillwater, MN) and antibodies to 
EBNA complex and early antigen (diffuse and restricted, EA-D and EA-R, 
respectively) by immunofluorescence assay. EBV DNA load was quantified in whole 
blood using the BWRF-1 primers as described elsewhere.
20
 Serum anti-HHV6 IgG 
titres were measured using an analogous assay (Panbio).
17
 Anti-HHV6 IgG was used 
as a marker of HHV6 exposure, while HHV6 DNA and anti-HHV6 IgM were used as 
markers of HHV6 reactivation or new infection.All viral assays were performed 
critically as the illustration from manufacturer, but some biomarkers might still be 
inaccurate and it was difficult for us to control this potential measurement error. 
However, there was no evidence that the potential measurement error was 
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significantly differential by disease activity. So we believed that the potential 
measurement error of viral biomarkers would not influence the validity of the result. 
Measurement of conversion to MS and relapse 
Conversion to MS was defined primarily as the occurrence of a second clinical 
demyelinating event, thus satisfying the diagnostic requirements of dissemination in 
time and space, or a single clinical episode plus para-clinical evidence, as per the 
2005 McDonald criteria (a minority of cases were diagnosed as 2010 McDonald 
criteria, following neurologist-ordered MRI assessment (n=20)).
21 22
 Conversion to 
MS was reported at annual review or assessed by neurologist at face-to-face review, 
as well as derived from review of neurological records. A relapse was defined 
according to the 2001 McDonald Criteria as the acute or subacute appearance or 
reappearance of a neurological abnormality (lasting at least 24 hours) in the absence 
of other potential explanatory factors.
22
 Relapses were reported at annual review and 
confirmed by review of the clinical notes, and only relapses which were diagnosed 
and verified by the study neurologist were included in this analysis. 
Measurement of disability progression 
Disability was assessed using the EDSS at 5-year review. For relapsing-onset cases, 
annualised change of EDSS was calculated with EDSS at 5-year review divided by 
the duration between date of 5-year review and date of FDE with the assumption that 
EDSS was 0 before FDE. However, for PPMS cases, accurate measurement of date of 
FDE was extremely difficult, so annualised change of EDSS was calculated with 
EDSS at 5-year review minus EDSS at study entry and divided by the duration 
between date of 5-year review and date of study entry. 
It is acknowledged that the increase of EDSS is not linear, however, the AusLong 
study participants were people with a first clinical diagnosis of demyelination at study 
entry and 87.6% had an EDSS score ≤ 4 at the 5-year review. Previous research has 
suggested that the disability progression is comparative linear when EDSS was ≤ 4. 
Time to particular EDSS hallmarks were less suitable as the participants were not 
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assessed frequently enough by neurologists to reliably determine the date participants 
reached an EDSS of three or four. Therefore, annualised change of EDSS in the 
AusLong study was the best measure of disability progression. 
6.4.3 Data analysis 
Mean and standard deviation, median and interquartile range were used as descriptive 
statistics. Data management: participants stating that they did not know if they had had 
IM were coded as ―no history of IM‖. Body mass index (BMI) was calculated as 
weight (kg) divided by squared height (m
2
).  
Ordinal logistic regression was used to assess the associations between baseline 
disease modifying therapy (DMT) and the levels of viral biomarkers. To verify the 
results of the association between baseline DMT and immune response to anti-EBNA 
IgG, we also analysed data from MS cases from the Tasmanian MS case-control 
study(n=136) and Southern Tasmanian Multiple Sclerosis Longitudinal (MSL) Study 
(n=198).
10 23
 In the Tasmanian MS case-control study, anti-EBNA IgG titres were 
measured using an ELISA assay (Panbio, Brisbane, Australia). In the MSL study, 
anti-EBNA IgG titres were measured using an indirect immunofluorescence assay 
(IFA) (Panbio Inc., Columbia, MD, USA). 
The effect of predictors on time-to-conversion and time-to-relapse was estimated 
using Cox proportional hazards models. Since Cox proportional hazards models allow 
cases to be censored before reaching endpoint, all available cases (n=279) but not 
those retained at 5-year review(n=236) were included in analyses. All analyses were 
adjusted for age, sex, study site, and for time to relapse analysis, baseline use of DMT 
was further adjusted. Since baseline 25(OH)D levels and history of tobacco smoking 
were not associated with MS clinical course (data not shown), they were not 
considered as covariates here. All covariates of interest satisfied the proportional 
hazards assumption. For conversion to MS analysis, the starting point was the date of 
first recorded symptom (FDE) onset. For better accuracy in determining the date of 
FDE, only relapsing-onset cases who had their FDE during the recruitment period 
(n=219) were selected for the analysis. Since we did not obtain the viral parameters 
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and IM information for all cases, only 167 and 216 cases were available for viral 
parameter and IM analysis, respectively. 
For the relapse analysis, multiple relapses that occurred for the same case were 
regarded as independent observations on the assumption that time until a prior event 
does not affect the composition of the risk set for a subsequent event. Although cases 
with more severe disease were potentially going to have a higher relapse rate but 
dissemination in space and time criteria for relapse means that a relapse shouldn‘t 
affect the risk of a subsequent one. And all relapses included were all 30+ days apart, 
they should be fully independent. We also clustered the relapses when they happened 
in the same case to control the potential correlation. The relapse analysis included all 
available relapse onset cases (n=260), because the starting point of this analysis was 
the date of the event that brought the participants into the study. Not all cases 
provided information for viral parameters and IM, so only 194 and 256 of 279 cases 
were available for viral parameter and IM analysis, respectively.  
Predictors of annualised change in EDSS were evaluated using linear regression 
adjusted for whether participants were having a relapse at the time of their 5-year 
review EDSS assessment. Because the annualised change in disability was highly 
skewed and for some cases the change of EDSS was zero, a log-transformation of the 
original score plus one was applied to satisfy linear regression assumptions of 
minimal heteroskedasticity. All means and coefficients, however, were back-
transformed and presented on the original scale of the change in EDSS variable. As 
the EDSS is designed for those with a diagnosis of MS, we included only those who 
had been diagnosed as RRMS or PPMS by the 5-year review (n=186). Amongst the 
remaining 186 cases, 144 and 183 were available for viral parameters and IM 
analysis, respectively. 
Chapter 6: Associations between immune responses to Epstein-Barr virus and Human 




6.5.1 Participant characteristics 
The mean age of the 279 participants with FCD in the Ausimmune Study was 38.7 
years and around roughly three-quarters were female (Table 1). Among the total 
cohort, 211 converted to MS and experienced 458 relapses. The distribution of 
categories of antibody titres at baseline for case participants are shown in Table 
1.EBV and HHV-6 DNA were detected in only a small proportion of all cases 
(~10%). Other characteristics of the total cohort and cases with an FDE during the 
recruitment period are shown in Table 1. 
Table 6.1 Demographic and clinical characteristics of the total cohort, those with an FDE during 
the recruitment period and those who retained at 5-year review and converted to MS and of the 
Ausimmune Study 
 Total cohort n(%) Cases with an FDE during the recruitment 
periodn(%) 
Total 279 219 
Female  214 (76.70) 168 (76.71) 
Study site   
 QLD 91 (32.62) 59 (26.94) 
 NSW 39 (13.98) 66 (30.14) 
 VIC 69 (24.73) 52 (23.74) 
 TAS 80 (28.67) 42 (19.18) 
MS course at study entry   
 FDE relapse-onset 260(93.19)  
 Progressive onset 19(6.81)  
DMT used at baseline 58 (20.79) 44 (20.09) 
Conversion to MS during 
study 
211 (75.63) 159 (72.60) 
Number of relapses during 
study  
458 347 
anti-EBNA IgG titre a   
 ≤40 44 (21.46) 37 (22.16) 
 160 89 (43.41) 76 (45.51) 
 ≥640 72 (35.12) 54 (32.34) 
anti-EBV-VCA IgG titre a   
 ≤160 39 (19.02) 33 (19.76) 
 640 110 (53.66) 87 (52.10) 
 ≥1280 56 (27.32) 47 (28.14) 
anti-EBV-EA-R IgG titre a   
 ≤10 69 (33.66) 60 (35.93) 
 40 66 (32.20) 52 (31.14) 
 ≥160 70 (34.15) 55 (32.93) 
anti-EBV-EA-D IgG titre a   
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 0 45 (21.95) 36 (21.56) 
 10 54 (26.34) 43 (25.75) 
 40 81 (39.51) 68 (40.72) 
 160-640 25 (12.20) 20 (11.98) 
Serum EBV DNA detection   
 Negative 180 (87.80) 145 (86.83) 
 Positive 25 (12.20) 22 (13.17) 
anti-HHV6 IgG titre a   
 ≤40 65 (31.86) 51 (30.72) 
 160 95 (46.57) 77 (46.39) 
 ≥640 44 (21.57) 38 (22.89) 
anti-HHV6 IgM titre a   
 0 193 (95.07) 156 (94.55) 
 20 7 (3.45) 6 (3.64) 
 40 3 (1.48) 3 (1.82) 
Serum HHV6 DNA detection   
 Negative 177 (86.34) 142 (85.03) 
 Positive 28 (13.66) 25 (14.97) 
 Mean (SD; Range) 
Age at study entry, years 38.72(9.75;18,58) 38.26 (9.68; 18, 58) 
MS duration from first 
symptoms  
to 5-year review, years b 
6.13 (2.49; 0.27, 
21.2) 
5.48 (1.32; 0.27, 8.08) 
 Median (IQR) 
EDSS at 5-year study review 2 (1; 2.5) 1.5 (1; 2.5) 
Annualised change of EDSS 0.27 (0.17; 0.43) 0.27 (0.18; 0.41) 
a: 205 cases had values for serum biomarkers; b: 236 cases retained in the 5-year review 
6.5.2 Association between baseline DMT and anti-EBV/HHV6 
There was no association between anti-EBNA IgG and anti-HHV6 IgG (r=0.11, 
p=0.26) in all cases. EBV or HHV6 biomarkers were not associated with a history of 
IM (p>0.05). 
With the ordinal logistical regression, those who used DMT before study entry were 
less likely to have higher levels of anti-EBNA IgG (OR 0.44, 95% CI: 0.23 - 0.84; 
p=0.01), the association was robust for adjustment for age and sex (OR 0.39, 95% CI: 
0.19 - 0.82; p=0.014) and enhanced after adjustment for age, sex, study centre and 
whether diagnosed as MS or not (OR 0.35, 95% CI: 0.16 - 0.76; p=0.008). However, 
there was no association in the cases of the Tasmanian case-control study (p=0.76) or 
MSL study (p=0.73), after adjustment for age and sex. Neither were other anti-EBV 
or anti-HHV6 biomarkers associated with baseline use of DMT. 
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6.5.3 Association between viral load & serological parameters of EBV 
and HHV6 and the hazard of conversion to MS 
We found no associations between EBV-VL, serological antibodies (anti-EA-R IgG, 
anti-EA-D IgG, anti-EBNA1 IgG, anti-VCA IgG), or a history of IM with the risk of 
conversion to MS (Table 2). We found a significant association between HHV6-VL 
and conversion to MS in the univariable analysis; however, after adjustment (age, sex, 
study site, BMI and baseline DMT), the association was no longer statistically 
significant (p=0.36). There was no association between anti-HHV6 IgM or anti-
HHV6 IgG and risk of conversion to MS (Table 2). 
Table 6.2Associations of baseline levels of viral markers and the hazard of conversion to MS in 
cases with an FDE during the recruitment period 
  Univariable analysis Multivariable analysis  
 Conversions/person 
-years (rate) 
HR (95% CI) p aHR (95% CI) p 
EBV DNA      
 Negative 109/316.85 (0.34) 1.00 (Reference)  1.00 (Reference)  
 Positive  16/51.57 (0.31) 0.90 (0.55, 1.49) 0.69 1.11 (0.70, 1.74) 0.66 
anti-EA-R IgG       
 ≤10 47/131.18 (0.36) 1.00 (Reference)  1.00 (Reference)  
 40 37/117.04 (0.32) 0.91 (0.59, 1.41) 0.66 0.88 (0.57, 1.35) 0.54 
 ≥160 41/120.2 (0.34) 0.96 (0.64, 1.44) 0.85 0.91 (0.59, 1.42) 0.68 
 Trend   0.84  0.67 
anti-EA-D IgG       
 0 26/73.87 (0.35) 1.00 (Reference)  1.00 (Reference)  
 10 34/89.54 (0.38) 1.00 (0.58, 1.70) 0.99 0.83 (0.47, 1.47) 0.53 
 40 50/168.08 (0.3) 0.86 (0.51, 1.44) 0.56 0.80 (0.46, 1.40) 0.43 
 160-640 15/36.93 (0.41) 1.10 (0.55, 2.18) 0.79 1.02 (0.53, 2.00) 0.94 
 Trend    0.79  0.64 
anti-EBNA IgG       
 ≤40 31/59.44 (0.52) 1.00 (Reference)  1.00 (Reference)  
 160 54/182.89 (0.3) 0.61 (0.38, 0.98) 0.043 0.69 (0.42, 1.13) 0.14 
 ≥640 40/126.09 (0.32) 0.63 (0.39, 1.04) 0.07 0.76 (0.48, 1.20) 0.23 
 Trend   0.10  0.32 
anti-VCA IgG      
 ≤160 28/49.75 (0.56) 1.00 (Reference)  1.00 (Reference)  
 640 62/211.24 (0.29) 0.61 (0.39, 0.97) 0.038 0.66 (0.41, 1.05) 0.08 
 ≥1280 35/107.43 (0.33) 0.63 (0.39, 1.03) 0.06 0.48 (0.29, 0.81) 0.005 
 Trend   0.10  0.006 
IM (those who did not know whether they had a history of IM were coded as no history of IM) 
 No 114/348.19 (0.33) 1.00 (Reference)  1.00 (Reference)  
 Yes 42/133.02 (0.32) 0.97 (0.68, 1.37) 0.86 0.89 (0.61, 1.3) 0.54 
IM (excluding those who did not know whether they had a history of IM) 
 No 102/318.73 (0.32) 1.00 (Reference)  1.00 (Reference)  
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 Yes 42/133.02 (0.32) 0.99 (0.7, 1.42) 0.98 0.92 (0.63, 1.34) 0.66 
HHV6 DNA      
 Negative 100/329.89 (0.3) 1.00 (Reference)  1.00 (Reference)  
 Positive  23/38.02 (0.6) 1.79 (1.14, 2.83) 0.012 1.29 (0.74, 2.28) 0.36 
anti-HHV6 IgM      
 0 116/333.16 (0.35) 1.00 (Reference)  1.00 (Reference)  
 20 3/27.44 (0.11) 0.39 (0.15, 0.97) 0.044 0.33 (0.15, 0.71) 0.005 
 40 2/5.83 (0.34) 0.81 (0.28, 2.37) 0.70 0.38 (0.13, 1.16) 0.09 
 Trend   0.17  0.010 
anti-HHV6 IgG       
 ≤40 33/141.57 (0.23) 1.00 (Reference)   1.00 (Reference)  
 160 60/134.36 (0.45) 1.62 (1.03, 2.54) 0.035 1.44 (0.89, 2.35) 0.14 
 ≥640 29/91.5 (0.32) 1.20 (0.75, 1.91) 0.46 1.13 (0.70, 1.82) 0.63 
 Trend   1.00  0.90 
Adjusted for age, sex, study site, BMI and baseline DMT in the primary analysis. Figures in boldface 
denote statistical significance (p<0.05). 
Abbreviations: HR, hazard ratio; aHR, adjusted hazard ratio; IM, infectious mononucleosis. 
 
6.5.4 Association between viral load & serological parameters of EBV 
and HHV6 and the hazard of relapse 
There was no association between EBV-VL and relapse risk (Table 3). However, we 
identified a dose-dependent association between anti-EA-R IgG and hazard of relapse. 
There were no associations between other serological EBV variables and risk of 
relapse. However, a history of IM was associated with a 50% increase in the hazard of 
relapse.  
There were no associations between detection of HHV6 DNA or serological 
parameters (anti-HHV6 IgG, anti-HHV6 IgM) and the risk of relapse (Table 3).  
 
Table 6.3Associations of baseline levels of viral markers and the hazard of relapse in all relapsing 
onset cases 
  Univariable analysis Multivariable analysis  
 Relapses/person- 
years (rate) 
HR (95% CI) p aHR (95% CI) p 
EBV DNA       
 Negative 298/930.45 (0.32) 1.00 (Reference)  1.00 (Reference)  
 Positive  48/139.27 (0.34) 1.09 (0.74, 1.62) 0.66 1.16 (0.84, 1.6) 0.35 
anti-EAR IgG       
 ≤10 98/374.07 (0.26) 1.00 (Reference)  1.00 (Reference)  
 40 97/342.77 (0.28) 1.07 (0.80, 1.45) 0.64 1.04 (0.78, 1.39) 0.80 
 160-640 151/352.89 (0.43) 1.49 (1.03, 2.17) 0.034 1.43 (1.05, 1.94) 0.022 
 Trend   0.039  0.023 
anti-EA-D IgG       
 0 73/232.11 (0.31) 1.00 (Reference)  1.00 (Reference)  
 10 84/277.96 (0.30) 0.90 (0.62, 1.29) 0.55 0.92 (0.64, 1.32) 0.64 
 40 142/438.73 (0.32) 0.99 (0.66, 1.50) 0.98 1.08 (0.74, 1.58) 0.69 
 160-640 47/120.93 (0.39) 1.17 (0.61, 2.28) 0.64 1.22 (0.70, 2.10) 0.48 
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 Trend    0.50  0.33 
anti-EBNA IgG       
 ≤40 77/228.79 (0.34) 1.00 (Reference)  1.00 (Reference)  
 160 156/468.11 (0.33) 0.94 (0.66, 1.34) 0.73 1.12 (0.80, 1.56) 0.51 
 ≥640 113/372.82 (0.30) 0.90 (0.59, 1.38) 0.63 1.05 (0.72, 1.55) 0.79 
 Trend   0.65  0.86 
anti-VCA IgG       
 ≤160 70/196.02 (0.36) 1.00 (Reference)  1.00 (Reference)  
 640 160/582.65 (0.27) 0.82 (0.54, 1.23) 0.33 0.81 (0.59, 1.11) 0.20 
 ≥1280 116/291.05 (0.40) 1.06 (0.73, 1.53) 0.78 0.95 (0.67, 1.33) 0.75 
 Trend   0.61  0.85 
IM (those who did not know whether they had a history of IM were coded as no history of 
IM) 
 
 No 284/1037.02 (0.27) 1.00 (Reference)  1.00 (Reference)  
 Yes 168/373.69 (0.45) 1.48 (1.10, 1.99) 0.010 1.52 (1.16, 2.00) 0.003 
IM (excluding those who did not know whether they had a history of IM)  
 No 263/934.48 (0.28) 1.00 (Reference)  1.00 (Reference)  
 Yes 168/373.69 (0.45) 1.46 (1.08, 1.98) 0.014 1.51 (1.15, 2) 0.003 
HHV6 DNA      
 Negative 280/909.59 (0.31) 1.00 (Reference)  1.00 (Reference)  
 Positive  66/160.14 (0.41) 1.26 (0.82, 1.93) 0.29 1.12 (0.73, 1.71) 0.61 
anti-HHV6 IgM       
 0 332/1003.29 (0.33) 1.00 (Reference)  1.00 (Reference)  
 20 4/37.86 (0.11) 0.39 (0.22, 0.69) 0.001 0.48 (0.30, 0.78) 0.003 
 40 4/13.45 (0.30) 0.79 (0.47, 1.32) 0.37 0.56 (0.32, 1.01) 0.054 
 Trend   0.09  0.011 
anti-HHV6 IgG       
 ≤40 112/337.88 (0.33) 1.00 (Reference)  1.00 (Reference)  
 160 163/498.52 (0.33) 0.97 (0.64, 1.47) 0.88 0.95 (0.65, 1.37) 0.78 
 ≥640 66/223.70 (0.30) 0.87 (0.57, 1.33) 0.52 0.92 (0.61, 1.39) 0.70 
 Trend   0.47  0.73 
Adjusted for age, sex, BMI study centres and disease modifying therapyat baseline. 
Figures in boldface denote statistical significance (p<0.05).  
Abbreviations: HR, hazard ratio; aHR, adjusted hazard ratio; IM, infectious mononucleosis. 
 
6.5.5 Association between immune response to EBV/HHV6 and 
clinical disability progression 
We examined the association between baseline markers of viral infection and 
annualised change of EDSS from the date of symptom onset to the 5-year review for 
participants who had been diagnosed with RRMS or PPMS by 5
th
 year review 
(n=144). There was a statistically significant increase in annualised EDSS progression 
as anti-HHV6 IgG titre increased (EDSS change per year of 0.37 for those with the 
highest anti-body level (≥640) compared to a 0.26 change per year for those with an 
anti-body level of 40) (Table 4). 
Table 6.4Associations of baseline levels of viral markers and the clinical disability progression 
among those who converted to MS at 5-year review 
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  Model a Model b 
 No. (%) β  (95% CI) P β  (95% CI) P 
EBV DNA      
 Negative 127 (88.19) 0.29 (0.25, 0.33) c  0.29 (0.26, 0.33) c  
 Positive  17 (11.81) +0.02 (-0.09, 0.14) 0.73 -0.01 (-0.12, 0.11) 0.88 
anti-EAR IgG       
 ≤10 50 (34.72) 0.29 (0.23, 0.35) c  0.30 (0.24, 0.36) c  
 40 45 (31.25) +0.02 (-0.08, 0.11) 0.73 +0.02 (-0.07, 0.11) 0.68 
 160-640 49 (34.03) 0.00 (-0.09, 0.09) 0.92 -0.04 (-0.13, 0.05) 0.41 
 Trend   0.92  0.44 
anti-EA-D IgG       
 0 32 (22.22) 0.32 (0.24, 0.39) c  0.32 (0.24, 0.40) c  
 10 40 (27.78) +0.03 (-0.08, 0.13) 0.61 +0.03 (-0.08, 0.14) 0.58 
 40 56 (38.89) -0.06 (-0.16, 0.04) 0.25 -0.06 (-0.17, 0.04) 0.21 
 160-640 16 (11.11) -0.06 (-0.20, 0.07) 0.37 -0.08 (-0.22, 0.07) 0.30 
 Trend    0.21  0.17 
anti-EBNA IgG       
 ≤40 32 (22.22) 0.29 (0.22, 0.37) c  0.29 (0.21, 0.37) c  
 160 60 (41.67) +0.01 (-0.09, 0.11) 0.85 0.02 (-0.08, 0.12) 0.64 
 ≥640 52 (36.11) -0.01 (-0.11, 0.09) 0.83 -0.01 (-0.11, 0.09) 0.90 
 Trend   0.79  0.80 
anti-VCA IgG       
 ≤160 27 (18.75) 0.25 (0.17, 0.34) c  0.26 (0.18, 0.34) c  
 640 78 (54.17) +0.06 (-0.04, 0.16) 0.23 +0.07 (-0.03, 0.17) 0.16 
 1280-5120 39 (27.08) +0.03 (-0.08, 0.14) 0.60 -0.02 (-0.13, 0.09) 0.78 
 Trend   0.70  0.74 
IM (those who did not know whether they had a history of IM were coded as no history of IM) 
 No 135 (73.77) 0.30 (0.26, 0.34) c  0.30 (0.26, 0.34) c  
 Yes 48 (26.23) +0.02 (-0.05, 0.10) 0.55 +0.02 (-0.06, 0.10) 0.60 
IM (excluding those who did not know whether they had a history of IM) 
 No 120 (71.43) 0.31 (0.27, 0.35) c  0.31 (0.27, 0.35) c  
 Yes 48 (28.57) +0.01 (-0.06, 0.09) 0.73 +0.01 (-0.07, 0.09) 0.83 
HHV6 DNA      
 Negative 120 (83.33) 0.30 (0.26, 0.34) c  0.30 (0.26, 0.34) c  
 Positive  24 (16.67) -0.04 (-0.13, 0.06) 0.47 -0.04 (-0.14, 0.06) 0.46 
anti-HHV6 IgM       
 0 137 (96.48) 0.29 (0.25, 0.33) c  0.29 (0.25, 0.33) c  
 20 3 (2.11) -0.10 (-0.33, 0.14) 0.42 -0.03 (-0.28, 0.23) 0.84 
 40 2 (1.41) +0.43 (0.02, 0.85) 0.039 +0.39 (-0.01, 0.80) 0.057 
 Trend   0.11  0.08 
anti-HHV6 IgG       
 ≤40 43 (30.07) 0.28 (0.22, 0.35) c  0.26 (0.19, 0.32) c  
 160 69 (48.25) -0.00 (-0.09, 0.08) 0.95 +0.03 (-0.06, 0.11) 0.55 
 ≥640 31 (21.68) +0.06 (-0.05, 0.16) 0.29 +0.11 (0.00, 0.22) 0.051 
 Trend   0.22  0.044 
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Results are presented as the mean (95% CI) of reference level of the predictor, then coefficient (95% CI) 
of other levels relative to reference. Significant results were denoted in bold and italic font.  
a: adjusted for relapse or not in the 5-year review; b: further adjusted for sex, age, study site, baseline 
BMI and baseline disease modifying therapy; c: annualised change of EDSS in reference group. 
6.6 Discussion 
Using one of the most comprehensive prospective studies of MS cases in the early 
stage of disease, we evaluated the roles of EBV and HHV6 infection in MS clinical 
course, including conversion to MS, relapse and disability progression. We found that 
a history of IM and higher levels of anti-EA-R IgG (≥ 640) at baseline were 
associated with a 50% greater hazard of relapse but this was not significantly 
associated with risk of conversion to MS. There were no other robust associations 
between viral load or serological markers of EBV infection and MS clinical course. 
Higher anti-HHV6 IgG titre was associated with a greater annualised change in 
disability, but was not associated with risk of conversion or hazard of relapse. Anti-
HHV6 IgM and HHV6 DNA were not associated with MS clinical course.   
The features of latency and reactivation of EBV led to the hypothesis that reactivation 
may be one factor in initiating relapses of MS. Higher levels of anti-EA-R IgG at 
baseline were associated with increased hazard of relapses, but no association of 
conversion to MS was seen. The disparate findings were unexpected, as there is some 
overlap between the two analyses. However, the relapse analysis included all people 
with RRMS, included all relapses and used the date of FCD as the starting point. The 
conversion to MS analysis excluded those where their FDE occurred prior to the 
recruitment period (n=41) because there was concern about measurement error for 
these people, and used FDE as the starting point. While conversion to MS was often 
determined by the second relapse, it could also occur by MRI lesions (n=20). One 
previous cohort study followed 19 patients for 1 year also found that patients with 
exacerbations during the follow-up period had an increasing of anti-EA-R IgG 
levels.
24
 However, most studies showed no associations between active EBV infection 
and clinical course of MS, and our study also found no associations of anti-EA-D IgG 
and EBV DNA at baseline and MS clinical course. Our previous MSL study found 
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that reactivation of EBV and HHV6 infection was not associated with relapse, and 
evidence for active EBV infection was seen in only a minority of the study cohort at 
any time point (detection of EBV DNA 29%; HHV6 DNA 1.8%).
25
 Some other 
groups‘ research have also shown no associations.
26 27
 Moreover, the absence of 
association of active EBV infection and MS onset suggested that no effects of active 
EBV infection with MS clinical course.
5 7 28 29
 
In agreement with our work, one recent study
9
 (BENEFIT) with 468 CIS cases 
followed for five years found that the risk of conversion to MS was similar in cases of 
highest and lowest category of baseline anti-EBNA1 IgG (HR 1.14, 95% CI: 0.76-
1.72). Three other studies that focused on disease activity also found no associations 
with anti-EBNA1 IgG levels at baseline.
10 11 16
No association between EBV infection 
and annualised change of EDSS was observed in our study, which is similar from 
results of the BENEFIT study (β=0.02, p=0.80).
9
 One other study found that anti-
EBNA-1 IgG levels were positively associated with change in EDSS (r=0.3, p=0.004) 




A history of IM was associated with a higher hazard of relapse in the present study. 
While IM is viewed as a risk factor for onset of MS
4
, to date, no study has focused on 
the association between a history of IM and MS clinical course. However, the absence 
of internal consistency between related outcomes (conversion to MS and change in 
EDSS) did give some concern as to the validity of the association with relapse. 
In this study, anti-HHV6 IgG was associated with annualised change in disability, but 
not with conversion or relapse, while markers of active HHV6 infection were not 
associated with MS clinical course. This does not align with our previous MSL 
study
10
 which found that a higher anti-HHV6 IgG was associated with a higher risk of 
relapse but not annualised change in disability in a sample of established MS followed 
for 2.5 years. It is hard to understand the reasons for the differential findings, although 
timing of assessment early in the MS course as opposed to established MS and low 
rates of DMT use are possible explanations. One other explanation is that the MSL 
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study took blood 6 monthly so would be more likely to detect a short term elevation in 
viral markers just before relapse than this study. A few studies showed some 
associations between HHV6 parameters and MS clinical course. One prospective 
study that followed 301 MS patients for two years found that anti-HHV6 IgG levels 
elevated to the highest level around two weeks prior to relapse (p=0.001)
17
.Some 
significant limitations in this study influenced the interpretation of the results: patients 
were all treated with interferon-beta, natalizumab or GA, not controlling for potential 
confounders such as tobacco smoking, vitamin D levels, genetic background, and no 
statement of the inclusion criteria. Other research showed a significant association 
between HHV6 parameters and disease activity on MRI.
18 30
Only a few studies have 
evaluated the role of active HHV6 infection in the clinical course of MS, and the 
findings have been inconsistent. Our MSL study showed that anti-HHV6 IgM and 
HHV6 viral load were not associated with the hazard of relapses or disability 
progression.
25
Berti et al found a higher number of cases to be HHV6 DNA positive 
during relapses (4/18 vs. 11/197, p=0.008), using 215 serum samples from 59 MS 
patients.
30
 However, this study failed to control for potential confounders, and the 
short duration of follow-up (5 months) may limit its generalisability.   
We observed that those who used DMTs at baseline were less likely to have higher 
levels of anti-EBNA IgG, which was an interesting finding suggesting that immune 
response to EBV could be down-regulated through DMTs. However, we could not 
replicate this significant association in the Tasmanian case-control and MSL studies. 
One possible explanation is that these participants in the baseline Ausimmune Study 
were incident cases with FCD, while participants in the other two studies were 
prevalent cases that were diagnosed as MS and in many cases had been on DMTs for 
many years. Two other studies also found that anti-EBNA levels did not fluctuate 
materially when DMTs were used, however, sample size in these studies were small 




Strengths of our study include the use of a prospective longitudinal study design 
following cases with a first diagnosis of CNS demyelination. We had a high retention 
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rate at 5 year follow-up (84.6%), and a high rate (76%) of conversion to MS among 
those follow-up. A limitation was that levels of anti-EBV/HHV6 and viral load were 
only measured at baseline, so investigation of the association between longitudinal 
immune response to HHV6/EBV and MS clinical course was impossible. As previous 
studies have suggested, anti-EBV/HHV6 IgG levels were comparatively stable over 
time,
33 34
 our capacity to detect associations was limited when active viral measures 
and disease activity were examined. So we cannot exclude the possibility that some 
results were produced by chance, replication in other similar cohorts is therefore 
desirable. Another limitation was that IM was happened years prior to study entry, 
and it was difficult for us to detect whether information about IM was accurately 
recorded at baseline interview. Although IM was decoded in two ways (those who did 
not know whether they had a IM before was decoded as no history of IM and 
missing), we still could not control the influence of recall bias fully. Dates of FDE 
and some relapses prior to study entry may be inaccurate especially for progressive-
onset cases, so for conversion to MS analysis, we have restricted to cases with date of 
FDE during study entry in the, and for relapse analysis, date of FCD was set as the 
starting time. Using annualised change of EDSS to measure the disability progression 
was also a limitation in the study, due to the non-linear distribution of EDSS. But in 
AusLong study, annualised change of EDSS is the most suitable variable to measure 
disability progression since most patients were still benign at 5-year review with 
EDSS ≤ 4, and some research in MSBase has suggested that EDSS was comparatively 
linear in the lower range. 
Since patients in AusLong study were recruited from relatively contemporary 
populations with a standardised protocol, birth cohort effect had a relatively less 
influence on the results. However, we still performed a sensitivity analysis based on 
the date of birth of the cases (1947-1969, 1961-1970, 1971-1988), and no significant 
interaction between exposures of interests and date of birth were found (data not 
shown). 
Our data provides some evidence that elevated levels of anti-EAR IgG and a history 
of IM are associated with the subsequent hazard of relapses, and anti-HHV6 with 
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disability progression. Overall, epidemiological studies do not support associations 
with markers of active EBV/HHV6 infection and clinical course, while the evidence 
on markers of latent infection is merely inconclusive.   
6.7 Postscript 
This chapter showed some associations between EBV/HHV6 infections and MS 
disease activity. The next chapter will examine whether stressful life events could 
influence MS clinical course. 
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Table 6.6 Comparison of those patients who did and those who did not have the 
data of viral biomarkers 
 
Participants with biomarkers 
measured at baseline interview 
(n=205) 
Participants without biomarkers 
measured at baseline interview (n=74) 
P 
Sex    
 Male 46 19 0.57 
 Female 159 55  
CDMS    
 No 42 20 0.25 
 Yes 163 54  
PPMS    
 No 194 66 0.11 
 Yes 11 8  
Age at 
FCD 
39.1 (9.8) 37.8 (9.7) 0.32 
 
Chapter 7 Positive stressful life events are associated with a lower hazard of relapses 
in early multiple sclerosis 
233 
 
Chapter 7 Positive perceived stressful life events are 
associated with a lower hazard of relapses in early multiple 
sclerosis 
7.1 preface 
This chapter will address the fourth aim of the thesis – whether perceived positive or 
negative stressful life events could influence conversion to MS, time to relapses and 
disability progression with a cohort of patients with as first clinical diagnosis of CNS 
demyelination. 
7.2 Abstract 
Background: Despite significant evidence that psychological factors may influence 
disease course in many chronic disorders, few studies have investigated the 
association of stressful life events (SLEs) both negative and positive with the clinical 
course of multiple sclerosis (MS), especially the effect of positive SLEs. 
Method: This prospective cohort study included data from 251 first episode of central 
nervous system demyelination subjects with SLE and clinical course variables 
measured prospectively up to 5–year post onset. SLEs were measured from 1 year 
prior to the event that brought subjects into the study to 5–year review. Conversion to 
MS and relapse were the primary study endpoints and were recorded by face-to-face 
neurological assessments and medical record reviews.  
Results: A greater number (p=0.035), higher perceived intensity (p=0.010) and load 
(p=0.052) and a longer duration of the events (p=0.042) that were perceived as 
positive were consistently associated with a reduced hazard of relapses in a dose-
dependent manner. Associations were less strong for conversion to MS. There were no 
associations between perceived negative SLEs and MS conversion or relapse risk. 
There were no associations between any SLEs variables and disability progression as 
measured by annualised change of expanded disability scale score. 
Conclusion: We found consistent evidence that positive perceptions of SLEs were 
associated with a reduced risk of relapses, suggesting that positive SLEs and possibly 
an overall positive psychological well-being may reduce disease activity. 
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Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of 
the central nervous system (CNS). The wide disseminations of lesions within the CNS 
leads to the diversity of clinical symptoms, amongst the protean clinical features 
associated with MS; psychological dysfunctions are some of the most prevalent in MS 
patients
1
 even in early disease stages
2
. Among the various risk factors implicated in 
MS, stress has been a frequently cited one. Current evidence
3-6
 has consistently 
suggested that stressful life events (SLE) are associated with a higher risk of relapse 
or disability progression in people with MS. Certainly also they are potent modulators 
of comorbid depression and anxiety, and thus germane to patient quality of life. 
A meta-analysis
3
 including 14 studies found that previous stressful life events were 
associated with a higher risk of relapse (effect size (measured as (mean1−mean2)/σ) 
0.53, 95% CI 0.40-0.65; p<0.0001). Although a subsequent systematic review
6
 found 
the high level of heterogeneity in the measurement of stress and diagnosis of MS 
relapse precluding a statistically robust meta-analysis, the authors still concluded that 
there was a relatively consistent between  SLEs and increased risk of MS onset or 
relapses. The association of SLEs and MS clinical course is of considerable interest 
given that psychological and well-being interventions aimed at improving coping may 
be potential non pharmacological interventions for MS. Indeed, a number of studies in 
MS patients have shown improvement of psychological and physical function after 
psychological interventions such as stress management therapy, and developing skills 
in active coping strategies
7-9
. 
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Recent studies have mainly focused on whether negative SLEs predict MS relapses
10
, 
with only a few studies exploring the effect of positive SLEs on MS clinical course
4 11 
12
. One prospective cohort study
4
, following 119 MS patients for 24 months, found 
that the absence of positive stressors was associated with a higher hazard of relapse 
(HR 3.14, CI 1.29-7.65). Some limitations in this study might influence our 
interpretation of the results: 1) Patients were comparatively benign, so the results may 
not be suitable to generalise to the whole MS populations, 2) At the last interview, 
around 50% of patients were lost, 3) diagnosis was not based on the MRI.Another 
study
11
 following 121 MS patients for 48 weeks, found a reduced risk of new T2 
lesions on MRI with increasing number of positive events (OR 0.74, 95% CI 0.55-
0.99, p=0.04). This study was built on a RCT study (which was designed to examine 
the role of stress management therapy on MS relapses) with a post-hoc analysis, 
which may influence the interpretation of the results and generalisation to the general 
population of individuals with MS. Conversely; evidence on the association between 
SLEs and disability progression in MS patients remains limited. One prospective 
cohort study, following 36 MS patients for 100 weeks, found no association between 
SLEs and disability progression
12
. 
There is thus a gap in the literature for studies which examine the prospective 
association between both positively and negatively perceived stressful life events with 
the whole of MS clinical course, including conversion to active disease, relapses, and 
disability progression. In this prospective cohort study, we have evaluated the 
association between SLEs and clinical course in demyelinating disease patients at the 
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early stages of disease, in particular, whether there are differential effects between 
positive and negative SLEs.   
7.4 Method 
7.4.1 Study design 
As described elsewhere
13
, the Ausimmune study is a multicentre (Brisbane city, 
Newcastle city and surrounds, Geelong city and the Western Districts of Victoria, and 
the state of Tasmania) case-control study which recruited individuals diagnosed as a 
first clinical diagnosis of CNS demyelination (FCD). All participants at recruitment 
were aged 18 to 59 years. A subsequent prospective cohort study, the Ausimmune 
Longitudinal (AusLong) study followed these cases prospectively (retention rate 
84.6% at 5 years). Participants completed an annual telephone review in addition to 
face-to-face reviews at 2-3 years and 5 years following their initial participation in the 
Ausimmune Study. Here we use the 5-year review data as the end point of our 
analysis as it was the last face to face review, i.e. the analysis period is from the first 
demyelinating event (FDE) to the 5-year review. Among the original 282 cases 
recruited to the Ausimmune study, 3 cases on review were found to not have an MS 
related event (one  neuromyelitis optica, one Susac‘s Syndrome, and one pineal 
germinoma),and were removed leaving a total of 279 cases. Of these, 251 cases with 
recorded SLEs data during follow-up to the 5
th
 year review constitute the cohort 
assessed in this study.  
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7.4.2 Measurement of MS clinical course 
Conversion to MS was often but not always, based on the occurrence of a second 
clinical demyelinating episode, thus satisfying the diagnostic requirements of 
dissemination in time and space, or a single episode plus paraclinical evidence, as per 
the 2005 McDonald criteria
14
 (a minority of cases were diagnosed following 
neurologist-ordered MRI (either at the 2/3 year or 5 year reviews) based on this latter 
criterion (n=20)). Conversion to MS was reported at annual review and cross-checked 
with neurological records.  
A relapse was defined according to the 2001 McDonald Criteria
15
 as the acute or 
subacute appearance or reappearance of a neurological abnormality (lasting at least 24 
hours) in the absence of other potential explanatory factors. Relapses were reported at 
annual review or from neurological records, and only relapses which were diagnosed 
and verified by a neurologist were included in this analysis.  
Disability was assessed by the Kurtzke Expanded Disability Status Scale (EDSS) at 5-
year review. Annualised change in EDSS was calculated by taking the 5-year review 
EDSS and dividing by the duration between the day before FDE (date of FDE being 
reviewed by clinical notes and confirmed by consensus of the neurological group) and 
the 5-year review, with the assumption that EDSS was 0 at the day before FDE in 
those with relapse onset MS. However, for PPMS cases, accurate measurement of 
date of FDE was extremely difficult, so annualised change of EDSS was calculated 
with EDSS at 5-year review minus EDSS at study entry and divided by the duration 
between date of 5-year review and date of study entry. 
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It is acknowledged that the increase of EDSS is not linear, however, the AusLong 
study participants were people with a first clinical diagnosis of demyelination at study 
entry and 87.6% had an EDSS score ≤ 4 at the 5-year review. Previous research has 
suggested that the disability progression is comparative linear when EDSS was ≤ 4. 
Time to particular EDSS hallmarks were less suitable as the participants were not 
assessed frequently enough by neurologists to reliably determine the date participants 
reached an EDSS of three or four. Therefore, annualised change of EDSS in the 
AusLong study was the best measure of disability progression. 
7.4.3 Measurement of stressful life events 
SLEs were assessed at yearly intervals up to 5-year review using a modified version 
(excluding any illness leading to study participation) of the Social Readjustment 
Rating Scale developed by Holmes & Rahe (SRRS)
16
. The SLEs here included 
questions relating to the participant‘s employment or financial issues, gaining/losing 
family members, changing personal circumstances (habits, lifestyle, relationships, and 
employment), experiencing personal achievement/disappointment, health related 
issues, problems with the law or having a close friend/relative experience the same. 
Participants were asked to report the presence/absence of each type of event from 12 
months prior to the event that brought cases to the AusImmune study to the 5
th
 year 
review, the duration of each event (by providing the year and months that this event 
continued) and the perceived severity (a five point scale allowing the participants to 
assess the degree of perceived severity: -5 (worst) to +5 (best) Likert scale). The 
negative or positive valence of SLEs was determined by participants‘ ratings of the 
SLEs they experienced; SLEs rated >0 were classified as positive and SLEs<0were 
Chapter 7 Positive stressful life events are associated with a lower hazard of relapses 
in early multiple sclerosis 
239 
 
classified as negative. Major negative SLEs
11
 were defined as SLEs associated with 
physical damage or family loss to the patients. Major positive SLEs (mean perceived 
severity>3) were defined as SLEs associated with gaining a new family member, 
getting married or a personal achievement.  
The total number of SLEs (SLE number) was calculated based on the total of reported 
SLE events. The total valence rating (SLE perceived severity) was calculated for both 
positive and negative events separately by addition of SLE Likert ratings. In addition, 
each SLE type was given a weight reflecting the amount of readjustment the event 
requires according to the load of each event (designed by Scully, devised by Holmes 
and Rahe and later reviewed by Scully et al. to reflect updates in culture change
17
), 
the total of these weights indicate a total load on coping capacity a given SLE might 
have on a participants of events (SLE load). A total duration of events (SLE duration) 
was calculated by summing the reported duration of each event. SLE number, SLE 
perceived severity, SLE load and SLE duration were calculated separately according 
to the perceived negative and positive events.  
To establish whether the timing of the SLEs was important in relation to the 
outcomes, SLE measures were calculated for 12 months and 6 months prior to each 
review for conversion to MS/relapse analyses. This window was chosen because a 
shorter risk window would have resulted in insufficient SLE events while a longer 
risk window would have reduced the sample size because the questionnaire only 
recorded the SLE information as far back as 12 months prior to event that brought 
them into the study. For disability progression analyses, annualised SLE measures 
from the date of one year prior to FCD to 5-year review were used as predictor.  
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7.4.4 Measurement of other covariates 
Our group previously demonstrated the significant association between body mass 
index (BMI) and MS clinical course, so BMI was also controlled in the multivariable 
model
18
.Height and weight were measured by a study nurse at baseline review using a 
standardised protocol
13
. Body mass index (BMI) was calculated as weight (kg) 
divided by squared height (m
2
). Other baseline measurements included the use of 
disease modifying therapy (DMT) and employment status. Patients who accepted 
DMTs in AusLong study were mostly administered with interferon-beta (88%), so 
DMTs use was code as yes/no in the analysis. When adjustment for the longitudinal 
use of DMTs, no significant difference with the primary analysis was seen (data not 
shown). So we used baseline DMTs in the primary analysis. 
 
Due to the insignificant association between history of smoking, immune response to 
Epstein-Barr virus, levels of vitamin D, past exposure to ultraviolet radiation and 
HLA-DR 15 genotype (data not shown), these factor were not adjusted in the 
multivariable model. 
7.4.5 Data analysis 
The effect of SLE and other covariates on time-to-conversion and time-to-relapse was 
calculated using Cox proportional hazards models, the latter for repeated events where 
multiple relapses by the same person are treated as independent observations but 
accounted for at the intra-individual level, and the time until a prior event dose not 
influence the composition of the risk set for a subsequent event. All variables of 
interest satisfied the proportional hazard assumption. 
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For conversion to MS analysis, the starting point is the date of FDE, and for relapse 
analysis, the starting point was the date of the event that brought the cases into the 
study
19
. Based on all available SLE data, we calculated the SLE variables 12 months 
and 6 months prior to each review in order to analyse its association with the 
subsequent occurrence of disease activity.  
Predictors of annualised change in EDSS were evaluated using linear regression, 
adjusted for whether persons were having a relapse at the time of their 5-year review 
EDSS assessment. Because the annualised change in disability was highly skewed and 
for some cases the change of EDSS was zero, a log-transformation of the original 
score plus one was applied to satisfy linear regression assumptions of minimal 
heteroskedasticity. All means and coefficients, however, are back-transformed (for the 
reference group, minus 1 was performed) and presented on the original scale of the 
change in EDSS variable. 
It is acknowledged that the increase of EDSS is not linear, however, the AusLong 
study participants were people with a first clinical diagnosis of demyelination at study 
entry and 87.6% had an EDSS score ≤ 4 at the 5-year review. Previous research has 
suggested that the disability progression is comparative linear when EDSS was ≤ 4. 
Time to particular EDSS hallmarks were less suitable as the participants were not 
assessed frequently enough by neurologists to reliably determine the date participants 
reached an EDSS of three or four. Therefore, annualised change of EDSS in the 
AusLong study was the best measure of disability progression. 
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Associations of other covariates (sex, age, employments status and baseline DMT) 
and annualised SLEs were analysed with linear regression.  
7.5 Results 
7.5.1 Characteristics of the cohort 
A total of 251 cases with SLE data and clinical follow-up data were included in this 
analysis, 76.9% were females and the mean age at study entry was 38.8 years. At the 
5-year review, 236 cases were still retained in the study. Among all cases, 18 were 
diagnosed as primary-progressive MS (PPMS), 180 as RRMS and 53 had not 
converted to MS at their final review. Therefore (198/251 = 78.9%) were diagnosed 
as MS before the 5
th
 year review. A total of 433 relapses occurred during follow-up. 
On average each participant experienced 0.57 negative SLEs and 0.76 positive SLEs 
per year. Other characteristics of the cohort are shown in Table 1. 
Table 7.1 Demographic and clinical characteristics of the cohort in the analysis 
 Total cohort n (%) 
Total 251 
Female  193 (76.9) 
Study site 
 QLD 75 (29.88) 
 NSW 35 (13.94) 
 VIC 65 (25.9) 
 TAS 76 (30.28) 
MS course at study entry 
 CIS/RRMS 233 (92.83) 
 PPMS 18 (7.17) 
Conversion during study 198 (78.88) 
Relapses during study  433 
Employed at baseline 204 (82.26) 
Used DMT at baseline 53 (21.12) 
 Mean (SD; Range) 
Annualised SLE numbers 1.22 (0.83; 0, 4.81) 
Annualised SLE numbers (positive) 0.57 (0.49; 0, 3.28) 
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7.5.2 Association between baseline covariates and SLEs 
Older age was associated with the reduced perceived positive SLEs (number, 
perceived severity, load and duration, p<0.001) while no association was found 
between age and perceived negative SLEs. Higher BMI at baseline was associated 
with a greater number of perceived negative SLEs, while there was no association 
with positive SLEs. There were no associations between sex, employment status or 
study centre and SLEs variables. 
7.5.3 Association between SLE and Hazard of Conversion to MS 
249 and 251 cases were included in the analysis of a risk window of 12 months and 6 
months, respectively. Total SLE number, load, perceived severity and duration were 
not associated with the hazard of conversion to MS for both the 12 month and 6 
month risk windows (Table 2). While some positive SLE variables had a dose-
dependent association with the rate of MS conversion, they did not reach statistical 
significance. When we restricted our analysis to major positive SLEs, there was still 
Annualised SLE numbers (negative) 0.76 (0.62; 0, 3.26) 
Annualised perceived SLE intensity 4.11 (3; 0, 15.97) 
Annualised perceived SLE intensity (positive) 2.05 (1.71; 0, 9.44) 
Annualised perceived SLE intensity (negative) 2.34 (2.11; 0, 9.94) 
Annualised SLE load  41.19 (28.72; 0.87, 155.08) 
Annualised SLE load (positive) 15.24 (11.33; 0.87, 69.77) 
Annualised SLE load (negative) 31.86 (25.53; 0.87, 151.98) 
Annualised SLE duration (days) 54.99 (66.18; 1.89, 479.01) 
Annualised SLE duration (positive, days) 22.15 (22.57; 1.09, 206.75) 
Annualised SLE duration (negative, days) 40.26 (62.95; 1.89, 463.96) 
Age at study entry, years 38.76 (9.79; 18, 58) 
MS duration from first symptoms to 5
th
 year review, years 6.42 (2.38; 2.33, 21.2) 
 Median (IQR) 
EDSS at 5
th
 year study review 2.00 (1.50, 2.75) 
Annualised change of EDSS 0.27 (0.18; 0.41) 
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no association between positive SLEs and risk of conversion (risk window of 12 
months and 6 months: test for trend p=0.49 & p=0.31, respectively). None of the 
negative SLE variables were associated with MS conversion, even when we restricted 
to major negative SLEs (risk window of 12 months and 6 months: test for trend 
p=0.82 & p=0.96, respectively). 
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Table 7.2 Associations between stressful life events and conversion to MS and relapses 





 12 months as risk window  6 months as risk window  12 months as risk window 6 months as risk window 
 aHR (95% CI) p aHR (95% CI) p aHR (95% CI) p aHR (95% CI) p 
SLE number prior to conversion/relapse         
 Total         
 0 1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference)  
 1 1.35 (0.94, 1.93) 0.102 1.13 (0.76, 1.68) 0.544 0.93 (0.70, 1.22) 0.596 1.00 (0.77, 1.31) 0.978 
 2 1.19 (0.80, 1.78) 0.393 0.91 (0.54, 1.54) 0.733 0.90 (0.69, 1.19) 0.463 0.79 (0.56, 1.13) 0.196 
 ≥3 0.92 (0.60, 1.41) 0.705 0.62 (0.29, 1.33) 0.216 0.84 (0.63, 1.11) 0.224 0.60 (0.38, 0.94) 0.027 
 Trend   0.910  0.358  0.224  0.028 
 Positive SLEs         
 0 1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference)  
 1 0.94 (0.65, 1.36) 0.755 0.85 (0.58, 1.27) 0.436 0.83 (0.64, 1.09) 0.179 0.88 (0.66, 1.18) 0.407 
 ≥2 0.82 (0.55, 1.23) 0.341 0.69 (0.35, 1.36) 0.279 0.77 (0.57, 1.03) 0.079 0.64 (0.40, 1.02) 0.060 
 Trend   0.347  0.194  0.035  0.054 
 Negative SLEs         
 0 1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference)  
 1 1.60 (1.13, 2.25) 0.008 1.03 (0.66, 1.61) 0.894 1.06 (0.82, 1.35) 0.668 1.03 (0.80, 1.33) 0.796 
 ≥2 1.18 (0.83, 1.67) 0.367 1.03 (0.61, 1.72) 0.925 1.10 (0.83, 1.46) 0.517 0.74 (0.50, 1.11) 0.147 
 Trend   0.133  0.888  0.493  0.277 
Perceived SLE intensity  
prior to conversion/relapse 
        
 Total         
 No events  1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference)  
 0-4 1.42 (0.97, 2.09) 0.074 1.25 (0.81, 1.95) 0.317 0.97 (0.73, 1.29) 0.856 1.01 (0.75, 1.35) 0.960 
 5-7 1.25 (0.86, 1.81) 0.248 0.89 (0.58, 1.37) 0.599 0.88 (0.64, 1.21) 0.427 0.85 (0.63, 1.16) 0.316 
 ≥8 0.92 (0.61, 1.39) 0.703 0.72 (0.38, 1.34) 0.298 0.83 (0.63, 1.09) 0.185 0.69 (0.48, 0.99) 0.047 
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 Trend  0.945  0.385  0.168  0.053 
 Positive SLEs         
 No events  1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference)  
 0-4 1.16 (0.79, 1.71) 0.456 0.95 (0.60, 1.51) 0.837 0.99 (0.76, 1.30) 0.953 0.95 (0.66, 1.36) 0.778 
 5-7 0.78 (0.50, 1.22) 0.283 0.69 (0.41, 1.17) 0.166 0.67 (0.50, 0.90) 0.007 0.70 (0.51, 0.98) 0.035 
 Trend   0.394  0.187  0.010  0.055 
 Negative SLEs         
 No events  1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference)  
 0-4 1.53 (1.08, 2.18) 0.018 0.85 (0.51, 1.41) 0.536 0.97 (0.74, 1.27) 0.833 0.94 (0.70, 1.26) 0.662 
 5-7 1.13 (0.79, 1.63) 0.495 1.17 (0.76, 1.80) 0.484 0.97 (0.74, 1.27) 0.834 0.86 (0.62, 1.19) 0.358 
 Trend   0.291  0.701  0.817  0.340 
SLE load prior to conversion/relapse         
 Total         
 No events 1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference)  
 0-40 1.18 (0.81, 1.72) 0.391 1.26 (0.86, 1.86) 0.239 0.96 (0.72, 1.29) 0.807 1.16 (0.85, 1.59) 0.349 
 >40-65 1.62 (1.04, 2.51) 0.033 0.96 (0.54, 1.71) 0.897 0.94 (0.70, 1.26) 0.686 0.82 (0.60, 1.13) 0.223 
 >65-100 1.09 (0.68, 1.74) 0.715 0.57 (0.26, 1.27) 0.167 0.86 (0.60, 1.22) 0.394 0.70 (0.46, 1.09) 0.115 
 >100 0.86 (0.54, 1.39) 0.548 0.83 (0.40, 1.71) 0.612 0.82 (0.59, 1.15) 0.255 0.63 (0.37, 1.06) 0.082 
 Trend  0.897  0.321  0.208  0.021 
 Positive SLEs         
 No events 1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference)  
 0-40 1.21 (0.73, 2.00) 0.470 1.14 (0.68, 1.90) 0.626 0.91 (0.60, 1.38) 0.643 1.04 (0.69, 1.57) 0.860 
 >40-65 0.95 (0.53, 1.69) 0.850 0.72 (0.38, 1.38) 0.322 0.72 (0.46, 1.12) 0.145 0.74 (0.44, 1.24) 0.256 
 >65-100 0.96 (0.60, 1.53) 0.856 0.84 (0.43, 1.63) 0.598 0.98 (0.71, 1.35) 0.910 0.91 (0.60, 1.39) 0.665 
 >100 0.68 (0.38, 1.21) 0.189 0.54 (0.22, 1.34) 0.187 0.63 (0.40, 0.99) 0.044 0.46 (0.23, 0.91) 0.026 
 Trend  0.289  0.139  0.052  0.036 
 Negative SLEs         
 No events 1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference)  
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 0-50 1.58 (1.06, 2.37) 0.026 1.11 (0.67, 1.84) 0.672 1.04 (0.79, 1.35) 0.799 1.06 (0.81, 1.39) 0.659 
 >50-95 1.43 (1.01, 2.01) 0.042 0.88 (0.50, 1.56) 0.671 1.03 (0.76, 1.39) 0.841 0.72 (0.47, 1.08) 0.110 
 >95 0.72 (0.40, 1.30) 0.277 1.02 (0.49, 2.13) 0.962 0.82 (0.56, 1.21) 0.317 0.74 (0.43, 1.28) 0.284 
 Trend   0.725  0.899  0.503  0.150 
SLE duration prior to events          
 Total         
 No events 1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference)  
 0-31 days 1.37 (0.96, 1.95) 0.087 1.14 (0.77, 1.68) 0.527 0.94 (0.71, 1.24) 0.655 1.01 (0.77, 1.32) 0.937 
 32-62 days 1.12 (0.74, 1.71) 0.584 0.80 (0.45, 1.40) 0.430 0.91 (0.69, 1.19) 0.485 0.75 (0.52, 1.07) 0.115 
 63-93 days 1.49 (0.90, 2.46) 0.122 0.51 (0.18, 1.47) 0.212 0.86 (0.61, 1.20) 0.373 0.53 (0.30, 0.91) 0.022 
 ≥94 days 0.74 (0.43, 1.27) 0.271 1.15 (0.50, 2.62) 0.747 0.80 (0.55, 1.18) 0.263 0.87 (0.51, 1.48) 0.609 
 Trend  0.809  0.510  0.196  0.044 
 Positive SLEs         
 No events 1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference)  
 0-31 days 1.06 (0.71, 1.59) 0.761 0.93 (0.61, 1.40) 0.712 0.86 (0.65, 1.15) 0.313 0.90 (0.67, 1.22) 0.505 
 ≥32 days 0.81 (0.52, 1.24) 0.334 0.62 (0.31, 1.23) 0.171 0.73 (0.53, 1.01) 0.057 0.62 (0.38, 1.00) 0.051 
 Trend   0.450  0.178  0.042  0.060 
 Negative SLEs         
 No events 1.00 (reference)  1.00 (reference)  1.00 (reference)  1.00 (reference)  
 0-31 days 1.53 (1.07, 2.18) 0.020 1.03 (0.66, 1.62) 0.898 0.97 (0.75, 1.25) 0.806 1.01 (0.78, 1.31) 0.937 
 ≥32 days 1.10 (0.77, 1.58) 0.605 0.96 (0.56, 1.66) 0.891 0.97 (0.73, 1.30) 0.860 0.69 (0.47, 1.02) 0.062 
 Trend   0.317  0.954  0.837  0.142 
Fonts in bold and italic denoted statistically significant association 
Adjusted for age, sex, study centres, BMI, baseline employment status and baseline DMTs
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7.5.4 Association between SLE and Hazard of Relapses 
Including 233 bout onset cases, we found that, in line with the previous conversion to 
MS analysis, total SLE number, load, perceived severity and duration were not 
associated with hazard of relapses for both the 12 month and 6 month risk windows 
(Table 2). However, we found that higher positive SLE variables in the previous 12 
months were consistently associated with a lower hazard of relapse, including SLE 
number, perceived severity, SLE load, and SLE duration. In contrast, there were no 
associations for negative SLE variables including for major negative SLE number 
(risk window of 12 months and 6 months: p=0.561 & p=0.154, respectively). The 
magnitude of effect strengthened when restricting to a risk window of 6 months, 
although the associations became borderline significant due to a lower number of SLE 
events. All associations were adjusted for age, sex, BMI, baseline employment status 
and baseline DMT use Enhancement of the magnitude after adjustment was mostly 
driven by the negative confounder age (Supplementary Table 2). 
7.5.5 Association between SLE and Annualised disability progression 
We found no association between any of the SLE variables, including positive or 
negative SLEs (number, perceived severity, load and duration) and annualised change 
of EDSS (Table 3). 
Table 7.3 Associations of baseline and longitudinal SLE variables and annualised 
change of EDSS 





 No. (%) β (95% CI) p β (95% CI) p 
SLE numbers      
 Total      
 0 - 3 31 (17.32) +0.33 (0.25, 0.42)
c
  +0.34 (0.26, 0.42)
 c
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 4 - 5 54 (30.17) -0.07 (-0.18, 0.03) 0.167 -0.08 (-0.19, 0.02) 0.105 
 6 - 8 43 (24.02) -0.01 (-0.12, 0.10) 0.823 -0.02 (-0.13, 0.09) 0.711 
 ≥9 51 (28.49) -0.03 (-0.14, 0.07) 0.528 -0.03 (-0.14, 0.07) 0.551 
 Trend    0.998  0.898 
 Positive SLEs      
 0 25 (13.97) +0.3 (0.21, 0.40)
 c
  +0.32 (0.23, 0.41)
 c
  
 1 - 2 57 (31.84) -0.01 (-0.12, 0.10) 0.829 -0.04 (-0.15, 0.07) 0.497 
 3 - 4 51 (28.49) +0.02 (-0.10, 0.13) 0.786 -0.02 (-0.13, 0.09) 0.711 
 ≥5 46 (25.70) -0.02 (-0.13, 0.10) 0.769 +0.01 (-0.11, 0.13) 0.846 
 Trend    0.917  0.624 
 Negative SLEs      
 0 - 1 42 (23.46) +0.32 (0.24, 0.39)
 c
  +0.32 (0.25, 0.39)
 c
  
 2  29 (16.20) -0.04 (-0.15, 0.07) 0.526 -0.04 (-0.14, 0.07) 0.526 
 3 - 5 61 (34.08) -0.04 (-0.13, 0.06) 0.448 -0.03 (-0.12, 0.06) 0.514 
 ≥6 47 (26.26) +0.01 (-0.09, 0.11) 0.882 0.00 (-0.10, 0.10) 0.954 
 Trend    0.916  0.968 
Perceived SLE intensity      
 Total      
 0-9 40 (22.35) +0.30 (0.23, 0.38)
 c
  0.31 (0.24, 0.39)
 c
  
 10-19 48 (26.82) -0.01 (-0.11, 0.08) 0.764 -0.03 (-0.13, 0.07) 0.575 
 20-32 45 (25.14) +0.01 (-0.09, 0.11) 0.816 -0.01 (-0.11, 0.09) 0.862 
 ≥33 46 (25.70) -0.02 (-0.11, 0.08) 0.763 0.00 (-0.11, 0.10) 0.935 
 Trend   0.909  0.915 
 Positive SLEs      
 0 - 4 39 (28.47) +0.34 (0.26, 0.42)
 c
  +0.33 (0.25, 0.41)
 c
  
 5 - 7 26 (18.98) -0.08 (-0.2, 0.04) 0.217 -0.05 (-0.18, 0.07) 0.385 
 8 - 14 38 (27.74) -0.01 (-0.12, 0.10) 0.831 -0.01 (-0.13, 0.10) 0.803 
 ≥15 34 (24.82) -0.03 (-0.14, 0.09) 0.646 0.00 (-0.12, 0.12) 0.988 
 Trend    0.845  0.917 
 Negative SLEs      
 0 - 4 53 (32.72) +0.32 (0.26, 0.38)
 c
  +0.33 (0.27, 0.39)
 c
  
 5 - 7 26 (16.05) -0.06 (-0.17, 0.05) 0.272 -0.07 (-0.17, 0.04) 0.212 
 8 - 14 41 (25.31) -0.04 (-0.14, 0.06) 0.410 -0.05 (-0.15, 0.04) 0.287 
 ≥15 42 (25.93) +0.01 (-0.08, 0.11) 0.799 -0.00 (-0.10, 0.09) 0.974 
 Trend    0.864  0.914 
SLE load       
 Total      
 0 - 110 44 (24.58) +0.30 (0.23, 0.37)
 c
  +0.30 (0.24, 0.37)
 c
  
 111 - 192 45 (25.14) -0.04 (-0.13, 0.06) 0.421 -0.03 (-0.13, 0.06) 0.505 
 193 - 300 45 (25.14) +0.03 (-0.07, 0.13) 0.513 +0.03 (-0.07, 0.13) 0.565 
 ≥301 45 (25.14) -0.01 (-0.10, 0.09) 0.904 -0.01 (-0.10, 0.09) 0.914 
 Trend   0.726  0.752 
 Positive SLEs      
 0 - 44 35 (22.29) +0.31 (0.23, 0.39)
 c
  +0.32 (0.24, 0.40)
 c
  
 45 - 80 42 (26.75) -0.01 (-0.12, 0.09) 0.799 -0.04 (-0.14, 0.07) 0.469 
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 81 - 124 40 (25.48) +0.01 (-0.10, 0.12) 0.840 -0.01 (-0.12, 0.10) 0.856 
 ≥125 40 (25.48) -0.02 (-0.13, 0.08) 0.657 +0.01 (-0.10, 0.12) 0.829 
 Trend   0.777  0.686 
 Negative SLEs      
 0 - 70 42 (24.56) +0.32 (0.25, 0.39)
 c
  +0.32 (0.25, 0.40)
 c
  
 71 - 140  43 (25.15) -0.04 (-0.14, 0.06) 0.453 -0.04 (-0.13, 0.06) 0.475 
 141 - 215 43 (25.15) -0.03 (-0.13, 0.07) 0.579 -0.02 (-0.12, 0.08) 0.655 
 ≥216 43 (25.15) +0.01 (-0.09, 0.11) 0.863 -0.01 (-0.11, 0.09) 0.863 
 Trend    0.809  0.939 
SLE duration       
 Total      
 0 - 123 days 32 (17.88) +0.33 (0.25, 0.41)
 c
  +0.34 (0.26, 0.42)
 c
  
 124 - 216 days 57 (31.84) -0.08 (-0.18, 0.02) 0.133 -0.10 (-0.19, 0.00) 0.055 
 217 - 338 days 45 (25.14) -0.02 (-0.12, 0.09) 0.746 +0.00 (-0.10, 0.11) 0.982 
 ≥339 days 45 (25.14) -0.00 (-0.11, 0.10) 0.954 +0.00 (-0.10, 0.11) 0.982 
 Trend   0.538  0.383 
 Positive SLEs      
 0 - 61 days 31 (19.75) 0.34 (0.25, 0.42)
 c
  0.34 (0.25, 0.42)
 c
  
 62 - 92 days 32 (20.38) -0.05 (-0.17, 0.07) 0.425 -0.07 (-0.19, 0.04) 0.204 
 93 - 170 days 45 (28.66) -0.03 (-0.14, 0.08) 0.564 -0.06 (-0.17, 0.05) 0.307 
 ≥171 days 49 (31.21) -0.05 (-0.16, 0.06) 0.382 +0.01 (-0.11, 0.12) 0.904 
 Trend    0.475  0.767 
 Negative SLEs      
 0 - 61 days 36 (21.05) +0.35 (0.27, 0.43)
 c
  +0.35 (0.27, 0.43)
 c
  
 62 - 100 days 29 (16.96) -0.08 (-0.19, 0.04) 0.190 -0.08 (-0.19, 0.03) 0.160 
 101 - 204 days 63 (36.84) -0.08 (-0.17, 0.02) 0.131 -0.08 (-0.18, 0.02) 0.121 
 ≥205 days 43 (25.15) -0.00 (-0.11, 0.10) 0.941 -0.01 (-0.12, 0.09) 0.798 
 Trend    0.928  0.796 
Fonts in bold and italic denoted statistically significant association 
a: adjusted for relapse or not at 5
th
 year review; b: further adjusted for 
age, sex, study centres, employment status and relapse numbers. 
c: mean annualised change of EDSS in reference group 
 
7.6 Discussion 
In this prospective cohort study, we examined the association of SLEs and MS 
clinical course. We found that greater number, higher perceived severity and load and 
a longer duration of the events that were perceived as positive were consistently 
associated with a reduced hazard of relapses in a dose-dependent manner. 
Associations were less strong for conversion to MS. We found no associations 
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between negative SLEs and MS conversion or relapse risk. Neither positive nor 
negative SLEs were associated with disability progression. 
Previous research has largely focused on the effects of negative events on MS clinical 
course, only two studies evaluated the relationship of positive SLE with MS, 
demonstrating some evidence of a beneficial impact on clinical course
4 11
. The 
associations were less strong for MS conversion, which may simply reflect the lower 
number of events in conversion analysis. Potential mechanisms underlying these 
associations could be through direct effects on the neuroendocrine system and 
immune responses, and an indirect effect via healthy behaviours and positive coping 
strategies (reviewed by Avvenuti and colleagues
20
). Our results indicated that events 
such as ―gaining a new family member (new baby born or parent remarried)‖ or ―you 
had an outstanding personal achievement (awards, grades, etc)‖ were factors that were 
experienced as predominantly positive. However, the effect may extend to smaller 
positive events such as weekend outings and social activity, which were not captured 
in our questionnaire. Indeed, positive psychological well-being has been associated 
with a decreasing hazard of mortality in a healthy (n=36,598; HR 0.82, p<0.001) as 
well as diseased populations (n=15,711; HR 0.98, p=0.030)
21
. A 2014 systematic 
review
22
 on intervention techniques to decrease stress in people with MS, including 
Cognitive Behaviours Therapy (CBT) and relaxation training, found support that 
stress-management interventions may help people with MS reduce perceived stress, 
improve quality of life, reduce mental health comorbidities, and improve outcomes 
associated with the disease. Our evidence warrants that these interventions could 
include a focus on the benefits of positive events.    
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The absence of an effect of negative SLEs on disease outcomes was unexpected in 
this study as a number of previous studies have found significant associations between 
negative SLEs and adverse MS clinical course
5 23 24
. Even limiting to major negative 
SLEs (loss of family/friend or physical injury), we found no association with any 
clinical outcomes. Different methodologies for classifying the valence of SLE could 
account for the disparities in findings across studies. Buljevac and colleagues
5
 only 
asked about perceived emotionally stressful events and asked patients to keep diaries. 
Two neurologists excluded diary events that were deemed to be directly connected to 
multiple sclerosis symptomatology. While Potagas and colleagues
23
  only looked at 
anxiety provoking stressful event and did not ask participants if they believe the event 
to be negative only if was stressful – an event can be stressful but ultimately viewed 
by the person as helpful. There are some other studies that are consistent with our 
findings. One study following 36 MS patients up to 100 weeks
12
 found that major 
negative SLEs were not associated with the emergence of new enhancing lesion on 
MRI. Some other research
25-27
assessing the association of occurrence of negative 
stressors with MS onset has typically found no significant associations. Nisipeanu and 
colleagues actually demonstrated a beneficial impact of ambient negative stress on 
clinical course
28
, following 32 MS patients for two months in Israel during the 1991 
Persian Gulf War when patients were under threat of missile attacks and finding that 
relapse rates were significantly lower during that period compared to the previous two 
year period (p<0.001). However, not controlling for potential confounders especially 
the treatment effects and small sample size influenced the validity of this study. 
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We found no evidence to support an association between SLEs and annualised change 
of EDSS. This is consistent with another prospective study
12
 that found that SLEs 
were not associated with disability progression as measured by EDSS (p>0.05). These 
results conflict with that found by Brown and colleagues, which
4
 even showed that 
acute stressors were associated with a slower progression of disability. With a cross-
sectional study design, our group recently found a positive association between higher 
psychological dysfunctions (fatigue, depression and anxiety) and higher EDSS score
2
. 
In this study, a shorter risk window (6 months compared to 12 months) was associated 
with a stronger effect on subsequent relapse, suggesting the effect of positive SLEs 
occurs biologically within months. A number of other studies modeled the lag 
between stressful life events and MS onset or relapse. One study
23
 found that after the 
emergence of SLEs, the risk of first and second relapse was increased (p<0.001), 
while there was no association with the third relapse (p=0.21). Similarly, a 
randomized controlled trial
7
 showed a stress management intervention was associated 
with decreased disease activity (measured as emergence of lesions in MRI), but these 
effects were not sustained beyond the intervention (24 weeks).  
A strength of this study is the prospective longitudinal design allowing the analysis 
where the SLEs occurred prior to the outcome (conversion to MS/relapses), therefore 
establishing the correct temporal relationship. Also, the method of reporting of SLEs 
was identical in all participants, using a form-based method rather than free-text 
response, therefore ensuring systematic measurement and reducing the risk of recall 
bias. Internal consistency is another strength in this study, as different but 
complementary SLE measures (number, perceived load, load and duration) found 
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agreeable results. Moreover, using two different risk windows found evidence of a 
stronger association when the interval between exposure and outcome was shorter, 
substantiating the validity of therelationship.  
Participants in AusLong study were recruited from relatively contemporary 
populations with a standardised protocol, therefore, birth cohort effect had a relatively 
less influence on the results. However, we still performed a sensitivity analysis based 
on the date of birth of the cases (1947-1969, 1961-1970, 1971-1988), and no 
significant interaction between SLEs variables and date of birth were found. 
One limitation of this study was not having measured potential confounders such as 
SLEs during childhood, which could be germane in MS onset. That said, our 
demonstration of a stronger association in closer temporal proximity to clinical 
outcomes may mean that these historical events may be less impactful than those 
measured later in life. Another limitation of the study is that we did not measure 
psychological dysfunctions (depression, fatigue and anxiety) until 5-year review, 
which can relatively predict negative physical and mental health outcomes. Similarly, 
we did not assess positive psychological states. SLEs were recorded retrospectively at 
annual review, so it was difficult to make sure every SLEs recorded was accurate 
(especially for SLEs recorded at 2/3-year review, which included SLEs happened 
from one year prior to FCD to 2/3-year review). Some patients might have the idea 
that stressors were associated with disease activity, which was able to result in the 
recall bias. We therefore performed another analysis to examine the role of relapse in 
SLEs, and no association between relapse and SLEs was seen (p=0.93). We could not 
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make sure every SLEs recorded were accurate, however, no evidence was seen that 
the potential misclassification of SLEs was recorded differential by relapses. 
In conclusion, we found consistent evidence that positive SLEs were associated with a 
reduced hazard of relapses, suggesting that positive SLEs and possibly an overall 
positive psychological well-being may be beneficial in MS clinical course. 
7.7 Postscript 
This chapter has provided some data on the experienced stressful life events in MS 
patients and their associations with disease activity and disability progression. The 
next chapter draws the conclusions from the previous studies and plans of the future 
research will be described. 
7.8 Reference 
1. Wood B, van der Mei IA, Ponsonby AL, et al. Prevalence and concurrence of 
anxiety, depression and fatigue over time in multiple sclerosis. Multiple 
sclerosis (Houndmills, Basingstoke, England) 2013;19(2):217-24. doi: 
10.1177/1352458512450351 [published Online First: 2012/06/26] 
2. Simpson S, Jr., Tan H, Otahal P, et al. Anxiety, depression and fatigue at 5-year 
review following CNS demyelination. Acta neurologica Scandinavica 2016 
doi: 10.1111/ane.12554 [published Online First: 2016/01/13] 
3. Mohr DC, Hart SL, Julian L, et al. Association between stressful life events and 
exacerbation in multiple sclerosis: a meta-analysis. Bmj 2004;328(7442):731. 
doi: 10.1136/bmj.38041.724421.55 
4. Brown RF, Tennant CC, Sharrock M, et al. Relationship between stress and relapse 
in multiple sclerosis: Part I. Important features. Multiple sclerosis 
(Houndmills, Basingstoke, England) 2006;12(4):453-64. [published Online 
First: 2006/08/12] 
5. Buljevac D, Hop WC, Reedeker W, et al. Self reported stressful life events and 
exacerbations in multiple sclerosis: prospective study. Bmj 
2003;327(7416):646. doi: 10.1136/bmj.327.7416.646 
6. Artemiadis AK, Anagnostouli MC, Alexopoulos EC. Stress as a risk factor for 
multiple sclerosis onset or relapse: a systematic review. Neuroepidemiology 
2011;36(2):109-20. doi: 10.1159/000323953 
7. Mohr DC, Lovera J, Brown T, et al. A randomized trial of stress management for 
the prevention of new brain lesions in MS. Neurology 2012;79(5):412-9. doi: 
Chapter 7 Positive stressful life events are associated with a lower hazard of relapses 
in early multiple sclerosis 
256 
 
10.1212/WNL.0b013e3182616ff9 [published Online First: 2012/07/13] 
8. Somer E, Golan D, Dishon S, et al. Patients with multiple sclerosis in a war zone: 
coping strategies associated with reduced risk for relapse. Multiple sclerosis 
(Houndmills, Basingstoke, England) 2010;16(4):463-71. doi: 
10.1177/1352458509358714 [published Online First: 2010/01/21] 
9. Pagnini F, Bosma CM, Phillips D, et al. Symptom changes in multiple sclerosis 
following psychological interventions: a systematic review. BMC neurology 
2014;14:222. doi: 10.1186/s12883-014-0222-z [published Online First: 
2014/12/01] 
10. Strober LB, Arnett PA. Stressful life events precede exacerbations of multiple 
sclerosis. Psychology, health & medicine 2015:1-9. doi: 
10.1080/13548506.2015.1093645 [published Online First: 2015/10/13] 
11. Burns MN, Nawacki E, Kwasny MJ, et al. Do positive or negative stressful events 
predict the development of new brain lesions in people with multiple 
sclerosis? Psychological medicine 2014;44(2):349-59. doi: 
10.1017/s0033291713000755 [published Online First: 2013/05/18] 
12. Mohr DC, Goodkin DE, Bacchetti P, et al. Psychological stress and the 
subsequent appearance of new brain MRI lesions in MS. Neurology 
2000;55(1):55-61. [published Online First: 2000/07/13] 
13. Lucas R, Ponsonby AL, McMichael A, et al. Observational analytic studies in 
multiple sclerosis: controlling bias through study design and conduct. The 
Australian Multicentre Study of Environment and Immune Function. Multiple 
sclerosis (Houndmills, Basingstoke, England) 2007;13(7):827-39. doi: 
10.1177/1352458507077174 [published Online First: 2007/09/21] 
14. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple 
sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology 
2011;69(2):292-302. doi: 10.1002/ana.22366 
15. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for 
multiple sclerosis: guidelines from the International Panel on the diagnosis of 
multiple sclerosis. Annals of neurology 2001;50(1):121-7. 
16. Holmes TH, Rahe RH. The Social Readjustment Rating Scale. Journal of 
psychosomatic research 1967;11(2):213-8. 
17. Scully JA, Tosi H, Banning K. Life Event Checklists: Revisiting the Social 
Readjustment Rating Scale after 30 Years. Educational and Psychological 
Measurement 2000;60(6):864-76. doi: 10.1177/00131640021970952 
18. Tettey P, Simpson S, Taylor B, et al. An adverse lipid profile and increased levels 
of adiposity significantly predict clinical course after a first demyelinating 
event. Journal of neurology, neurosurgery, and psychiatry 2017;88(5):395-
401. doi: 10.1136/jnnp-2016-315037 [published Online First: 2017/03/23] 
19. Pan G, Simpson S, Jr., van der Mei I, et al. Role of genetic susceptibility variants 
in predicting clinical course in multiple sclerosis: a cohort study. Journal of 
neurology, neurosurgery, and psychiatry 2016;87(11):1204-11. doi: 
10.1136/jnnp-2016-313722 [published Online First: 2016/08/26] 
20. Avvenuti G, Baiardini I, Giardini A. Optimism's Explicative Role for Chronic 
Diseases. Frontiers in psychology 2016;7:295. doi: 10.3389/fpsyg.2016.00295 
[published Online First: 2016/03/15] 
21. Chida Y, Steptoe A. Positive psychological well-being and mortality: a 
Chapter 7 Positive stressful life events are associated with a lower hazard of relapses 
in early multiple sclerosis 
257 
 
quantitative review of prospective observational studies. Psychosomatic 
medicine 2008;70(7):741-56. doi: 10.1097/PSY.0b013e31818105ba 
[published Online First: 2008/08/30] 
22. Reynard AK, Sullivan AB, Rae-Grant A. A systematic review of stress-
management interventions for multiple sclerosis patients. International journal 
of MS care 2014;16(3):140-4. doi: 10.7224/1537-2073.2013-034 [published 
Online First: 2014/10/23] 
23. Potagas C, Mitsonis C, Watier L, et al. Influence of anxiety and reported stressful 
life events on relapses in multiple sclerosis: a prospective study. Multiple 
sclerosis (Houndmills, Basingstoke, England) 2008;14(9):1262-8. doi: 
10.1177/1352458508095331 [published Online First: 2008/08/30] 
24. Mohr DC, Goodkin DE, Nelson S, et al. Moderating Effects of Coping on the 
Relationship Between Stress and the Development of New Brain Lesions in 
Multiple Sclerosis. Psychosomatic medicine 2002;64(5):803-9. doi: 
10.1097/01.psy.0000024238.11538.ec 
25. Nielsen NM, Pedersen BV, Stenager E, et al. Stressful life-events in childhood 
and risk of multiple sclerosis: a Danish nationwide cohort study. Multiple 
sclerosis (Houndmills, Basingstoke, England) 2014;20(12):1609-15. doi: 
10.1177/1352458514528761 [published Online First: 2014/04/02] 
26. Nielsen NM, Bager P, Simonsen J, et al. Major stressful life events in adulthood 
and risk of multiple sclerosis. Journal of neurology, neurosurgery, and 
psychiatry 2014;85(10):1103-8. doi: 10.1136/jnnp-2013-307181 [published 
Online First: 2014/03/13] 
27. Riise T, Mohr DC, Munger KL, et al. Stress and the risk of multiple sclerosis. 
Neurology 2011;76(22):1866-71. doi: 10.1212/WNL.0b013e31821d74c5 
[published Online First: 2011/06/01] 
28. Nisipeanu P, Korczyn AD. Psychological stress as risk factor for exacerbations in 
multiple sclerosis. Neurology 1993;43(7):1311-2. 
Chapter 7 Positive stressful life events are associated with a lower hazard of relapses in early multiple sclerosis 
258 
 
7.9 Supplementary Tables 
 
Table 7.4 Univariable associations of stressful stress life events and conversion to MS. 
 12 months as risk window 6 months as risk window 
 failures/person-years (rate) HR (95% CI) p failures/person-years (rate) HR (95% CI) p 
SLE numbers prior to conversion       
 Total       
 0 105/340.03 (0.31) 1.00 (reference)  140/434.65 (0.32) 1.00 (reference)  
 1 39/108.88 (0.36) 1.26 (0.88, 1.79) 0.203 35/108.96 (0.32) 1.04 (0.71, 1.53) 0.841 
 2 28/98.93 (0.28) 1.03 (0.69, 1.53) 0.878 16/68.50 (0.23) 0.79 (0.46, 1.36) 0.395 
 ≥3 24/115.45 (0.21) 0.83 (0.55, 1.27) 0.393 7/51.45 (0.14) 0.53 (0.25, 1.14) 0.104 
 Trend    0.558   0.107 
 Positive SLEs       
 0 143/436.33 (0.33) 1.00 (reference)  166/515.61 (0.32) 1.00 (reference)  
 1 31/131.47 (0.24) 0.79 (0.55, 1.13) 0.197 23/99.06 (0.23) 0.77 (0.51, 1.15) 0.206 
 ≥2 22/95.5 (0.23) 0.85 (0.57, 1.27) 0.440 9/48.89 (0.18) 0.71 (0.35, 1.42) 0.331 
 Trend    0.240   0.151 
 Negative SLEs       
 0 118/410.32 (0.29) 1.00 (reference)  156/498.11 (0.31) 1.00 (reference)  
 1 42/113.84 (0.37) 1.51 (1.06, 2.14) 0.021 26/98.96 (0.26) 0.96 (0.61, 1.49) 0.846 
 ≥2 36/139.14 (0.26) 1.06 (0.75, 1.50) 0.741 16/66.48 (0.24) 0.86 (0.52, 1.42) 0.547 
 Trend    0.371   0.550 
Perceived SLE intensity  
prior to conversion 
      
 Total       
 No events  105/340.03 (0.31) 1.00 (reference)  140/434.65 (0.32) 1.00 (reference)  
 0-4 30/78.81 (0.38) 1.4 (0.96, 2.04) 0.080 24/67.23 (0.36) 1.26 (0.81, 1.96) 0.304 
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 5-7 31/101.58 (0.31) 1.1 (0.76, 1.57) 0.621 24/102.22 (0.23) 0.76 (0.50, 1.17) 0.220 
 ≥8 30/142.88 (0.21) 0.81 (0.54, 1.2) 0.292 10/59.45 (0.17) 0.61 (0.33, 1.14) 0.121 
 Trend   0.461   0.092 
 Positive SLEs       
 No events  105/340.03 (0.31) 1.00 (reference)  140/434.65 (0.32) 1.00 (reference)  
 0-4 27/91.81 (0.29) 1.16 (0.79, 1.71) 0.456 17/63.98 (0.27) 0.93 (0.57, 1.50) 0.765 
 5-7 26/135.16 (0.19) 0.78 (0.50, 1.22) 0.283 15/83.96 (0.18) 0.61 (0.36, 1.02) 0.059 
 Trend    0.394   0.067 
 Negative SLEs       
 No events  105/340.03 (0.31) 1.00 (reference)  140/434.65 (0.32) 1.00 (reference)  
 0-4 37/101 (0.37) 1.50 (1.04, 2.15) 0.028 18/84.43 (0.21) 0.80 (0.47, 1.34) 0.395 
 5-7 41/151.98 (0.27) 1.02 (0.73, 1.44) 0.904 24/81.01 (0.30) 0.98 (0.65, 1.49) 0.940 
 Trend    0.619   0.727 
SLE load prior to conversion       
 Total       
 No events 105/340.03 (0.31) 1.00 (reference)  140/434.65 (0.32) 1.00 (reference)  
 0-40 26/76.90 (0.34) 1.13 (0.77, 1.65) 0.534 26/69.33 (0.38) 1.24 (0.84, 1.83) 0.277 
 >40-65 27/62.98 (0.43) 1.49 (0.99, 2.23) 0.054 18/63.91 (0.28) 0.91 (0.53, 1.57) 0.741 
 >65-100 19/86.54 (0.22) 0.87 (0.55, 1.37) 0.544 7/56.55 (0.12) 0.44 (0.20, 0.95) 0.036 
 >100- 19/96.84 (0.20) 0.79 (0.49, 1.28) 0.341 7/37.99 (0.18) 0.70 (0.34, 1.45) 0.340 
 Trend   0.523   0.066 
 Positive SLEs       
 No events 105/340.03 (0.31) 1.00 (reference)  140/434.65 (0.32) 1.00 (reference)  
 0-40 16/57.07 (0.28) 1.01 (0.63, 1.63) 0.965 11/35.98 (0.31) 0.98 (0.59, 1.64) 0.951 
 >40-65 12/57.62 (0.21) 0.72 (0.41, 1.26) 0.254 8/45.85 (0.17) 0.58 (0.29, 1.16) 0.123 
 >65-100 15/57.89 (0.26) 0.97 (0.61, 1.54) 0.900 8/31.29 (0.26) 0.91 (0.43, 1.91) 0.795 
 >100- 10/54.39 (0.18) 0.72 (0.40, 1.29) 0.275 5/34.82 (0.14) 0.54 (0.22, 1.32) 0.177 
 Trend   0.252   0.102 
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 Negative SLEs       
 No events 105/340.03 (0.31) 1.00 (reference)  140/434.65 (0.32) 1.00 (reference)  
 0-50 34/87.67 (0.39) 1.55 (1.03, 2.33) 0.038 21/75.06 (0.28) 1.12 (0.67, 1.87) 0.677 
 >50-95 32/89.02 (0.36) 1.29 (0.92, 1.80) 0.136 14/56.96 (0.25) 0.73 (0.42, 1.25) 0.252 
 >95- 12/76.29 (0.16) 0.66 (0.37, 1.19) 0.165 7/32.28 (0.22) 0.83 (0.40, 1.74) 0.624 
 Trend    0.855   0.354 
SLE duration prior to conversion       
 Total       
 No events 105/340.03 (0.31) 1.00 (reference)  140/434.65 (0.32) 1.00 (reference)  
 0-31 days 40/109.62 (0.36) 1.27 (0.90, 1.81) 0.175 36/109.35 (0.33) 1.05 (0.72, 1.53) 0.804 
 32-62 days 24/92.25 (0.26) 1.00 (0.66, 1.52) 0.990 12/62.48 (0.19) 0.69 (0.38, 1.25) 0.217 
 63-93 days 13/40.08 (0.32) 1.22 (0.72, 2.09) 0.456 4/34.59 (0.12) 0.44 (0.16, 1.23) 0.118 
 ≥94 days 14/81.32 (0.17) 0.67 (0.40, 1.13) 0.135 6/22.49 (0.27) 0.99 (0.43, 2.25) 0.974 
 Trend   0.353   0.183 
 Positive SLEs       
 No events 105/340.03 (0.31) 1.00 (reference)  140/434.65 (0.32) 1.00 (reference)  
 0-31 days 31/127.81 (0.24) 0.88 (0.6, 1.28) 0.494 23/95.96 (0.24) 0.80 (0.53, 1.22) 0.303 
 ≥32 days 22/99.16 (0.22) 0.83 (0.55, 1.27) 0.394 9/51.99 (0.17) 0.62 (0.31, 1.27) 0.194 
 Trend    0.336   0.114 
 Negative SLEs       
 No events 105/340.03 (0.31) 1.00 (reference)  140/434.65 (0.32) 1.00 (reference)  
 0-31 days 42/113.15 (0.37) 1.45 (1.01, 2.08) 0.043 27/99.02 (0.27) 0.96 (0.61, 1.49) 0.843 
 ≥32 days 36/139.83 (0.26) 1.00 (0.70, 1.43) 0.993 15/66.42 (0.23) 0.81 (0.48, 1.36) 0.420 
 Trend    0.632   0.444 








Table 7.5 Univariable associations of stressful stress life events and relapses. 
 12 months as risk window 6 months as risk window 
 failures/person-years (rate) HR (95% CI) p failures/person-years (rate) HR (95% CI) p 
SLE numbers prior to relapse       
 Total       
 0 191/515.63 (0.37) 1.00 (reference)  265/741.89 (0.36) 1.00 (reference)  
 1 98/319.54 (0.31) 0.97 (0.74, 1.27) 0.825 105/313.24 (0.34) 1.03 (0.79, 1.35) 0.831 
 2 65/216.23 (0.30) 0.92 (0.71, 1.20) 0.540 39/156.35 (0.25) 0.80 (0.57, 1.12) 0.185 
 ≥3 79/284.86 (0.28) 0.89 (0.66, 1.21) 0.462 24/124.78 (0.19) 0.65 (0.41, 1.02) 0.063 
 Trend    0.424   0.054 
 Positive SLEs       
 0 286/784.95 (0.36) 1.00 (reference)  339/967.83 (0.35) 1.00 (reference)  
 1 88/327.08 (0.27) 0.83 (0.64, 1.09) 0.182 70/259.75 (0.27) 0.89 (0.67, 1.19) 0.440 
 ≥2 59/224.24 (0.26) 0.84 (0.62, 1.14) 0.266 24/108.68 (0.22) 0.72 (0.45, 1.16) 0.177 
 Trend    0.136   0.139 
 Negative SLEs       
 0 228/699.57 (0.33) 1.00 (reference)  308/908.45 (0.34) 1.00 (reference)  
 1 105/329.06 (0.32) 1.13 (0.89, 1.45) 0.310 91/274.43 (0.33) 1.06 (0.83, 1.35) 0.657 
 ≥2 100/307.64 (0.33) 1.08 (0.81, 1.45) 0.604 34/153.39 (0.22) 0.74 (0.51, 1.09) 0.130 
 Trend    0.504   0.279 
Perceived SLE intensity prior to relapse       
 Total       
 No events  191/515.63 (0.37) 1.00 (reference)  265/741.89 (0.36) 1.00 (reference)  
 0-4 88/276.00 (0.32) 1.01 (0.76, 1.35) 0.926 79/234.10 (0.34) 1.05 (0.78, 1.41) 0.742 
 5-7 60/209.93 (0.29) 0.88 (0.65, 1.20) 0.423 50/188.44 (0.27) 0.82 (0.61, 1.11) 0.206 
 8- 94/334.70 (0.28) 0.89 (0.67, 1.18) 0.427 39/171.84 (0.23) 0.75 (0.53, 1.07) 0.116 
 Trend   0.353   0.090 
Chapter 7 Positive stressful life events are associated with a lower hazard of relapses in early multiple sclerosis 
262 
 
 Positive SLEs       
 No events  191/515.63 (0.37) 1.00 (reference)  265/741.89 (0.36) 1.00 (reference)  
 0-4 75/228.35 (0.33) 1.03 (0.78, 1.36) 0.841 48/164.69 (0.29) 0.97 (0.68, 1.39) 0.889 
 5-7 72/322.97 (0.22) 0.72 (0.54, 0.97) 0.032 46/203.74 (0.23) 0.74 (0.54, 1.02) 0.070 
 Trend    0.044   0.104 
 Negative SLEs       
 No events  191/515.63 (0.37) 1.00 (reference)  265/741.89 (0.36) 1.00 (reference)  
 0-4 105/320.28 (0.33) 1.05 (0.79, 1.40) 0.741 75/240.11 (0.31) 0.97 (0.72, 1.30) 0.830 
 5-7 100/316.41 (0.32) 1.00 (0.76, 1.30) 0.974 50/187.71 (0.27) 0.85 (0.63, 1.17) 0.324 
 Trend    0.976   0.349 
SLE load prior to relapse       
 Total       
 No events 191/515.63 (0.37) 1.00 (reference)  265/741.89 (0.36) 1.00 (reference)  
 0-40 62/209.50 (0.30) 0.94 (0.70, 1.26) 0.669 67/191.37 (0.35) 1.17 (0.86, 1.59) 0.333 
 >40-65 74/215.97 (0.34) 1.05 (0.79, 1.39) 0.751 61/195.95 (0.31) 0.88 (0.65, 1.20) 0.428 
 >65-100 48/173.60 (0.28) 0.88 (0.62, 1.25) 0.471 22/111.03 (0.20) 0.64 (0.42, 0.98) 0.039 
 >100- 58/215.69 (0.27) 0.87 (0.61, 1.23) 0.422 18/91.30 (0.20) 0.70 (0.41, 1.20) 0.194 
 Trend   0.434   0.042 
 Positive SLEs       
 No events 191/515.63 (0.37) 1.00 (reference)  265/741.89 (0.36) 1.00 (reference)  
 0-40 39/138.57 (0.28) 0.90 (0.62, 1.32) 0.604 33/98.10 (0.34) 1.03 (0.70, 1.54) 0.866 
 >40-65 28/122.85 (0.23) 0.72 (0.45, 1.14) 0.161 23/108.00 (0.21) 0.76 (0.45, 1.27) 0.299 
 >65-100 47/142.44 (0.33) 1.07 (0.78, 1.47) 0.673 27/91.30 (0.30) 0.95 (0.62, 1.46) 0.810 
 >100- 33/147.68 (0.22) 0.72 (0.45, 1.14) 0.161 11/70.21 (0.16) 0.53 (0.28, 1.04) 0.065 
 Trend   0.219   0.088 
 Negative SLEs       
 No events 191/515.63 (0.37) 1.00 (reference)  265/741.89 (0.36) 1.00 (reference)  
 0-50 96/272.95 (0.35) 1.14 (0.87, 1.49) 0.355 81/224.60 (0.36) 1.12 (0.85, 1.47) 0.435 
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 >50-95 67/201.32 (0.33) 1.01 (0.76, 1.35) 0.928 28/126.45 (0.22) 0.67 (0.45, 1.00) 0.050 
 >95- 42/156.52 (0.27) 0.88 (0.58, 1.33) 0.534 16/72.87 (0.22) 0.79 (0.44, 1.41) 0.416 
 Trend    0.677   0.155 
SLE duration prior to relapse       
 Total       
 No events 191/515.63 (0.37) 1.00 (reference)  265/741.89 (0.36) 1.00 (reference)  
 0-31 days 98/314.27 (0.31) 0.98 (0.75, 1.29) 0.886 105/310.85 (0.34) 1.03 (0.79, 1.35) 0.818 
 32-62 days 60/206.62 (0.29) 0.93 (0.71, 1.21) 0.570 35/151.69 (0.23) 0.75 (0.53, 1.06) 0.104 
 63-93 days 38/132.21 (0.29) 0.93 (0.66, 1.32) 0.699 14/90.23 (0.16) 0.54 (0.31, 0.92) 0.025 
 ≥94 days 46/167.54 (0.27) 0.84 (0.56, 1.26) 0.398 14/41.61 (0.34) 1.03 (0.61, 1.74) 0.914 
 Trend   0.364   0.100 
 Positive SLEs       
 No events 191/515.63 (0.37) 1.00 (reference)  265/741.89 (0.36) 1.00 (reference)  
 0-31 days 88/323.32 (0.27) 0.87 (0.66, 1.15) 0.336 70/257.02 (0.27) 0.91 (0.67, 1.22) 0.524 
 ≥32 days 59/229.48 (0.26) 0.83 (0.60, 1.15) 0.261 24/111.41 (0.22) 0.70 (0.44, 1.14) 0.155 
 Trend    0.195   0.145 
 Negative SLEs       
 No events 191/515.63 (0.37) 1.00 (reference)  265/741.89 (0.36) 1.00 (reference)  
 0-31 days 104/323.13 (0.32) 1.06 (0.82, 1.36) 0.668 91/271.71 (0.33) 1.03 (0.80, 1.34) 0.818 
 ≥32 days 101/313.56 (0.32) 0.99 (0.74, 1.33) 0.947 34/156.11 (0.22) 0.71 (0.49, 1.04) 0.077 
 Trend    0.998   0.176 
Fonts in bold and italic denoted statistically significant association
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Chapter 8: Summary and future directions 
Treatments for relapsing MS patients advanced markedly during the last decade, but 
conversion to secondary-progressive stage could not be prevented for relapsing MS patients. 
Mechanisms underlying the disease progression and conversion to secondary-progressive 
stage are still illusive. Therapeutic options for progressive MS patients were limited; only one 
recent phase 3 RCT showed patients with ocrelizumab were associated with decreased rate of 
clinical progression
1
. However, subjects chosen in this study were comparatively benign and 
some patients still experienced periodical exacerbations. Therefore, preventing and treating 
MS from other perspectives is of great importance. Understanding what factors drive the 
progression of MS especially when these factors are modifiable may divulge these essential 
findings for people with MS. 
Some large prospective cohort studies endeavoured to deal with these puzzles, but no 
consistent conclusion has been achieved. BENEFIT and MSL study
2 3
 showed that higher 
levels of anti-EBNA IgG were not associated with subsequent conversion to MS and 
relapses, but results from some other good-quality studies
4 5
 were not in line with this finding. 
Although a number of well-designed studies
6-8
 found tobacco smoking could accelerate the 
progression of MS, some study
2
 still showed a negative result. Relapse rate decreased 
significantly during pregnancy and increased in the first 3 months postpartum, but the long-
term effects of pregnancy on MS clinical course is still less certain
9-12
.  
This thesis evaluated established and potential risk factors and their effects on ASO of MS, 
which assists in the evidence base for strategies that delay and prevent the onset of MS. The 
thesis also explored the associations between viral infections and SLEs on conversion to MS, 
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time to relapses, and disability progression, contributing to the understanding of the 
mechanisms underlying disease progression. 
8.1 Summary of findings and implications 
In Chapter 4, the first aim of the thesis was addressed using a unique and large international 
database, including 21 countries with 22162 diagnosed MS patients. We found a significant 
association between latitude of residence and ASO, and variation of UVR was the possible 
candidate underlying this latitudinal gradient. When compared to patients living in lower 
latitudes, the onset of symptoms was 1.9 years earlier among those residing at higher 
latitudes, and a similar relationship was found for ambient UVR. Our study also 
demonstrated that sex was associated with ASO, with female patients having on average a 5-
month earlier onset than male patients. ASO in relapsing-onset patients was approximately 9 
years earlier than that for progressive-onset patients. Optimising sun exposure and vitamin D 
during the life course was estimated to make an important impact at the population level on 
the prevention of MS
13
. Our findings seem to suggest that this may also delay the onset in 
patients with MS. Population health messages that counter the decrease of outdoor behaviour 
in our young generations will be important to prevent and possibly delay MS.  
Chapter 5 addressed the second aim of the thesis. We examined the effects of detailed 
environmental/behavioural factors on ASO. We found that a history of tobacco smoking was 
associated with 3.05-years later ASO, whereas a history of marijuana use was associated with 
2.80-years earlier ASO. In agreement with the first study in this thesis, progressive-onset 
cases had later ASO than relapsing onset cases, and an initial presentation of cerebral 
function impairment was associated with an approximately 4years later onset. This study 
found that sex, offspring number, latitude of study site, and UVR exposure were not 
associated with ASO, which does not neatly align with the first study. Small sample size and 
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less latitudinal spread may partly explain the difference. We also found that a history of 
infectious mononucleosis, HLA-DR15 and HLA-A2 genotypes, latitude, UVR, and serum 
vitamin D metabolite levels were not significantly associated with ASO. To examine whether 
the results were due to an age or cohort effect, we repeated the analysis in the matched 
healthy controls. Each control was given the ASO of the matched cases. If the association 
was also observed in controls, then that is likely due to an age or cohort effect. We found no 
association between smoking status and ASO (never smokers vs. ever smokers: adjusted 
β=+0.11 years, 95% CI -1.54 - 1.77, p=0.89), suggesting the significant association in cases 
was not due to an age or cohort effect. Few studies have examined factors associated with 
symptom onset, and the examination is challenged by cohort effects and inherent correlation 
exposures and the outcome measure. Therefore, additional studies are required to examine 
age of onset effects.  
Chapter 5 reported the associations between EBV and HHV6 infections on the MS clinical 
course (conversion to MS, time to relapses, and annualised change of EDSS). Although a 
higher immune response to anti-EBNA IgG has been confirmed to contribute to the onset of 
MS, we found no association between levels of anti-EBNA IgG and MS clinical course, and 
other serological parameters such as EBV DNA, early antigen (diffuse and restricted), and 
viral capsid antigen were not associated with any measured MS clinical course. A history of 
infectious mononucleosis at baseline was associated with increased hazard of relapse, but not 
with conversion to MS, although the direction and magnitude were similar. No association 
was found between serological or viral load parameters of HHV6 and any clinical course 
outcome. Thus, while the evidence is overwhelming that EBV is causally related to the onset 
of MS, its role in the clinical course is far less certain
2
. 
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In Chapter 6, we evaluated the effects of SLEs on MS clinical course. For conversion to MS 
and relapses analysis, we summarised SLE information 6 or 12 months prior to conversion to 
MS or relapse and evaluated its influence on subsequent disease activity. We found that a 
greater number, higher perceived severity and load, and a longer duration of the events that 
were perceived as positive were consistently associated with a reduced hazard of relapse in a 
dose-dependent manner. Associations were less strong for conversion to MS, however. There 
were no associations between perceived negative SLEs and MS conversion or relapse risk. 
These findings offer a positive new story to people with MS and can empower them to 
increase their focus on positive events. The findings are very suitable to be translated into 
practice and align with the beneficial health effects of interventions that reduce stress.  
In summary, the findings from this thesis underline the importance of modifiable 
environmental or behavioural factors on delaying the age of disease onset and reducing the 
hazard of conversion to MS and relapses.  
8.2 Future directions 
Future directions as suggested by this thesis are to: 
1. Determine whether the other lifestyle factors such as smoking, physical 
activity, offspring number prior to onset, and alcohol and coffee consumption 
could influence the clinical course of MS. 
In relation to the clinical course in patients with MS, there are other 
modifiable factors, such as tobacco smoking, physical activity, offspring 
number prior to onset, alcohol and coffee consumption, which have not been 
assessed in this thesis. The overall evidence base in relation to these variables 
and MS clinical course is relatively low7-9 12 14-20. This could assist in the 
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understanding of the mechanism underlying MS progression. Furthermore, our 
findings may help clinicians to provide some advice with direct and stronger 
evidence for considering adding these interventions as a strategy for 
prevention of disease progression in MS patients at the early stage (some 
therapeutic studies suggested that only interventions at the early stage can 
influence the long-term prognosis21).  
2. Determine association of effects between demographic factors and initial 
clinical symptoms on MS clinical course 
a. Examining whether absence/presence of some presentations at disease 
onset (pyramid, cerebellar, brainstem, sensory, bowel and bladder, 
cerebral and visual dysfunction) could influence MS clinical course 
b. Examining whether gender, latitude, and education levels could 
influence MS clinical course 
Although current studies have confirmed the effects of some demographic 
factors such as latitude of residence and gender on MS onset
22
, their 
associations with MS clinical course are still unclear. At baseline 
interview, demographic information and initial symptoms at FDE were 
recorded and confirmed by study neurologists. Clarifying the absence or 
presence of the association between demographic or initial symptoms at 
FDE and subsequent disease activity and disability progression could help 
the clinicians to predict the prognosis of MS patients from disease onset, 
and may assist in the clarifying of the pathological pathways influencing 
the progression of MS.  
Chapter 8: Summary and future directions 
269 
 
3. Determine whether established modifiable risk factors (EBV infection, 
infectious mononucleosis, vitamin D levels, UVR, and smoking) could 
influence MS clinical course at the late stage (conversion from RRMS to 
SPMS) 
This thesis did not discuss associations between some modifiable factors at the 
early stage and long-term MS clinical course. Current disease-modifying 
treatments are effective for relapsing-remitting patients, but there is a lack of 
treatment options when they convert to SPMS
23
. Therefore, preventing 
patients from converting to SPMS is a primary target for relapsing-onset 
patients. Our study could assist in the understanding of the mechanisms 
underlying the association between currently established risk factors and 
conversion from RRMS to SPMS, and preventing the disease progression via 
modifying behaviours. 
4. Determine whether frequency of relapses at the early stage could predict the 
disability progression and conversion to SPMS. 
Current disease-modifying treatments are able to reduce the frequency of relapses for 
MS patients, but the association between relapse rate and long-term disability accrual 
is still uncertain. Although some treatment studies
24-29
 demonstrated the positive 
relationship between relapse frequency and long-term disability progression, one 
prospective cohort study
30
 suggested that only disease activity within 2 years after 
onset could influence the long-term disability progression and conversion to SPMS. 
With measurement of relapse frequency up to 10 years after disease onset, this study 
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may aid in the understanding of the predictable effects of early clinical factors on 
long-term disease. 
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